<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13973926
    </Internal_Number>
    <TrialID>NCT06360289
    </TrialID>
    <Last_Refreshed_on>20 May 2024
    </Last_Refreshed_on>
    <Public_title>Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
    </Public_title>
    <Scientific_title>Observational Study of Neurofilament Light Chain (NfL) Levels in Asymptomatic Carriers of the TTR Gene Variants and Patients With hATTR Amyloidosis With Polyneuropathy, Including Patients Who Undergo Treatment Change - NeuroFeeL Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20240408
    </Date_registration3>
    <Date_registration>08/04/2024
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06360289
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 25, 2024
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alnylam Clinical Trial Information Line
    </Contact_Lastname>
    <Contact_Email>clinicaltrials@alnylam.com
    </Contact_Email>
    <Contact_Tel>1-877-ALNYLAM
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Carrier of a documented pathogenic TTR variant confirmed with genotyping with predicted&#x0D;&lt;br&gt;        disease onset within 5 years and not diagnosed with hATTR amyloidosis with polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Confirmed diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR variant&#x0D;&lt;br&gt;        confirmed with genotyping&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Participant is able to understand the study and does not oppose participating in the&#x0D;&lt;br&gt;        study after reviewing the content of the PIS provided.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A known condition (other than hATTR amyloidosis) that can cause nerve damage and&#x0D;&lt;br&gt;             affect NfL levels&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Estimated glomerular filtration rate (eGFR) &lt;45 milliliters per minute per 1.73 meters&#x0D;&lt;br&gt;             squared (mL/min/1.73 m^2)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently enrolled in a clinical study for any investigational agent.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Amyloidosis, Transthyretin-Related;Asymptomatic Carrier State
    </Condition>
    <Intervention>Other: Standard of Care
    </Intervention>
    <Primary_outcome>NfL Levels in Asymptomatic Carriers of a TTR Variant and Symptomatic hATTR Patients With Polyneuropathy at Baseline;Change in NfL Levels Over Time in Asymptomatic Carriers of a TTR Variant and Symptomatic hATTR Patients With Polyneuropathy
    </Primary_outcome>
    <Secondary_outcome>Correlation Between the NfL Levels and Various Biological and Clinical Activity Parameters in Asymptomatic Carriers of a TTR Variant and Symptomatic hATTR Patients With Polyneuropathy at Baseline;Correlation Between the Change in NfL Levels and Various Biological and Clinical Activity Parameters in Asymptomatic Carriers of a TTR Variant and Symptomatic hATTR Patients With Polyneuropathy;Comparison of the Measured NfL Levels to the Normal Levels Expected to be Seen in the General Population by Using the Existing Reference Ranges and Databases;Time to Onset of Active Disease in Asymptomatic Carriers of TTR Variants;Disease Progression in Symptomatic hATTR Amyloidosis Patients with Polyneuropathy
    </Secondary_outcome>
    <Secondary_ID>ALN-TTR-NT-003
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14037566
    </Internal_Number>
    <TrialID>CTIS2023-507385-11-00
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Long-Term Follow-Up of Subjects Treated With NTLA-2001
    </Public_title>
    <Scientific_title>Long-Term Follow-Up of Subjects Treated With NTLA-2001 - ITL-2001-CL-999                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Intellia Therapeutics Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20240408
    </Date_registration3>
    <Date_registration>08/04/2024
    </Date_registration>
    <Source_Register>Clinical Trials Information System
    </Source_Register>
    <web_address>https://euclinicaltrials.eu/app/#/view/2023-507385-11-00?lang=en
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>65+
    </Inclusion_agemax>
    <Inclusion_gender>Female: yes Male: yes
    </Inclusion_gender>
    <Date_enrollement>16/04/2024
    </Date_enrollement>
    <Target_size>74
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial: 0
    </Study_design>
    <Phase>Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): yes Therapeutic use - (Phase IV): no
    </Phase>
    <Countries>Sweden;United Kingdom;New Zealand
    </Countries>
    <Contact_Firstname>Clinical Trials Department
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email>clinicalscience@intelliatx.com
    </Contact_Email>
    <Contact_Tel>+18338880387
    </Contact_Tel>
    <Contact_Affiliation>Intellia Therapeutics Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.,2. A subject has provided informed consent for the LTFU study.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Not applicable.
    </Exclusion_Criteria>
    <Condition>-Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
-Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) &lt;br&gt;MedDRA version: 20.0Level: PTClassification code: 10007509Term: Cardiac amyloidosisSystem Organ Class: 100000004849 &lt;br&gt;MedDRA version: 20.0Level: PTClassification code: 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16];MedDRA version: 20.0Level: PTClassification code: 10007509Term: Cardiac amyloidosisSystem Organ Class: 100000004849;MedDRA version: 20.0Level: PTClassification code: 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 100000004850
    </Condition>
    <Intervention>Product Name: NTLA-2001,Product Code: PRD8425756,Pharmaceutical Form: LIQUID,Other descriptive name: ,Strength: Messenger Rna Encoding Cas9 7mg, Single Guide Rna Targeting The Human Ttr Gene 3.5mg,Current Sponsor code: NTLA-2001
    </Intervention>
    <Primary_outcome>Main Objective:To evaluate the long-term safety of NTLA-2001 in previously treated subjects;Secondary Objective:To evaluate long-term pharmacodynamic effects of  NTLA-2001 in previously treated subjects;Primary end point(s):For ATTR-CM and ATTRv-PN subjects, incidence of: • Treatment-related SAEs • Protocol-specified AESIs
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s):PD biomarkers for ATTR over time: • Serum TTR • Serum prealbumin
    </Secondary_outcome>
    <Secondary_ID>U1111-1296-5487;2022-003405-30;NCT05697861
    </Secondary_ID>
    <Source_Support>Intellia Therapeutics, Inc.
    </Source_Support>
    <Secondary_Sponsor>Medpace Finland Oy
    </Secondary_Sponsor>
    <Ethics_review_status>Authorized
    </Ethics_review_status>
    <Ethics_review_approval_date>16/04/2024
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13903843
    </Internal_Number>
    <TrialID>NCT06365593
    </TrialID>
    <Last_Refreshed_on>22 April 2024
    </Last_Refreshed_on>
    <Public_title>hATTR Polyneuropathy in Russia
    </Public_title>
    <Scientific_title>A Multicenter Observational retrosPective Registry of patIents With Transthyretin aMyloid polynEuropathy (hATTR-PN) and chRonic Idiopathic Axonal Polyneuropathy (CIAP) in the Population of the Russian Federation
    </Scientific_title>
    <Acronym>PRIMER
    </Acronym>
    <Primary_sponsor>AstraZeneca
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20240301
    </Date_registration3>
    <Date_registration>01/03/2024
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06365593
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 29, 2023
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Russian Federation
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>AstraZeneca Clinical Study Information Center
    </Contact_Lastname>
    <Contact_Email>information.center@astrazeneca.com
    </Contact_Email>
    <Contact_Tel>1-877-240-9479
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with hATTR-PN or CIAP ;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The diagnosis of hATTR-PN or CIAP was established between the 1st January 2017 and the&#x0D;&lt;br&gt;             1st March 2024;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of at least 1 month between the date of hATTR-PN or CIAP diagnosis and the&#x0D;&lt;br&gt;             date of inclusion;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 18 years at the time of hATTR-PN or CIAP diagnosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participation in any clinical trial with investigational product from the moment&#x0D;&lt;br&gt;             of diagnosis of ATTR PN or CIAP until the end of retrospective follow-up period.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Transthyretin Amyloidosis
    </Condition>
    <Primary_outcome>In order to describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Mean age at the hATTR-PN or CIAP diagnosis information will be collected;In order to describe the baseline demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Proportion of women and men will be collected;In order to describe the baseline demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Proportion of patients with each race and ethnicity will be collected;to describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIA, information on Proportion of patients from each federal district of the Russian Federation will be collected;in order to describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, tha following Anthropometric characteristics will be collected:;In order to describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients with underweight will be collected;in order to describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Proportion of patients with negative lifestyle factors will be collected:;in order to describe the baseline demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Proportion of patients with positive family history in close relatives will be collected;to describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP, information on Mean (or median) time from the first symptoms of neuropathy to the diagnosis of PN will be collected;to describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP, Proportion of patients with different firstly suspected etiology of PN will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP, information on Mean (or median) time from first PN manifestation/diagnosis to the hATTR-PN or CIAP diagnosis will be collected;To describe the baseline electrophysiological and clinical characteristics of patients, Proportion of patients with chronic sensory or sensorimotor polyneuropathy and progressive chronic polyneuropathy among patients with CIAP will be calculated;To describe the baseline clinical characteristics of patients with hATTR-PN and CIAP, Proportion of patients with each result of TTR gene testing will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients with each clinical manifestation will be calculated:;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients with each PND score will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients with each score by each parameter of neurological examination will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Mean point by MRS will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Mean point by INCAT scale (total score, arm disability, leg disability) will be collected;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Mean left ventricular ejection fraction (LVEF) will be collected;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information Mean wall thickness of the left ventricular (LV) will be collected;To describe the baseline electrophysiological characteristics of patients with hATTR-PN and CIAP, information Mean variables based on the results of electrophysiological investigation, including the following (on both extremities) will be collected;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients with diagnosis of HFpEF will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Mean NT-proBNP level will be collected;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information Mean estimated glomerular filtration rate (eGFR) will be collected;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Mean urine albumin-to-creatinine ratio (UACR) in a spot urine sample will be collected;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients with a positive paraprotein blood test result will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, information on Mean blood pressure (BP) (systolic and diastolic) and Mean heart rate (HR);To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients with each concomitant disease will be calculated;To describe the baseline electrophysiological, clinical and demographic characteristics of patients with hATTR-PN and CIAP in the Russian Federation, Proportion of patients underwent surgery for CTS to the moment of diagnosis will be calculated
    </Primary_outcome>
    <Secondary_outcome>To arrange a score to select patients with axonal neuropathy who deserve screening for TTR mutation.
    </Secondary_outcome>
    <Secondary_ID>D8450R00005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14002619
    </Internal_Number>
    <TrialID>NCT06414746
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
    </Public_title>
    <Scientific_title>A Multicenter Observational Retrospective-prospective Study of Prevalence, Clinical Characteristics of Hereditary Transthyretin Amyloidosis Polyneuropathy in Russian Patients Undergoing Surgery for CTS in Real Clinical Practice
    </Scientific_title>
    <Acronym>LOCUS
    </Acronym>
    <Primary_sponsor>AstraZeneca
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20240216
    </Date_registration3>
    <Date_registration>16/02/2024
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06414746
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 29, 2023
    </Date_enrollement>
    <Target_size>880
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Russian Federation
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>AstraZeneca Clinical Study Information Center
    </Contact_Lastname>
    <Contact_Email>information.center@astrazeneca.com
    </Contact_Email>
    <Contact_Tel>1-877-240-9479
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        for the retrospective phase are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with the established diagnosis of CTS undergoing surgical intervention&#x0D;&lt;br&gt;             between the 1st January 2021 and the 1st September 2024.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age = 18 years at the time of surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Additional inclusion criteria for the prospective phase are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Provided written informed consent for the prospective phase of the study (including&#x0D;&lt;br&gt;             molecular genetic testing).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Bilateral CTS;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Presence of =1 of the following features (red flags):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. CIDP or polyneuropathy of unknown etiology in the family history;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Spinal canal stenosis of the lumbar region;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Autonomic dysfunction, defined by the presence of =1 of the following symptoms:&#x0D;&lt;br&gt;                  i. gastrointestinal complaints (constipation, chronic diarrhea, or both); ii.&#x0D;&lt;br&gt;                  erectile dysfunction; iii. orthostatic hypotension;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Gait disorders;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Sweating disorders, anhidrosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Paresthesia and burning of the skin of the distal extremities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               7. Distal symmetrical paresis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               8. Hypotrophy and hypotension of limb muscles, areflexia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               9. Biceps tendon rupture&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              10. Aortic valve stenosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              11. Diagnosis of HFpEF&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              12. Unexplained weight loss =5 kilos at any timepoint since the onset of symptoms of&#x0D;&lt;br&gt;                  CTS;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              13. Left ventricular hypertrophy (based on electro- or echocardiographic criteria&#x0D;&lt;br&gt;                  documented in the patient's medical record);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              14. Heart rhythm disorders;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              15. Renal abnormalities, defined by =1 of the following features - i. documented&#x0D;&lt;br&gt;                  diagnosis of chronic kidney disease (CKD); ii. decreased estimated glomerular&#x0D;&lt;br&gt;                  filtration rate (eGFR &lt;60 mL/min/1.73m2); iii. increased serum creatinine (SCr)&#x0D;&lt;br&gt;                  above reference range of the local laboratory; iv. albuminuria (=30 mg/g of&#x0D;&lt;br&gt;                  creatinine or =30 mg/24h ); v. proteinuria (according to urinalysis results).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;              16. Ophthalmology disorder defined by =1 of the following features - i. vitreous body&#x0D;&lt;br&gt;                  inclusions (opacification); ii. Glaucoma; iii. pupillary disorders; iv.&#x0D;&lt;br&gt;                  vitrectomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Absence of previously established ATTR PN diagnosis (ICD-10 code ?85.1, "Neuropathic&#x0D;&lt;br&gt;             hereditary familial amyloidosis").&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        for the retrospective phase are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Participation in any interventional trial within the period since surgical&#x0D;&lt;br&gt;             intervention until the end of current study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Additional exclusion criteria for the prospective phase are:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Previously performed TTR genetic testing;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Verified B12 deficiency;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. History of alcohol abuse according to the patient's medical record.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Transthyretin Amyloidosis;Carpal Tunnel Syndrome;Polyneuropathy;Amyloidosis
    </Condition>
    <Primary_outcome>To define the prevalence of ATTR PN in patients undergoing surgery for CTS in routine clinical practice in the Russian Federation
    </Primary_outcome>
    <Secondary_outcome>To assess general demographic characteristics of patients with ATTR PN in Russia - Mean age (years) at the onset of CTS symptoms;To assess general demographic characteristics of patients with ATTR PN in Russia: Mean age (years) at the onset of polyneuropathy symptoms;to assess general demographic characteristics of patients with ATTR PN in Russia: Proportion of patients with late (&gt;50 years) diagnosis of ATTR PN;to assess general demographic characteristics of patients with ATTR PN in Russia: Mean age (years) at the time of CTS surgery;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Number and proportion of patients with specific characteristic of index CTS download;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with CTS recurrence after surgery;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients undergoing repeat surgery for CTS after the index operation;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with PN progression after surgery;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Proportion of patients with different number of red flags:;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Mean age (years) at ATTR PN diagnosis;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of women and men;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Mean body mass index (BMI) and proportion of patients with different BMI dimensions at the time of surgery and at Visit 1:;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Proportion of patients with a history of unexplained weight loss (=5 kg) at any point since symptom onset;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Mean and median time from CTS symptom onset (months) to ATTR PN diagnosis;To assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Median number of physicians seen since symptom onset before the correct ATTR PN diagnosis;To assess general demographic and clinical characteristics of patients with ATTR PN in Russia: Median number of hospitalizations for PN before the correct ATTR PN diagnosis;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Number of patients with previously established incorrect diagnosis according to medical records, specifically with:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with family history of neuropathic disease;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with specific peripheral neurological manifestations:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN: Proportion of patients with specific Polyneuropathy Disability (PND) classes:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Proportion of patients with specific distribution of polyneuropathy symptoms:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with autonomic neurological manifestations, including specifically:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant cardiac manifestations, including specifically:;Number of patients taking specific groups of cardiovascular medications at the time of CTS surgery and at the time of prospective visit:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant ophthalmologic manifestations, including specifically;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - Number of patients with concomitant musculoskeletal manifestations, including specifically:;Mean and median serum NT-proBNP (pg/ml) concentration;Proportion of patients with laboratory confirmed paraproteinemia;Mean and median urine albumin-creatinine ratio (UACR, mg/g of creatinine);Proportion of patients with diagnosed CKD, including specifically;Number of patients with concomitant renal dysfunction, including specifically;Number of patients with confirmed length-dependent peripheral sensory-motor neuropathy based on NCS results;Mean and median measured peripheral sensory nerve conduction velocities;Number of patients with reduced peripheral sensory nerve conduction velocity at =1 site;Mean and median measured peripheral motor nerve conduction velocities;Number of patients with reduced motor sensory nerve conduction velocity at =1 site;Mean and median measured sensory action potential (SAP) amplitudes;Number of patients with reduced/absent SAP amplitude at =1 site;Mean and median measured distal compound muscle action potential (dCMAP) amplitudes;Mean and median measured proximal compound muscle action potential (pCMAP) amplitudes;Number of patients with reduced/absent dCMAP amplitude at =1 site;Number of patients with reduced/absent pCMAP amplitude at =1 site;Proportion of patients with each score by each parameter of neurological examination;Number of patients in the specific categories of the modified Rankin scale;Proportion of patients with specific number of points according to Inflammatory Neuropathy Cause and Treatment (INCAT) upper extremity scale;Median number of points according to INCAT upper extremity scale;Proportion of patients with specific number of points according to INCAT lower extremity scale;Median number of points according to INCAT lower extremity scale;Mean and median number of points according to combined clinical and electrophysiological score;To describe data on the results of genetic testing for ATTR in CTS patients undergoing surgery:Number and proportion of patients with specific TTR gene mutations;to assess general demographic and clinical characteristics of patients with ATTR PN in Russia - Proportion of patients with previously established incorrect diagnosis according to medical records, specifically with:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with autonomic neurological manifestations, including specifically:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant cardiac manifestations, including specifically:;proportion of patients taking specific groups of cardiovascular medications at the time of CTS surgery and at the time of prospective visit:;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant ophthalmologic manifestations, including specifically;To describe data on the presence of cardiovascular, neurological and other comorbidities in Russian patients with ATTR PN - proportion of patients with concomitant musculoskeletal manifestations, including specifically:;proportion of patients with concomitant renal dysfunction, including specifically;proportion of patients with confirmed length-dependent peripheral sensory-motor neuropathy based on NCS results;proportion of patients with reduced peripheral sensory nerve conduction velocity at =1 site;proportion of patients with reduced motor sensory nerve conduction velocity at =1 site;proportion of patients with reduced/absent SAP amplitude at =1 site;proportion of patients with reduced/absent dCMAP amplitude at =1 site;proportion of patients with reduced/absent pCMAP amplitude at =1 site;proportion of patients in the specific categories of the modified Rankin scale
    </Secondary_outcome>
    <Secondary_ID>D8451R00001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14023514
    </Internal_Number>
    <TrialID>DRKS00032447
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Improving the health of children and adolescents with autoinflammatory diseases
    </Public_title>
    <Scientific_title>Improving the health of children and adolescents with autoinflammatory diseases - Pro-AID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Deutsches Rheuma-Foschungszentrum Berlin
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20240104
    </Date_registration3>
    <Date_registration>04/01/2024
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00032447
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>None
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/01/2024
    </Date_enrollement>
    <Target_size>250
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: health services research  
    </Study_design>
    <Phase/>
    <Countries>Austria;Germany
    </Countries>
    <Contact_Firstname>Tatjana
    </Contact_Firstname>
    <Contact_Lastname>Welzel
    </Contact_Lastname>
    <Contact_Address>Charitéplatz 1
    </Contact_Address>
    <Contact_Email>tatjana.welzel@ukbb.ch
    </Contact_Email>
    <Contact_Tel>+493028460632
    </Contact_Tel>
    <Contact_Affiliation>Deutsches Rheuma-Forschungszentrum Berlin
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: - autoinflammatory disease diagnosed by paediatric rheumatologist&#x0D;&lt;br&gt;- written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: - Lack of cognitive maturity to understand the requirements and content of the project&#x0D;&lt;br&gt;- Diagnoses: systemic JIA, CRMO
    </Exclusion_Criteria>
    <Condition>FMF (familial Mediterranean fever), NLRP3-AID (CAPS = Cryopyrin associated periodic syndromes), MKD (mevalonate kinase deficiency), TRAPS (TNF receptor associated periodic fever syndrome), PFAPA, DIRA (Deficiency of the IL-1 receptor antagonist), DITRA (Deficiency of the IL-36 receptor antagonist), NLRP12-AID (FCAS2 = Familial cold autoinflammatory syndrome 2), Aicardi-Goutières Syndrome (AGS), STING-Associated Vasculopathy with Onset in Infancy (SAVI), Chilblain Lupus, CANDLE (PRAAS) Syndrom, COPA Syndrome, Deficiency of Adenosine Deaminase 2 (DADA2), M. Behcet, unclassified and other AID
ORPHA:210115 ORPHA:325004 ORPHA:342 ORPHA:32960 ORPHA:42642 ORPHA:247868 ORPHA:309025 ORPHA:51  ORPHA:404546 ORPHA:90280 ORPHA:117 ORPHA:425120 ORPHA:208650 ORPHA:444092 &lt;br&gt;E85.0 &lt;br&gt;M35.2;Non-neuropathic heredofamilial amyloidosis;Behçet disease;E85.0;M35.2
    </Condition>
    <Intervention>Group 1: Prospective observation of prevalent and incident cases with AID approximately every 6 months for a total of 24 months&lt;br&gt;- Physician reports &lt;br&gt;on diagnosis, age at onset of disease at baseline&lt;br&gt;every 6 months on disease activity, therapy, clinical manifestations, concomitant diseases, selected laboratory parameters&lt;br&gt;at the last visit, additionally on disease damage (using ADDI)&lt;br&gt;- Patient/parent information &lt;br&gt;on symptom onset, doctor contacts and time to diagnosis at baseline&lt;br&gt;every 6 months on overall health, coping with illness, quality of life, family burden (FaBel), adherence to therapy, satisfaction with therapy
    </Intervention>
    <Primary_outcome>Disease activity (physician global assessment on a numerical rating scale of 0-10, NRS) at each visit
    </Primary_outcome>
    <Secondary_outcome>Disease activity (patient global assessment on a numerical rating scale of 0-10) at each visit&#x0D;&lt;br&gt;Damage (ADDI) at last visit&#x0D;&lt;br&gt;Coping with disease, NRS, at each visit&#x0D;&lt;br&gt;Quality of life (PedsQL 3.0 and 4.0, EQ-5D), at each visit&#x0D;&lt;br&gt;Family burden (FaBel), at each visit&#x0D;&lt;br&gt;Therapy adherence (JAMAR), at each visit&#x0D;&lt;br&gt;Satisfaction with therapy (Likert scale), at each visit
    </Secondary_outcome>
    <Source_Support>Kindness for Kids - Stiftung für Kinder mit Seltenen Erkrankungen
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>27/10/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ekaachen@ukaachen.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission an der Medizinischen Fakultät der RWTH Aachen
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-241-8089963
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ekaachen@ukaachen.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00032447#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13391343
    </Internal_Number>
    <TrialID>NCT05925621
    </TrialID>
    <Last_Refreshed_on>9 October 2023
    </Last_Refreshed_on>
    <Public_title>Cognitive Neurology Unit Clinical Registry
    </Public_title>
    <Scientific_title>Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Beth Israel Deaconess Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230622
    </Date_registration3>
    <Date_registration>22/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05925621
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>95 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 16, 2023
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational [Patient Registry]
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dan Z Press, MD
    </Contact_Lastname>
    <Contact_Email>dpress@bidmc.harvard.edu
    </Contact_Email>
    <Contact_Tel>(617) 667-4074
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  o Patient meets clinical criteria for mild cognitive impairment or early dementia from&#x0D;&lt;br&gt;             Alzheimer's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient has evidence of cognitive impairment on neuropsychological testing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient has not progressed to the moderate stage of dementia based on&#x0D;&lt;br&gt;                  neuropsychological testing or clinical judgement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Amyloid PET imaging positive&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  CSF p-Tau/Abeta42 ration &gt;0.023 and ABeta42 &lt; 1027**&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  3T MRI in past 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient has a care partner&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient under the care of an appropriate BI-Lahey amyloid clinic&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patient is on a stable medication regimen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  o Recent stroke or suspected TIA in the past year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Active autoimmune or immunological disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal&#x0D;&lt;br&gt;                  antibodies or their derivatives&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Bleeding disorder with Plts &lt; 50,000 or INR &gt; 1.5&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  On warfarin, heparin, or DOAC&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  On dual antiplatelet therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Non Alzheimer disease cause of dementia/MCI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  ApoE e4 homozygote&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Alzheimer Disease
    </Condition>
    <Intervention>Drug: Lecanemab
    </Intervention>
    <Primary_outcome>To Determine Whether Anti-Amyloid Mabs Slow Cognitive And Functional Decline;To Identify Any Associations Between Side Effects And Patient Characteristics;To Establish The Time Course Of Clinical Benefits
    </Primary_outcome>
    <Secondary_ID>2023P000494
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13944437
    </Internal_Number>
    <TrialID>NCT05873868
    </TrialID>
    <Last_Refreshed_on>6 May 2024
    </Last_Refreshed_on>
    <Public_title>Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
    </Public_title>
    <Scientific_title>MyocardON-TTR - Myocardial Effects in Patients With Hereditary Transthyretin-mediated Amyloidosis With Polyneuropathy Treated With Patisiran or Vutrisiran
    </Scientific_title>
    <Acronym>MyocardON-TTR
    </Acronym>
    <Primary_sponsor>Rennes University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230515
    </Date_registration3>
    <Date_registration>15/05/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05873868
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 12, 2024
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>France
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Erwan Donal;Erwan Donal
    </Contact_Lastname>
    <Contact_Email>;erwan.donal@chu-rennes.fr
    </Contact_Email>
    <Contact_Tel>;299284321
    </Contact_Tel>
    <Contact_Affiliation>Rennes University Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients aged 18 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with hereditary transthyretin amyloidosis (ATTRv) with stage 1 or 2&#x0D;&lt;br&gt;             polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient not previously treated for ATTRv&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients for whom treatment with patisiran or vutrisiran has been initiated by a&#x0D;&lt;br&gt;             hospital neurologist in accordance with recommendations for a minimum of 24 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with NYHA stage 1 and 2 cardiac disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Beneficiary of a social security scheme&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Person who does not object to his/her participation in the research&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients treated with Tafamidis simultaneously with patisiran or vutrisiran&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults under legal protection (legal guardianship, curatorship, guardianship), persons&#x0D;&lt;br&gt;             deprived of liberty.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications to the explorations provided for in the protocol: claustrophobia,&#x0D;&lt;br&gt;             metallic implant contraindicating MRI, woman of childbearing age&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin Amyloidosis;Amyloidosis, Hereditary
    </Condition>
    <Intervention>Other: Six minutes walk test;Other: Kansas City questionnaire;Other: COMPASS31 self questionnaire
    </Intervention>
    <Primary_outcome>Difference in longitudinal relaxation time (T1) per mapping between M0 and M24
    </Primary_outcome>
    <Secondary_outcome>Difference in Kansas City Cardiomyopathy Questionnaire score between M0 and M24;Difference in Compass31 questionnaire score between M0 and M24;Difference in distance obtained in the 6-minute walking test between M0 and M24;Difference in Perugini Grading Score between M0 and M24;Difference in the value of the global longitudinal strain between M0 and M24;Difference in the value of the global left atrial longitudinal strain between M0 and M24;Difference in the value of the global strain of the right ventricular free wall between M0 and M124;Evolution of myocardial work between M0 and M24
    </Secondary_outcome>
    <Secondary_ID>35RC22_9817_MyocardON-TTR
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13548887
    </Internal_Number>
    <TrialID>NCT05950867
    </TrialID>
    <Last_Refreshed_on>20 November 2023
    </Last_Refreshed_on>
    <Public_title>Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.
    </Public_title>
    <Scientific_title>Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause: a Prospective Monocentric Study (CAP-TTR)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universitair Ziekenhuis Brussel
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230421
    </Date_registration3>
    <Date_registration>21/04/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05950867
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>60 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 28, 2023
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Screening. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Belgium
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Veronique Bissay, MD, Phd;Véronique Bissay, MD,Phd;Veronique Bissay, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;veronique.bissay@uzbrussel.be;veronique.bissay@uzbrussel.be
    </Contact_Email>
    <Contact_Tel>;+32 2 477 68 01;+32 2 477 68 01
    </Contact_Tel>
    <Contact_Affiliation>UZ Brussel - VUB;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber&#x0D;&lt;br&gt;             neuropathy (SFN) without well-defined etiology.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age: &gt;= 60 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male and female gender&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known cause of polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other types of peripheral neuropathy than chronic axonal length-dependent&#x0D;&lt;br&gt;             polyneuropathy (CAP) and/or small-fiber neuropathy (SFN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients younger than 60 years&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Polyneuropathy;Amyloidosis
    </Condition>
    <Intervention>Diagnostic Test: ECG + echocardiography;Other: Answering questionnaires
    </Intervention>
    <Primary_outcome>Primary Outcome: Evaluation of prevalence of wild-type cardiac amyloidosis in our CAP and/or SFN population without well known cause.;Primary Outcome: Evaluation of prevalence of wild-type cardiac amyloidosis in our CAP and/or SFN population without well known cause;Primary Outcome: Evaluation of prevalence of wild-type cardiac amyloidosis in our CAP and/or SFN population without well known cause
    </Primary_outcome>
    <Secondary_outcome>Secondary outcome: severity and evolution;Secondary outcome: severity and evolution;Secondary outcome: severity and evolution;Secondary outcome: severity and evolution;Secondary outcome: red flags that could increase the awareness of neurologists for wild-type TTR-cardiac amyloidosis;Secondary outcome: red flags that could increase the awareness of neurologists for wild-type TTR-cardiac amyloidosis;Secondary outcome: red flags that could increase the awareness of neurologists for wild-type TTR-cardiac amyloidosis
    </Secondary_outcome>
    <Secondary_ID>EC-2023-115
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14022508
    </Internal_Number>
    <TrialID>DRKS00031084
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>„From App to Bedside“ - Utility evaluation of Ada-symptom-analysis for detection of familial Mediterranean fever
    </Public_title>
    <Scientific_title>„From App to Bedside“ - Utility evaluation of Ada-symptom-analysis for detection of familial Mediterranean fever - Appraise-Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Charité - Universitätsmedizin Berlin
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230317
    </Date_registration3>
    <Date_registration>17/03/2023
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00031084
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>20/03/2023
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: screening 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Rheumatologie
    </Contact_Firstname>
    <Contact_Lastname>Neue Therapien
    </Contact_Lastname>
    <Contact_Address>Luisenstr. 13, 3.OG
    </Contact_Address>
    <Contact_Email>rheumastudien@charite.de
    </Contact_Email>
    <Contact_Tel>+4930450513025
    </Contact_Tel>
    <Contact_Affiliation>Studienabteilung Rheumatologie - Neue Therapien
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: For both groups:&#x0D;&lt;br&gt;- Consent to participate in the research project&#x0D;&lt;br&gt;- Signed consent to scientific data collection, data storage and data processing&#x0D;&lt;br&gt;- Understanding of the German language&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Group 1:&#x0D;&lt;br&gt;- Diagnosis of FMF suspected by Ada symptom-analysis&#x0D;&lt;br&gt;- as well as no confirmed diagnosis of FMF yet&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Group 2:&#x0D;&lt;br&gt;- Medical diagnosis of FMF within the last 5 years before inclusion in this research project
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: For both groups:&#x0D;&lt;br&gt;- Persons incapable of giving consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;E85.0;Non-neuropathic heredofamilial amyloidosis;E85.0
    </Condition>
    <Intervention>Group 1: Adults with Ada-app suspected diagnosis of familial Mediterranean fever (FMF)&lt;br&gt;Group 2: Adults with diagnosed FMF by a physician
    </Intervention>
    <Primary_outcome>Survey of the time from the onset of initial symptoms to diagnosis and comparison of both patient groups
    </Primary_outcome>
    <Secondary_outcome>- Comparison of both patient groups with regard to medical diagnostic already used and number of visits by a physician regarding diagnosis FMF&#x0D;&lt;br&gt;- Recording of the number of sick days in the last 2 years due to FMF before diagnosis and in the last year before inclusion&#x0D;&lt;br&gt;- Calculation of the cost savings potential when implementing the app as an access authorisation for a quick specialist consultation&#x0D;&lt;br&gt;- Physicians assessment of the benefits of Ada's pre-diagnostic assessment&#x0D;&lt;br&gt;- Reliability of Ada's disease suggestions
    </Secondary_outcome>
    <Source_Support>Novartis Pharma GmbH;Ada Health GmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>24/02/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkommission@charite.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Charité – Universitätsmedizin Berlin
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>(+49)30-450517222
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkommission@charite.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00031084#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13877037
    </Internal_Number>
    <TrialID>NCT05697861
    </TrialID>
    <Last_Refreshed_on>8 April 2024
    </Last_Refreshed_on>
    <Public_title>Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
    </Public_title>
    <Scientific_title>Long-Term Follow-Up of Subjects Treated With NTLA-2001
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Intellia Therapeutics
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230113
    </Date_registration3>
    <Date_registration>13/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05697861
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 10, 2023
    </Date_enrollement>
    <Target_size>72
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>New Zealand;Sweden;United Kingdom;New Zealand;Sweden;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Trial Manager at Intellia
    </Contact_Lastname>
    <Contact_Email>clinicalscience@intelliatx.com
    </Contact_Email>
    <Contact_Tel>1-833-888-0387
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. A subject has completed or discontinued from an Intellia-sponsored clinical study in&#x0D;&lt;br&gt;             which a complete or partial dose of NTLA-2001 was received.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. A subject has provided informed consent for the LTFU study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy;Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy;Wild-Type Transthyretin Cardiac Amyloidosis
    </Condition>
    <Primary_outcome>Incidence of Treatment-related SAEs and Protocol-specified AESIs
    </Primary_outcome>
    <Secondary_outcome>PD biomarkers for ATTR including serum TTR and serum prealbumin
    </Secondary_outcome>
    <Secondary_ID>2022-003405-30;ITL-2001-CL-999
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14022115
    </Internal_Number>
    <TrialID>DRKS00030545
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Tübingen registry for familial Mediterranean fever and other autoinflammatory diseases
    </Public_title>
    <Scientific_title>Tübingen registry for familial Mediterranean fever and other autoinflammatory diseases - TÜRF³                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Universitätsklinik Tübingen - Rheumatologie
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20221021
    </Date_registration3>
    <Date_registration>21/10/2022
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00030545
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>01/09/2019
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Jörg
    </Contact_Firstname>
    <Contact_Lastname>Henes
    </Contact_Lastname>
    <Contact_Address>Otfried-Müller-Strasse 10
    </Contact_Address>
    <Contact_Email>joerg.henes@med.uni-tuebingen.de
    </Contact_Email>
    <Contact_Tel>07071-2980681
    </Contact_Tel>
    <Contact_Affiliation>Universitätsklinik Tübingen - Rheumatologie
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Age &gt;/= 18 Jahre&lt;br&gt;autoinflammatory disease&lt;br&gt;informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: age &lt; 18y&lt;br&gt;missing consent
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;E85.0 &lt;br&gt;M35.8;Non-neuropathic heredofamilial amyloidosis;Other specified systemic involvement of connective tissue;E85.0;M35.8
    </Condition>
    <Intervention>Group 1: Observational study - 1 arm&lt;br&gt;Underlying autoinflammatory disease&lt;br&gt;Clinical manifestations&lt;br&gt;Origin&lt;br&gt;Ethnicity&lt;br&gt;Religious affiliation&lt;br&gt;Mutation status&lt;br&gt;Education level
    </Intervention>
    <Primary_outcome>Identification of clinical differences of subgroups, including questions of patient origin, familial clustering, and relevant other autoimmune diseases.
    </Primary_outcome>
    <Secondary_outcome>not applicable
    </Secondary_outcome>
    <Source_Support>Universitätsklinik Tübingen - Rheumatologie
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/08/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethik.kommission@med.uni-tuebingen.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission an der Medizinischen  Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-7071-2977661
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethik.kommission@med.uni-tuebingen.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00030545#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13805389
    </Internal_Number>
    <TrialID>NCT05311488
    </TrialID>
    <Last_Refreshed_on>18 March 2024
    </Last_Refreshed_on>
    <Public_title>Early Detection of Neuropathy in ATTRv
    </Public_title>
    <Scientific_title>Early Detection of Peripheral Neuropathy in Hereditary Transthyretin Amyloidosis
    </Scientific_title>
    <Acronym>EDONA
    </Acronym>
    <Primary_sponsor>University of Pennsylvania
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220316
    </Date_registration3>
    <Date_registration>16/03/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05311488
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 14, 2022
    </Date_enrollement>
    <Target_size>47
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Chafic Karam, MD;Brian Drachman;Sami Khella, MD;Janice Pieretti, MD
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>University of Pennsylvania;University of Pennsylvania;University of Pennsylvania;University of Pennsylvania
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age 30 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients with known TTR mutations and neuropathy, patients with TTR mutation and no&#x0D;&lt;br&gt;             symptoms within less than 10 years of typical onset of disease., or healthy persons&#x0D;&lt;br&gt;             without neuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with neuropathy other than TTR amyloid&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects with risk factors for neuropathy (diabetes, history of neuropathy in the&#x0D;&lt;br&gt;             family, neurotoxic drugs) or with neurological disorder associated with elevated NFL&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        The following distribution of age ranges will be considered when enrolling healthy&#x0D;&lt;br&gt;        participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  5 patients age 30-40&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  5 patients age 40-50&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  5 patients age 50-60&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  5 patients age 60-70&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        The following age limitations will be in place for asymptomatic TTR carriers. The idea is&#x0D;&lt;br&gt;        to select patients that are likely to develop evidence of disease within the next 10 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non V122I mutation&gt; or =30&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  V122I&gt; or = 55&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Amyloidosis, Transthyretin-Related
    </Condition>
    <Intervention>Diagnostic Test: neurofilament light chain;Diagnostic Test: In-vivo Meissner Corpuscle imaging;Diagnostic Test: Nerve conduction study
    </Intervention>
    <Primary_outcome>Change in Serum neurofilament light chain;Meissner corpuscles
    </Primary_outcome>
    <Secondary_outcome>Quantitative sensory testing;Neuropathy symptoms questionnaire;Neuropathy impairment score
    </Secondary_outcome>
    <Secondary_ID>849579
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Ionis Pharmaceuticals, Inc.;AstraZeneca
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11526327
    </Internal_Number>
    <TrialID>NCT05087953
    </TrialID>
    <Last_Refreshed_on>1 November 2021
    </Last_Refreshed_on>
    <Public_title>Autonomic Evaluation of Patients With Hereditary Amyloidotic Cardiomyopathy: Hereditary Amyloidotic Heart Disease
    </Public_title>
    <Scientific_title>Comparative Analysis of the Autonomic Profile Between Patients With Hereditary Amyloidotic Cardiomyopathy Caused by Transthyretin and Patients With Transthyretin Gene Mutation, Without Cardiomyopathy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Sao Paulo General Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211008
    </Date_registration3>
    <Date_registration>08/10/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05087953
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2022
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Bruno VK Bueno, MD
    </Contact_Lastname>
    <Contact_Email>vazkerges@gmail.com
    </Contact_Email>
    <Contact_Tel>+55(11)98187-7226
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  FAC group: patients with familial familial amyloidotic cardiomyopathy (FAC).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-FAC group: patients with transthyretin gene mutations who do not have FAC.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Control group: healthy, asymptomatic individuals without comorbidities and without&#x0D;&lt;br&gt;             transthyretin gene mutations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreement and signing the informed consent form.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Autonomic Nervous System Disease;Amyloid Neuropathies
    </Condition>
    <Intervention>Diagnostic Test: Head-Up Tilt table test;Diagnostic Test: Heart Rate Variability
    </Intervention>
    <Primary_outcome>Autonomic response profile of patients with FAC.
    </Primary_outcome>
    <Secondary_outcome>Correlation between dysautonomia and electrophysiological cardiac disturbances.;Correlation between dysautonomy and structural cardiac alterations.
    </Secondary_outcome>
    <Secondary_ID>SDC 5045/20/074
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Fleury
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13397707
    </Internal_Number>
    <TrialID>NCT05071300
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    </Public_title>
    <Scientific_title>An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210923
    </Date_registration3>
    <Date_registration>23/09/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05071300
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 4, 2022
    </Date_enrollement>
    <Target_size>140
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Argentina;Australia;Brazil;Canada;Cyprus;France;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;Argentina;Australia;Brazil;Canada;Cyprus;France;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ionis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email>IonisHATTRPNstudy@clinicaltrialmedia.com
    </Contact_Email>
    <Contact_Tel>(844) 483-0646
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Satisfactory completion of ION-682884-CS3 (NCT04136184) (Index Study) as judged by the&#x0D;&lt;br&gt;             Investigator and Sponsor, or diagnosis of hATTR-PN and satisfactory completion of&#x0D;&lt;br&gt;             either study ISIS 420915-CS101 or study 2018-P001436 (NCT03702829) (both are&#x0D;&lt;br&gt;             Investigator-Sponsored studies with inotersen - the unconjugated version of&#x0D;&lt;br&gt;             Eplontersen) as judged by the Investigator and Sponsor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Must have given written informed consent (signed and dated) and any authorizations&#x0D;&lt;br&gt;             required by local law and be able to comply with all study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Satisfy the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Females: must be non-pregnant and non-lactating and either:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                    -  Surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral&#x0D;&lt;br&gt;                       salpingectomy, bilateral oophorectomy);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                    -  Post-menopausal (defined as 12 months of spontaneous amenorrhea in females &gt;&#x0D;&lt;br&gt;                       55 years of age or, in females = 55 years, 12 months of spontaneous&#x0D;&lt;br&gt;                       amenorrhea without an alternative medical cause and follicle-stimulating&#x0D;&lt;br&gt;                       hormone (FSH) levels in the postmenopausal range for the laboratory&#x0D;&lt;br&gt;                       involved;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                    -  Abstinent*;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                    -  If engaged in sexual relations of child-bearing potential, agree to use&#x0D;&lt;br&gt;                       highly effective contraceptive methods from the time of signing the informed&#x0D;&lt;br&gt;                       consent form until at least 24 weeks after the last dose of Eplontersen and&#x0D;&lt;br&gt;                       agree to receive pregnancy tests per protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Males: Surgically sterile (i.e., bilateral orchidectomy) or abstinent*, if&#x0D;&lt;br&gt;                  engaged in sexual relations with a woman of child-bearing potential (WOCBP), the&#x0D;&lt;br&gt;                  participant or the participant's non-pregnant female partner must use a highly&#x0D;&lt;br&gt;                  effective contraceptive method from the time of signing the informed consent form&#x0D;&lt;br&gt;                  until at least 24 weeks after the last dose of Eplontersen. *Abstinence (i.e.,&#x0D;&lt;br&gt;                  refraining from heterosexual intercourse throughout the duration of study&#x0D;&lt;br&gt;                  participation) is only acceptable as true abstinence, i.e., when this is in line&#x0D;&lt;br&gt;                  with the preferred and usual lifestyle of the participant. Periodic abstinence&#x0D;&lt;br&gt;                  (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration&#x0D;&lt;br&gt;                  of abstinence for the duration of a trial and withdrawal are not acceptable&#x0D;&lt;br&gt;                  methods of contraception.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Willingness to adhere to vitamin A supplementation per protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. Have any new condition or worsening of existing condition that in the opinion of the&#x0D;&lt;br&gt;        Investigator or Sponsor would make the participant unsuitable for enrollment or could&#x0D;&lt;br&gt;        interfere with the participant taking part in or completing the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    </Condition>
    <Intervention>Drug: Eplontersen
    </Intervention>
    <Primary_outcome>Change From Baseline in Platelet Count;Number of Participants With Clinically Significant Changes From Baseline in Renal Function;Change From Baseline in Adverse Events;Change From Baseline in Number of Concomitant Medications Used;Number of Participants With Clinically Significant Changes From Baseline in Vital Signs;Change From Baseline in Body Weight;Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings;Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Tests;Number of Participants With Clinically Significant Changes From Baseline in Electrocardiogram (ECG) Parameters;Number of Participants With Clinically Significant Changes From Baseline in Thyroid Panel Tests;Number of Participants With Clinically Significant Changes From Baseline in Coagulation Tests;Number of Participants With Clinically Significant Changes From Baseline in Inflammatory Panel Tests;Number of Participants With Clinically Significant Changes From Baseline in Complement and Immunogenicity Tests
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in Neuropathy Impairment Score (NIS);Change From Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Questionnaire;Change From Baseline in Neuropathy Symptom and Change Score (NSC);Change From Baseline in Serum Transthyretin (TTR) Concentration;Change From Baseline in Physical Component Summary Score (PCS) of 36-Item Short Form Survey (SF-36);Change From Baseline in Polyneuropathy Disability Score (PND);Change From Baseline in Modified Body Mass Index (mBMI);Change From Baseline in Composite Autonomic Symptom Score-31 (COMPASS-31);Change From Baseline in 5 Level EQ-5D (EQ-5D-5L)
    </Secondary_outcome>
    <Secondary_ID>2021-001427-40;ION-682884-CS13
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>12903406
    </Internal_Number>
    <TrialID>ChiCTR2100050713
    </TrialID>
    <Last_Refreshed_on>20 March 2023
    </Last_Refreshed_on>
    <Public_title>Clinical study on the relationship between serum amyloid A and apolipoprotein A-I and the severity and prognosis of sepsis
    </Public_title>
    <Scientific_title>Clinical study on the relationship between serum amyloid A and apolipoprotein A-I and the severity and prognosis of sepsis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Northern Jiangsu People's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210903
    </Date_registration3>
    <Date_registration>2021-09-03
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=133094
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>90
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2021-09-20
    </Date_enrollement>
    <Target_size>control group:50;sepsis group:50;
    </Target_size>
    <Study_type>Observational study
    </Study_type>
    <Study_design>Factorial
    </Study_design>
    <Phase>0
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Yu Jiangquan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>98 Nantong Road West, Yangzhou, Jiangsu
    </Contact_Address>
    <Contact_Email>yujiangquan2021@163.com
    </Contact_Email>
    <Contact_Tel>+86 18051060659
    </Contact_Tel>
    <Contact_Affiliation>Northern Jiangsu People's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Adult patients (aged &gt;=18 years);&#x0D;&lt;br&gt;2. Meet sepsis 3 criteria: presence of infection, combined SOFA score &gt;= 2.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Sepsis occurred in the past 1 month;&#x0D;&lt;br&gt;2. Long-term use of lipid-lowering drugs;&#x0D;&lt;br&gt;3. Hyperlipidemia;&#x0D;&lt;br&gt;4. Patients who have received antibiotic therapy within 72 hours before admission;&#x0D;&lt;br&gt;5. Pregnancy;&#x0D;&lt;br&gt;6. Organ transplantation;&#x0D;&lt;br&gt;7. Liver cirrhosis;&#x0D;&lt;br&gt;8. Patients with blood diseases;&#x0D;&lt;br&gt;9. Chronic organ dysfunction;&#x0D;&lt;br&gt;10. Administration of tumor or immunosuppressive agents;&#x0D;&lt;br&gt;11. Patients with terminal disease;&#x0D;&lt;br&gt;12. Eliminate patients who were sedated with propofol during the course of the disease;&#x0D;&lt;br&gt;13. Eliminate patients who received parenteral nutrition during the course of the disease.
    </Exclusion_Criteria>
    <Condition>Sepsis
    </Condition>
    <Intervention>control group:No;sepsis group:No;
    </Intervention>
    <Primary_outcome>Apolipoprotein A1;serum amyloid A;
    </Primary_outcome>
    <Secondary_outcome>high density lipoprotein;C reactive protein;procalcitonin;
    </Secondary_outcome>
    <Source_Support>Jiangsu Province Young Medical Talent Project; Yangzhou Key Medical Talent Project
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/09/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>sbyyll2012@163.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>He Yanyan
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+86 514 87373694
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>sbyyll2012@163.com
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13833579
    </Internal_Number>
    <TrialID>JPRN-jRCTs031210288
    </TrialID>
    <Last_Refreshed_on>1 April 2024
    </Last_Refreshed_on>
    <Public_title>SD-BATON
    </Public_title>
    <Scientific_title>Stratification of Dementia with Biomarkers for Amyloid, Tau and other Neuropathological changes - SD-BATON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Nakamura Akinori
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210830
    </Date_registration3>
    <Date_registration>30/08/2021
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCTs031210288
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>Not applicable
    </Inclusion_agemin>
    <Inclusion_agemax>&lt;= 90age old
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>06/10/2021
    </Date_enrollement>
    <Target_size>450
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>single arm study, open(masking not used), uncontrolled control, single assignment, diagnostic purpose
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>Akinori
    </Contact_Firstname>
    <Contact_Lastname>Nakamura
    </Contact_Lastname>
    <Contact_Address>7-430 Morioka, Obu, Aichi, Japan
    </Contact_Address>
    <Contact_Email>nakamura@ncgg.go.jp
    </Contact_Email>
    <Contact_Tel>+81-562-46-2311
    </Contact_Tel>
    <Contact_Affiliation>National Center for Geriatrics and Gerontology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Cognitively unimpaired individuals:A person who has no complaint about memory, and those who have complaints but do not show obvious abnormalities in cognitive function tests.  Age is 20 to 90 years old, regardless of gender.&lt;br&gt;Patients: AD, MCI, DLB, FTLD, VaD, PSP, CBS, PPA, iNPH, elderly tauopathy, and other neurodegenerative diseases that cause dementia.  Age is up to 90 years (regardless of age limit and gender)&lt;br&gt;1) Written informed consent is obtained. If a subject's cognitive ability is considered to be declined to understand the consent, his/her family or legally acceptable representative must provide the written informed consent.&lt;br&gt;2) A subject with good general condition, who has no problem to perform all necessary examinations.&lt;br&gt;3) Community-dwelling individuals and outpatients of the hospitals which are involved in the project. Participants for the J-TRC and Nagoya University cohort clinical studies who meet the participation criteria for this study with reference to the test results already conducted.&lt;br&gt;4) Participants for the NCGG-SGS cohort who meet the participation criteria of this research with reference to the test results that have already been conducted.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Clinical history of brain tumors, traumatic brain injury, or progressive neurodegenerative disorders other than dementia. However, cerebrovascular dementia is not excluded. &lt;br&gt;2) Use of medications with antidepressants or antipsychotics. History of alcohol or other drug addiction. Any uncontrolled significant medical condition, abnormal thyroid function, vitamin B1 deficiency, or vitaminB12 deficiency. Use of therapeutic agents for dementia such as donepezil and galantamine does not affect the selection of subjects.&lt;br&gt;3) Significant deformity/disorders of the spine or hip joint that causes pain or discomfort during examinations. &lt;br&gt;4) Contraindications to MRI imaging such as, internal implants that operate electrically, magnetically or mechanically. E.g., cardiac pacemakers, internal nerve stimulators, bone growth stimulators, internal defibrillators, and cochlear implants.
    </Exclusion_Criteria>
    <Condition>Cognitively unimpaired individuals, MCI, Dementia (AD and non-AD, including DLB and FTLD)
    </Condition>
    <Intervention>Amyloid beta-PET, Tau-PET, FDG-PET, MRI, MEG, blood sampling, neuropsychological test, questionnaire
    </Intervention>
    <Primary_outcome>1) Relationships of A-T-N(Amyloid, Tau, Neurodegeneration) and other dementia-related biomarkers (imaging and blood-based biomarkers) with clinical symptoms.&lt;br&gt;2) Performances of the blood-based A-T-N and other biomarkers when corresponding imaging data (e.g. PET) are used as the standard of truth (SOT). Also, correlations between the blood-based and imaging biomarkers will be evaluated.
    </Primary_outcome>
    <Secondary_outcome>1) Using longitudinal observation data, factors (e.g. age, gender, cognitive function, lifestyle, risk factors, genome) that affect disease progression such as the Amyloid beta and tau accumulation, neurodegeneration, and cognitive decline will be quantitatively analyzed. Also, interactions of overlapping pathologies including, vascular lesions and DLB-related pathophysiological changes are analyzed.&lt;br&gt;2) An integrated stratification algorithm that can estimate the risk of dementia in asymptomatic individuals, and can predict a type of dementia and its progression, will be developed and validated.
    </Secondary_outcome>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>30/07/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>helsinki@qst.go.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>National Institutes for Quantum Science and  Technology Certified Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-43-206-4706
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>helsinki@qst.go.jp
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13369116
    </Internal_Number>
    <TrialID>NCT05023889
    </TrialID>
    <Last_Refreshed_on>26 September 2023
    </Last_Refreshed_on>
    <Public_title>Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
    </Public_title>
    <Scientific_title>Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Austin Neuromuscular Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210811
    </Date_registration3>
    <Date_registration>11/08/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05023889
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 3, 2022
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Early Phase 1
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Yessar Hussain, MD;Yessar M Hussain, M.D.
    </Contact_Lastname>
    <Contact_Email>yessar@austinneuromuscle.com;yessar@austinneuromuscle.com
    </Contact_Email>
    <Contact_Tel>5129200140;512-920-0140
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female &gt;18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Diagnosis of symptomatic polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. wtATTR based on cardiac biopsy or Tc99m PYP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Negative hATTR sequencing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. 0 to 0.5 gram/dl serum monoclonal protein.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. No history of other secondary causes of neuropathy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Have adequate complete blood counts and liver function tests&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other Causes of neuropathy as determined by the principle investigator.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Has known human immunodeficiency virus (HIV) infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Primary AL.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. NYHA Class IV at the Screening visit. 5. Has any of the following laboratory parameter&#x0D;&lt;br&gt;             assessments at screening:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Aspartate transaminase (AST) or alanine transaminase (ALT) levels ?2.0 × the&#x0D;&lt;br&gt;                  upper limit of normal (ULN).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Total bilirubin ?ULN. Patients with elevated total bilirubin that is secondary to&#x0D;&lt;br&gt;                  documented Gilbert's syndrome are eligible if total bilirubin &amp;lt;2 × ULN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. International normalized ratio (INR) ?1.5 (unless patient is on anticoagulant&#x0D;&lt;br&gt;                  therapy, in which case excluded if INR ?3.5).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  6. Has eGFR &lt; 30 mL/min/1.73 m2 (using the modification of diet in renal disease&#x0D;&lt;br&gt;                  [MDRD] formula). 7. Is currently taking diflunisal; if previously on this agent,&#x0D;&lt;br&gt;                  must have at least a 6-month wash-out prior to dosing (Day 1).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  8. Is currently taking doxycycline, or tauroursodeoxycholic acid; if previously&#x0D;&lt;br&gt;                  on any of these agents must have completed a 30-day wash-out prior to dosing (Day&#x0D;&lt;br&gt;                  1).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  9. Received prior TTR-lowering treatment or participated in a gene therapy trial&#x0D;&lt;br&gt;                  for amyloidosis. 10. Current or future participation in another investigational&#x0D;&lt;br&gt;                  device or drug study, Scheduled to occur during this study, or has received an&#x0D;&lt;br&gt;                  investigational agent or device within 30 days (or 5 half-lives of the&#x0D;&lt;br&gt;                  investigational drug, whichever is longer) prior to dosing (Day 1). In the case&#x0D;&lt;br&gt;                  of investigational TTR stabilizer drugs, washout for 6 months prior to dosing&#x0D;&lt;br&gt;                  (Day 1) is required; this does not apply to patients who are on tafamidis at&#x0D;&lt;br&gt;                  baseline (per inclusion Criterion 4).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  11. Requires treatment with calcium channel blockers (eg, verapamil, diltiazem)&#x0D;&lt;br&gt;                  or digitalis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  12. Other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due&#x0D;&lt;br&gt;                  to valvular heart disease, or cardiomyopathy due to ischemic heart disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  13. Has non-amyloid disease affecting exercise testing (eg, severe chronic&#x0D;&lt;br&gt;                  obstructive pulmonary disease, severe arthritis, or peripheral vascular disease&#x0D;&lt;br&gt;                  affecting ambulation).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  14. Had acute coronary syndrome or unstable angina within the past 3 months. 15.&#x0D;&lt;br&gt;                  Has history of sustained ventricular tachycardia or aborted ventricular&#x0D;&lt;br&gt;                  fibrillation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;                  16. Has persistent elevation of systolic (?180 mmHg) and diastolic (?100 mmHg)&#x0D;&lt;br&gt;                  blood pressure that is considered uncontrolled by physician.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        17-Has untreated hypo- or hyperthyroidism. 18-Prior or planned heart, liver, or other organ&#x0D;&lt;br&gt;        transplant. 19. Had a malignancy within 5 years, except for basal or squamous cell&#x0D;&lt;br&gt;        carcinoma of the skin or carcinoma in situ of the cervix that has been successfully&#x0D;&lt;br&gt;        treated.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        20. Has other medical conditions or comorbidities which, in the opinion of the Investigator&#x0D;&lt;br&gt;        would interfere with study compliance or data interpretation. 21. Female Is not willing to&#x0D;&lt;br&gt;        comply with the contraceptive requirements during the study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        22. History of illicit drug abuse within the past 5 years that in the opinion of the&#x0D;&lt;br&gt;        Investigator would interfere with compliance with study procedures or follow-up visits.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Polyneuropathies;Wild Type ATTR Amyloidosis;Wild-Type Transthyretin-Related (ATTR)Amyloidosis;Wild-Type Transthyretin Cardiac Amyloidosis;Transthyretin Amyloidosis
    </Condition>
    <Intervention>Drug: patisiran
    </Intervention>
    <Primary_outcome>Change in Neurological Impairment Score;Norfolk QOL-DN;COMPASS 31score
    </Primary_outcome>
    <Secondary_outcome>PND Polyneuropathy disability (PND) Score;Karnofsky, performance status score;EuroQOL;EMG -Electromyography;Tilt Table Test;Optional exploratory nerve and muscle biopsy
    </Secondary_outcome>
    <Secondary_ID>001 amendment 02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Alnylam Pharmaceuticals
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11172941
    </Internal_Number>
    <TrialID>NCT04963985
    </TrialID>
    <Last_Refreshed_on>21 July 2021
    </Last_Refreshed_on>
    <Public_title>The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients
    </Public_title>
    <Scientific_title>The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Peking University Third Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210627
    </Date_registration3>
    <Date_registration>27/06/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04963985
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2021
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Dongsheng Fan
    </Contact_Lastname>
    <Contact_Email>dsfan@sina.com
    </Contact_Email>
    <Contact_Tel>13701023871
    </Contact_Tel>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Participants are eligible to be included in the study only if all of the following criteria&#x0D;&lt;br&gt;        apply:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Age and Sex:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female participants between the ages of 18 and 80 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Type of Participant and Disease Characteristics:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Participants who are willing and able to comply with all scheduled visits, treatment&#x0D;&lt;br&gt;             plan, laboratory tests, lifestyle considerations and other study procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Participants have amyloid documented by biopsy in accordance with institutional site&#x0D;&lt;br&gt;             standard of care (Biopsy must have been performed within 5 years of enrollment).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Participants must have a TTR mutation that is associated with ATTR-PN. (See Section&#x0D;&lt;br&gt;             8.2.6.3 for further details).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participants have peripheral and/or autonomic neuropathy with a Karnofsky Performance&#x0D;&lt;br&gt;             Status =50 (refer to Appendix 5).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Stages of disease according to symptom severity-stage I.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Informed Consent:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Capable of giving signed informed consent as described in Appendix 1, which includes&#x0D;&lt;br&gt;             compliance with the requirements and restrictions listed in the informed consent&#x0D;&lt;br&gt;             document (ICD) and in this protocol.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Participants are excluded from the study if any of the following criteria apply:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Medical Conditions:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other acute or chronic medical or psychiatric condition including recent (within the&#x0D;&lt;br&gt;             past year) or active suicidal ideation or behavior or laboratory abnormality that may&#x0D;&lt;br&gt;             increase the risk associated with study participation or investigational product&#x0D;&lt;br&gt;             administration or may interfere with the interpretation of study results and, in the&#x0D;&lt;br&gt;             judgment of the investigator, would make the participant inappropriate for entry into&#x0D;&lt;br&gt;             this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Prior/Concomitant Therapy:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs),&#x0D;&lt;br&gt;             defined as greater than 3-4 times/month. The following NSAID are allowed:&#x0D;&lt;br&gt;             acetylsalicylic acid, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone,&#x0D;&lt;br&gt;             naproxen, nimesulide, piroxicam, and sulindac.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Use of diflunisal, tauroursodeoxycholate, doxycycline or a TTR stabilizing agent, or&#x0D;&lt;br&gt;             other experimental interventions for familial amyloidosis within 30 days prior to the&#x0D;&lt;br&gt;             study entry and/or during study participation. Participants who are taking or who have&#x0D;&lt;br&gt;             previously taken tafamidis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Previous administration with an investigational drug within 30 days or 5 half-lives&#x0D;&lt;br&gt;             preceding the first dose of investigational product used in this study (whichever is&#x0D;&lt;br&gt;             longer).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Diagnostic Assessments:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participant has primary (light chain) or secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. If female, participant is pregnant or breast feeding, or plans to be pregnant or&#x0D;&lt;br&gt;             breast feeding in the next 18 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Participant has received prior liver or any other organ except cornea transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Participant has no recordable sensory threshold for vibration perception in both feet,&#x0D;&lt;br&gt;             as measured by CASE IV or participant requires significant assistance with ambulation&#x0D;&lt;br&gt;             or is wheel chair bound.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Participants with positive results for hepatitis B surface antigen (HBsAg),&#x0D;&lt;br&gt;             anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Participant has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt;2 times upper limit of normal (ULN) that in the medical&#x0D;&lt;br&gt;             judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Participants with cardiomyopathy specific TTR mutations (Val122Ile, Leu111Met,&#x0D;&lt;br&gt;             Ile68Leu).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Participant has a co-morbidity anticipated to limit survival to less than 18 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Participant has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes&#x0D;&lt;br&gt;             Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse,&#x0D;&lt;br&gt;             Fabry disease, Lyme disease, sarcoidosis, Sjogren's Syndrome, Systemic Lupus&#x0D;&lt;br&gt;             Erythematosus, alcohol dependency, celiac disease, Chronic Inflammatory Demyelinating&#x0D;&lt;br&gt;             Polyneuropathy, and chronic inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Other Exclusions:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Investigator site staff members directly involved in the conduct of the study and&#x0D;&lt;br&gt;             their family members, site staff members otherwise supervised by the investigator, or&#x0D;&lt;br&gt;             Pfizer employees, including their family members, directly involved in the conduct of&#x0D;&lt;br&gt;             the study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin Amyloidosis
    </Condition>
    <Intervention>Drug: Tafamidis Pill
    </Intervention>
    <Primary_outcome>TTR stabilization compared with Baseline
    </Primary_outcome>
    <Secondary_outcome>TTR stabilization;TTR concentration;Neuropathy Impairment Score:NIS-LL (lower limb);TQOL score and 5 domains as measured by the Norfolk QOL - Diabetic Neuropathy (Norfolk QOL-DN);TQOL score and 5 domains asmeasured by the Norfolk;"S7 NTs NDS" as measured by nerve conduction studies (NCS), vibration detection threshold (VDT) and heart rate response to deep breathing (HRDB).;Modified Body Mass Index (mBMI).;36-item survey form (SF-36).;EQ-5D-5L Index Score.
    </Secondary_outcome>
    <Secondary_ID>M2020466
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13432493
    </Internal_Number>
    <TrialID>JPRN-jRCTs031210156
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Efficacy of Cholestimide in ATTRv Amyloidosis
    </Public_title>
    <Scientific_title>Evaluation of Efficacy and Safety of Cholestimide for Diarrhea in Patients with ATTRv Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Yoshiki Sekijima
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210621
    </Date_registration3>
    <Date_registration>21/06/2021
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCTs031210156
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 20age old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>21/06/2021
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>single arm study, open(masking not used), uncontrolled control, parallel assignment, treatment purpose
    </Study_design>
    <Phase>3
    </Phase>
    <Contact_Firstname>Mochizuki
    </Contact_Firstname>
    <Contact_Lastname>Yusuke
    </Contact_Lastname>
    <Contact_Address>3-1-1 Asahi, Matsumoto-shi, Nagano-ken, 390-8621, Japan
    </Contact_Address>
    <Contact_Email>sannai@shinshu-u.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-263372673
    </Contact_Tel>
    <Contact_Affiliation>Shinshu university department of medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Patients aged 20 years or older with a diagnosis of ATTRv amyloidosis&lt;br&gt;2) Patients with diarrhea symptoms that are difficult to control with existing symptomatic medications for diarrhea (Bristol Stool Shape Scale 6 or higher)&lt;br&gt;3) Patients who are able to comply with their medication and keep an appropriate diary.&lt;br&gt;4) Patients who have given written consent based on the free will of the subject after receiving sufficient explanation for participation in this study.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients who do not meet any of the following exclusion criteria will be included.&lt;br&gt;(1) Patients for whom consent cannot be obtained&lt;br&gt;(2) Patients who have contraindications to the use of the study drug (patients with complete obstruction of the biliary tract, patients with intestinal obstruction, patients with a history of hypersensitivity to the components of Corevine Tablets 500 mg).&lt;br&gt;(3) Other patients who are judged by the principal investigator to be unsuitable as subjects.
    </Exclusion_Criteria>
    <Condition>ATTR variant amyloidosis &lt;br&gt;amyloidosis, transthyretin;Amyloid Neuropathies, Familial;amyloidosis, transthyretin
    </Condition>
    <Intervention>At the time of diarrhea, cholestimide 500 mg given orally, three tablets twice daily before breakfast and dinner.The maximum daily dosage is 6 tablets, and the interval between doses should be at least 2 hours.
    </Intervention>
    <Primary_outcome>Change in the frequency of diarrhea before and after treatment
    </Primary_outcome>
    <Secondary_outcome>Changes in the following items before and after treatment.&lt;br&gt;&lt;br&gt;1 Bristol Stool Form Scale&lt;br&gt;2 primary symptoms&lt;br&gt;3 Blood concentration of 7a-hydroxy-4-cholesten-3-one(C4)&lt;br&gt;4 mBMI&lt;br&gt;5 EQ-5D-5L
    </Secondary_outcome>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>md_rinri@shinshu-u.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Shinshu University Certified Review Board of Clinical Research
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-263-37-2572
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>md_rinri@shinshu-u.ac.jp
    </Ethics_review_contact_email>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>31/03/2023
    </results_date_posted>
    <results_date_completed>16/01/2023
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11131374
    </Internal_Number>
    <TrialID>EUCTR2021-000037-14-ES
    </TrialID>
    <Last_Refreshed_on>5 July 2021
    </Last_Refreshed_on>
    <Public_title>A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
    </Public_title>
    <Scientific_title>A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Prothena Biosciences Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210609
    </Date_registration3>
    <Date_registration>09/06/2021
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000037-14
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>01/07/2021
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Portugal;United States;Czechia;Taiwan;Greece;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Brazil;Australia;Denmark;Netherlands;Germany;Korea, Republic of
    </Countries>
    <Contact_Firstname>Regulatory Affairs
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>77 Sir John Rogerson’s Quay, Block C
    </Contact_Address>
    <Contact_Email>regaffairs@prothena.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Prothena Biosciences Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Aged =18 years&lt;br&gt;2.Newly diagnosed and AL amyloidosis treatment naive&lt;br&gt;3.Bone marrow demonstrating clonal plasma cells&lt;br&gt;4.Confirmed diagnosis of AL amyloidosis by the following:&lt;br&gt;-Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance &lt;br&gt;AND&lt;br&gt;-Confirmatory immunohistochemistry OR mass spectroscopy of AL amyloidosis&lt;br&gt;5.Confirmed diagnosis of AL amyloidosis by mass spectrometry or immunoelectron microscopy of amyloid material in tissue biopsy if the subject meets any of the following:&lt;br&gt;-Is black or African American&lt;br&gt;-Is over 75 years of age with concurrent monoclonal gammopathy&lt;br&gt;-Has a history of familial amyloidosis and has concurrent monoclonal gammopathy&lt;br&gt;OR&lt;br&gt;-If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc DPD), hydroxymethylenediphosphonate (99mTc HMDP), or pyrophosphate (99mTc PYP) scintigraphy&lt;br&gt;6.Cardiac involvement as defined by all of the following:&lt;br&gt;-Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure&lt;br&gt;-Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole &gt;12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening &lt;br&gt;7.Confirmed Mayo Stage IV as defined by:&lt;br&gt;-NT-proBNP =1800 pg/mL and &lt;br&gt;-Troponin-T &gt;0.03 ng/mL and&lt;br&gt;-dFLC =18 mg/dL&lt;br&gt;8.Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly&lt;br&gt;9.Adequate bone marrow reserve, hepatic function, and renal function, as demonstrated by:&lt;br&gt;-Absolute neutrophil count =1.0 × 10e9/L&lt;br&gt;-Platelet count =75 × 10e9/L&lt;br&gt;-Hemoglobin =9 g/dL&lt;br&gt;-Total bilirubin = 2 × the upper limit of normal (ULN)&lt;br&gt;-Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase =3 × ULN &lt;br&gt;-Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase =3 × ULN&lt;br&gt;-Alkaline phosphatase (ALP) =5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)&lt;br&gt;-Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration equation &lt;br&gt;10.Seated systolic blood pressure (BP) 90 to 180 mmHg&lt;br&gt;11.Distance walked during each Screening 6MWT is &gt;30 meters and &lt;550 meters&lt;br&gt;12.Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug, and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration &lt;br&gt;13.Male subjects must be surgically sterile or must agree to use highly effective physician approved contraception from Screening to 90 days following the last study drug administration&lt;br&gt;14.Ability to understand and willingness to sign an informed consent form prior to i
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Non-AL amyloidosis&lt;br&gt;2.NT-proBNP &gt;8500 pg/mL&lt;br&gt;3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma &lt;br&gt;*Note that subjects who meet the IMWG definition of symptomatic multiple myeloma with signs and/or symptoms attributable only to associated amyloidosis are potentially eligible upon approval of the Sponsor.&lt;br&gt;4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study&lt;br&gt;5.Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with the subject’s ability to safely receive treatment or complete study assessments&lt;br&gt;6.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&lt;br&gt;7.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area &lt;1.0 cm2) or severe congenital heart disease&lt;br&gt;8.ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:&lt;br&gt;-First degree AV-block&lt;br&gt;-Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)&lt;br&gt;-Right or left bundle branch block&lt;br&gt;-Atrial fibrillation with a controlled ventricular rate (uncontrolled [&gt;110 bpm] ventricular rate is not allowed [determined by an average of 3 beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG])&lt;br&gt;9.Peripheral neuropathy assessed as National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 2 with pain, Grade 3, or Grade 4&lt;br&gt;10.Subject is receiving oral or intravenous antibiotics, antifungals, or antivirals within 1 week of Month 1-Day 1 with the exception of prophylactic oral agents&lt;br&gt;11.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1&lt;br&gt;12.Prior radiotherapy within 4 weeks of Month 1-Day 1&lt;br&gt;13.Major surgery within 4 weeks of Month 1-Day 1 or planned major surgery during the study&lt;br&gt;14.Active malignancy with the exception of any of the following:&lt;br&gt;-Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer&lt;br&gt;-Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for 2 years&lt;br&gt;-Low-risk prostate cancer with Gleason score &lt;7 and prostate specific antigen &lt;10 ng/mL&lt;br&gt;-Any other cancer from which the subject has been disease-free for =2 years&lt;br&gt;15.History of severe allergy to any of the components of birtamimab such as histidine/L histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 or history of Grade =3 infusion-related AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine (or an equivalent H1 antihistamine) or acetaminophen (or its equivalent, paracetamol)&lt;br&gt;16.Known or history of uncontrolled, active HIV, hepatitis B or hepatitis C, or SARS-CoV-2 infection&lt;br&gt;17.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11 1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid&lt;br&gt;18.Treatment with another investigational agent within 30 days of Month 1-Day 1&lt;br&gt;19.Women who are pregnant or lactating&lt;br&gt;20.Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject’s risk by participating in the study&lt;br&gt;21.Subjec
    </Exclusion_Criteria>
    <Condition>AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded  immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossia &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10036673
Term: Primary amyloidosis
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Birtamimab&lt;br&gt;Product Code: Birtamimab&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: BIRTAMIMAB&lt;br&gt;CAS Number: 1608108-91-3&lt;br&gt;Current Sponsor code: birtamimab&lt;br&gt;Other descriptive name: Humanized IgG1 kappa antiamyloid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care when administered intravenously in Mayo Stage IV subjects with AL amyloidosis by assessing time to all-cause mortality.;Secondary Objective: To evaluate birtamimab plus standard of care compared to placebo plus standard of care on the following:&lt;br&gt;• Change from baseline to Month 9 in health-related quality of life using the Short Form-36 questionnaire Version 2 (SF-36v2)&lt;br&gt;• Change from baseline to Month 9 in the 6-Minute Walk Test (6MWT) distance;Primary end point(s): Time to all-cause mortality;Timepoint(s) of evaluation of this end point: -Interim Efficacy Analysis will be conducted when approximately 50% (or 24) of the events have occurred&lt;br&gt;-Primary Analysis - for all-cause mortality, all deaths occurring after the first infusion of study drug (i.e., Study Day 1) through the study’s last subject last visit will be included.
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): •Change from baseline to Month 9 in the Physical Component Summary (PCS) score of the SF-36v2&lt;br&gt;•Change from baseline to Month 9 in the 6MWT distance (meters);Timepoint(s) of evaluation of this end point: from baseline until Month 9
    </Secondary_outcome>
    <Secondary_ID>NEOD001-301;146070
    </Secondary_ID>
    <Source_Support>Prothena Biosciences Limited
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>28/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13701130
    </Internal_Number>
    <TrialID>EUCTR2021-000037-14-PL
    </TrialID>
    <Last_Refreshed_on>19 February 2024
    </Last_Refreshed_on>
    <Public_title>English: A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis


    </Public_title>
    <Scientific_title>English: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Prothena Biosciences Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210602
    </Date_registration3>
    <Date_registration>02/06/2021
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000037-14
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>20/08/2021
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2 
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Hungary;United States;Czechia;Japan;United Kingdom;Portugal;Spain;Greece;Canada;Austria;Netherlands;Belgium;Ireland;Taiwan;Poland;Korea, Republic of;Denmark;Italy;Israel;Australia;France;Türkiye;Germany
    </Countries>
    <Contact_Firstname>Regulatory Affairs
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>77 Sir John Rogerson’s Quay, Block C
    </Contact_Address>
    <Contact_Email>regaffairs@prothena.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Prothena Biosciences Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Aged =18 years and legal age of consent according to local regulations&lt;br&gt;2.Newly diagnosed and AL amyloidosis treatment naive with cardiac involvement&lt;br&gt;3.Confirmed diagnosis of AL amyloidosis &lt;br&gt;4. Confirmed Mayo Stage IV AL Amyloidosis as defined by NT -proBNP = 1800 pq/mL and Troponin-T =0.025 ng/mL (mcg/L) or high sensitivity cardiac troponin T = 40ng/L and  dFLC =18mg/dL&lt;br&gt;5. Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly&lt;br&gt;A comprehensive list of inclusion criteria can be found in protocol.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 75&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 75&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Non-AL amyloidosis&lt;br&gt;2.NT-proBNP &gt;8500 pg/mL&lt;br&gt;3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma, except for malignancy biomarker of involved/and uninvolved serum free light chain ratio =100&lt;br&gt;4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study&lt;br&gt;5.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&lt;br&gt;6.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area &lt;1.0 cm2) or severe congenital heart disease&lt;br&gt;7.ECG evidence of acute ischemia or active conduction system abnormalities &lt;br&gt;8.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1&lt;br&gt;9.Prior radiotherapy within 4 weeks of Month 1-Day 1&lt;br&gt;10.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11 1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid&lt;br&gt;11.Waldenström's macroglobulinemia and/or immunoglobulin M monoclonal gammopathy&lt;br&gt; A comprehensive list of exclusion criteria can be found in protocol.&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded  immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossia &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10036673
Term: Primary amyloidosis
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Birtamimab&lt;br&gt;Product Code: Birtamimab&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: BIRTAMIMAB&lt;br&gt;CAS Number: 1608108-91-3&lt;br&gt;Current Sponsor code: birtamimab&lt;br&gt;Other descriptive name: Humanized IgG1 kappa antiamyloid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care when administered intravenously in Mayo Stage IV subjects with AL amyloidosis by assessing time to all-cause mortality.;Secondary Objective: To evaluate birtamimab plus standard of care compared to placebo plus standard of care on the following:&lt;br&gt;• Change from baseline to Month 9 in the 6-Minute Walk Test (6MWT) distance&lt;br&gt;• Change from baseline to Month 9 in health related quality of life using the Short Form-36 questionnaire Version 2 (SF-36v2);Primary end point(s): Time to all-cause mortality;Timepoint(s) of evaluation of this end point: Time from the first dose of study drug until death or end of study over 9 months&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): •Change from baseline to Month 9 in the 6MWT distance (meters)&lt;br&gt;•Change from baseline to Month 9 in the Physical Component Summary (PCS) score of the SF-36v2&lt;br&gt;;Timepoint(s) of evaluation of this end point: from baseline until Month 9
    </Secondary_outcome>
    <Secondary_ID>NEOD001301;NCT04973137;146070;2021-000037-14-DK
    </Secondary_ID>
    <Source_Support>Prothena Biosciences Limited
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>17/06/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11471017
    </Internal_Number>
    <TrialID>EUCTR2021-000037-14-PT
    </TrialID>
    <Last_Refreshed_on>8 October 2021
    </Last_Refreshed_on>
    <Public_title>A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
    </Public_title>
    <Scientific_title>A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Prothena Biosciences Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210528
    </Date_registration3>
    <Date_registration>28/05/2021
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000037-14
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>10/09/2021
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Portugal;United States;Czechia;Taiwan;Greece;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Brazil;Australia;Denmark;Netherlands;Germany;Korea, Republic of
    </Countries>
    <Contact_Firstname>Regulatory Affairs
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>77 Sir John Rogerson’s Quay, Block C
    </Contact_Address>
    <Contact_Email>regaffairs@prothena.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Prothena Biosciences Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Aged =18 years&#x0D;&lt;br&gt;2.Newly diagnosed and AL amyloidosis treatment naive&#x0D;&lt;br&gt;3.Bone marrow demonstrating clonal plasma cells&#x0D;&lt;br&gt;4.Confirmed diagnosis of AL amyloidosis by the following:&#x0D;&lt;br&gt;-Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance &#x0D;&lt;br&gt;AND&#x0D;&lt;br&gt;-Confirmatory immunohistochemistry OR mass spectroscopy of AL amyloidosis&#x0D;&lt;br&gt;5.Confirmed diagnosis of AL amyloidosis by mass spectrometry or immunoelectron microscopy of amyloid material in tissue biopsy if the subject meets any of the following:&#x0D;&lt;br&gt;-Is black or African American&#x0D;&lt;br&gt;-Is over 75 years of age with concurrent monoclonal gammopathy&#x0D;&lt;br&gt;-Has a history of familial amyloidosis and has concurrent monoclonal gammopathy&#x0D;&lt;br&gt;OR&#x0D;&lt;br&gt;-If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc DPD), hydroxymethylenediphosphonate (99mTc HMDP), or pyrophosphate (99mTc PYP) scintigraphy&#x0D;&lt;br&gt;6.Cardiac involvement as defined by all of the following:&#x0D;&lt;br&gt;-Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure&#x0D;&lt;br&gt;-Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole &gt;12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening &#x0D;&lt;br&gt;7.Confirmed Mayo Stage IV as defined by:&#x0D;&lt;br&gt;-NT-proBNP =1800 pg/mL and &#x0D;&lt;br&gt;-Troponin-T &gt;0.03 ng/mL and&#x0D;&lt;br&gt;-dFLC =18 mg/dL&#x0D;&lt;br&gt;8.Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly&#x0D;&lt;br&gt;9.Adequate bone marrow reserve, hepatic function, and renal function, as demonstrated by:&#x0D;&lt;br&gt;-Absolute neutrophil count =1.0 × 10e9/L&#x0D;&lt;br&gt;-Platelet count =75 × 10e9/L&#x0D;&lt;br&gt;-Hemoglobin =9 g/dL&#x0D;&lt;br&gt;-Total bilirubin = 2 × the upper limit of normal (ULN)&#x0D;&lt;br&gt;-Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase =3 × ULN &#x0D;&lt;br&gt;-Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase =3 × ULN&#x0D;&lt;br&gt;-Alkaline phosphatase (ALP) =5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)&#x0D;&lt;br&gt;-Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration equation &#x0D;&lt;br&gt;10.Seated systolic blood pressure (BP) 90 to 180 mmHg&#x0D;&lt;br&gt;11.Distance walked during each Screening 6MWT is &gt;30 meters and &lt;550 meters&#x0D;&lt;br&gt;12.Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug, and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration &#x0D;&lt;br&gt;13.Male subjects must be surgically sterile or must agree to use highly effective physician approved contraception from Screening to 90 days following the last study drug administration&#x0D;&lt;br&gt;14.Ability to understand and willingness to sign a
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Non-AL amyloidosis&#x0D;&lt;br&gt;2.NT-proBNP &gt;8500 pg/mL&#x0D;&lt;br&gt;3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma &#x0D;&lt;br&gt;*Note that subjects who meet the IMWG definition of symptomatic multiple myeloma with signs and/or symptoms attributable only to associated amyloidosis are potentially eligible upon approval of the Sponsor.&#x0D;&lt;br&gt;4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study&#x0D;&lt;br&gt;5.Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with the subject’s ability to safely receive treatment or complete study assessments&#x0D;&lt;br&gt;6.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&#x0D;&lt;br&gt;7.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area &lt;1.0 cm2) or severe congenital heart disease&#x0D;&lt;br&gt;8.ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:&#x0D;&lt;br&gt;-First degree AV-block&#x0D;&lt;br&gt;-Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)&#x0D;&lt;br&gt;-Right or left bundle branch block&#x0D;&lt;br&gt;-Atrial fibrillation with a controlled ventricular rate (uncontrolled [&gt;110 bpm] ventricular rate is not allowed [determined by an average of 3 beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG])&#x0D;&lt;br&gt;9.Peripheral neuropathy assessed as National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 2 with pain, Grade 3, or Grade 4&#x0D;&lt;br&gt;10.Subject is receiving oral or intravenous antibiotics, antifungals, or antivirals within 1 week of Month 1-Day 1 with the exception of prophylactic oral agents&#x0D;&lt;br&gt;11.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1&#x0D;&lt;br&gt;12.Prior radiotherapy within 4 weeks of Month 1-Day 1&#x0D;&lt;br&gt;13.Major surgery within 4 weeks of Month 1-Day 1 or planned major surgery during the study&#x0D;&lt;br&gt;14.Active malignancy with the exception of any of the following:&#x0D;&lt;br&gt;-Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer&#x0D;&lt;br&gt;-Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for 2 years&#x0D;&lt;br&gt;-Low-risk prostate cancer with Gleason score &lt;7 and prostate specific antigen &lt;10 ng/mL&#x0D;&lt;br&gt;-Any other cancer from which the subject has been disease-free for =2 years&#x0D;&lt;br&gt;15.History of severe allergy to any of the components of birtamimab such as histidine/L histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 or history of Grade =3 infusion-related AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine (or an equivalent H1 antihistamine) or acetaminophen (or its equivalent, paracetamol)&#x0D;&lt;br&gt;16.Known or history of uncontrolled, active HIV, hepatitis B or hepatitis C, or SARS-CoV-2 infection&#x0D;&lt;br&gt;17.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11 1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid&#x0D;&lt;br&gt;18.Treatment with another investigational agent within 30 days of Month 1-Day 1&#x0D;&lt;br&gt;19.Women who are pregnant or lactating&#x0D;&lt;br&gt;20.Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject’s risk by particip
    </Exclusion_Criteria>
    <Condition>AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded  immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossia &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10036673
Term: Primary amyloidosis
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Birtamimab&lt;br&gt;Product Code: Birtamimab&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: BIRTAMIMAB&lt;br&gt;CAS Number: 1608108-91-3&lt;br&gt;Current Sponsor code: birtamimab&lt;br&gt;Other descriptive name: Humanized IgG1 kappa antiamyloid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care when administered intravenously in Mayo Stage IV subjects with AL amyloidosis by assessing time to all-cause mortality.;Primary end point(s): Time to all-cause mortality;Secondary Objective: To evaluate birtamimab plus standard of care compared to placebo plus standard of care on the following:&lt;br&gt;• Change from baseline to Month 9 in health-related quality of life using the Short Form-36 questionnaire Version 2 (SF-36v2)&lt;br&gt;• Change from baseline to Month 9 in the 6-Minute Walk Test (6MWT) distance;Timepoint(s) of evaluation of this end point: -Interim Efficacy Analysis will be conducted when approximately 50% (or 24) of the events have occurred&lt;br&gt;-Primary Analysis - for all-cause mortality, all deaths occurring after the first infusion of study drug (i.e., Study Day 1) through the study’s last subject last visit will be included.&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): •Change from baseline to Month 9 in the Physical Component Summary (PCS) score of the SF-36v2&#x0D;&lt;br&gt;•Change from baseline to Month 9 in the 6MWT distance (meters)&#x0D;&lt;br&gt;;Timepoint(s) of evaluation of this end point: from baseline until Month 9
    </Secondary_outcome>
    <Secondary_ID>146070;2021-000037-14-DK;NEOD001-301
    </Secondary_ID>
    <Source_Support>Prothena Biosciences Limited
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/09/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11313308
    </Internal_Number>
    <TrialID>EUCTR2018-002548-10-IT
    </TrialID>
    <Last_Refreshed_on>30 August 2021
    </Last_Refreshed_on>
    <Public_title>PET/MRI study of amyloid burden in patients with Cerebral Amyloid Angiopathy-related inflammation
    </Public_title>
    <Scientific_title>PET/MRI study of amyloid burden in patients with Cerebral Amyloid Angiopathy-related inflammation - CAA AMY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>OSPEDALE SAN RAFFAELE
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210524
    </Date_registration3>
    <Date_registration>24/05/2021
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002548-10
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: no&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>10/10/2019
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: no
Number of treatment arms in the trial: 1

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>Unità operativa di Medicina Nuclear
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Via Olgettina, 60
    </Contact_Address>
    <Contact_Email>incerti.elena@hsr.it
    </Contact_Email>
    <Contact_Tel>0226432717
    </Contact_Tel>
    <Contact_Affiliation>IRCCS Ospedale San Raffaele
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;male patients; diagnosis of CAA-RI; age&gt;55 years.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 3&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 7&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Evidence of focal cerebral, physical, psychiatric or metabolic disorders that may otherwise account for the cognitive disturbances; patients with hepatic or renal insufficiency; hypersensitivity to the active substance or to any of the following excipients: ascorbic acid, ethanol anhydrous, macrogol 400, sodium ascorbate, water for injections; wearers of pacemakers, clips or metal prostheses; contraindications to PET and MRI.&lt;br&gt;This medicine contains up to 1.5 mmol sodium (ie 33 mg) per dose. This must be taken into consideration in patients on a low sodium diet.&lt;br&gt;This medicine contains 15% by volume of ethanol (alcohol), that is up to 1.2 g per dose equivalent to 30 mL of beer or 12.5 mL of wine. This can be dangerous for those suffering from alcoholism, and must also be taken into consideration in high-risk groups such as patients with liver disease or epilepsy.&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>cerebral amyloid angiopathy related inflammation (CAA-ri) &lt;br&gt;MedDRA version: 21.1
Level: PT
Classification code 10068044
Term: Cerebral amyloid angiopathy
System Organ Class: 10029205 - Nervous system disorders
 &lt;br&gt;MedDRA version: 21.1
Level: PT
Classification code 10068044
Term: Cerebral amyloid angiopathy
System Organ Class: 10029205 - Nervous system disorders
;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
    </Condition>
    <Intervention>&lt;br&gt;Trade Name: Neuraceq 300MBQ/ML SOLUZIONE INIETTABILE USO ENDOVENOSO FLACONCINO (VETRO) – 1 FLACONCINO MONODOSE&lt;br&gt;Product Name: Neuraceq&lt;br&gt;Product Code: [18FFlorbetaben]&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;CAS Number: 902143-01-5&lt;br&gt;Current Sponsor code: [18F]Florbetaben&lt;br&gt;Other descriptive name: [18F]Florbetaben&lt;br&gt;Concentration unit: MBq megabecquerel(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 300-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: to characterize the pattern of amyloid burden in patients with cerebral amyloid angiopathy- related inflammation;Secondary Objective: to define presence and severity of cerebrovascular damage in patients with cerebral amyloid angiopathy- related inflammation; to correlate data obtained from the amyloid-PET exam with specific parameters of cerebrovascular damage;Primary end point(s): use of [18F]Florbetaben radiotracer as a biomaker to be used in the clinical field, in combination with PET, in CAA-RI;Timepoint(s) of evaluation of this end point: end of study
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): correlation with cerebrovascular damage for diagnostic purposes;Timepoint(s) of evaluation of this end point: end of study
    </Secondary_outcome>
    <Secondary_ID>CAAAMY
    </Secondary_ID>
    <Source_Support>Unità Operativa di Medicina Nucleare, IRCCS Ospedale San Raffaele
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>10/10/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11174259
    </Internal_Number>
    <TrialID>EUCTR2021-000037-14-HU
    </TrialID>
    <Last_Refreshed_on>21 July 2021
    </Last_Refreshed_on>
    <Public_title>A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
    </Public_title>
    <Scientific_title>A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Prothena Biosciences Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210520
    </Date_registration3>
    <Date_registration>20/05/2021
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000037-14
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>08/07/2021
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Portugal;United States;Czechia;Taiwan;Greece;Spain;Turkey;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Brazil;Australia;Denmark;Netherlands;Germany;Korea, Republic of
    </Countries>
    <Contact_Firstname>Regulatory Affairs
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>77 Sir John Rogerson’s Quay, Block C
    </Contact_Address>
    <Contact_Email>regaffairs@prothena.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Prothena Biosciences Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Aged =18 years&#x0D;&lt;br&gt;2.Newly diagnosed and AL amyloidosis treatment naive&#x0D;&lt;br&gt;3.Bone marrow demonstrating clonal plasma cells&#x0D;&lt;br&gt;4.Confirmed diagnosis of AL amyloidosis by the following:&#x0D;&lt;br&gt;-Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance &#x0D;&lt;br&gt;AND&#x0D;&lt;br&gt;-Confirmatory immunohistochemistry OR mass spectroscopy of AL amyloidosis&#x0D;&lt;br&gt;5.Confirmed diagnosis of AL amyloidosis by mass spectrometry or immunoelectron microscopy of amyloid material in tissue biopsy if the subject meets any of the following:&#x0D;&lt;br&gt;-Is black or African American&#x0D;&lt;br&gt;-Is over 75 years of age with concurrent monoclonal gammopathy&#x0D;&lt;br&gt;-Has a history of familial amyloidosis and has concurrent monoclonal gammopathy&#x0D;&lt;br&gt;OR&#x0D;&lt;br&gt;-If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc DPD), hydroxymethylenediphosphonate (99mTc HMDP), or pyrophosphate (99mTc PYP) scintigraphy&#x0D;&lt;br&gt;6.Cardiac involvement as defined by all of the following:&#x0D;&lt;br&gt;-Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure&#x0D;&lt;br&gt;-Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole &gt;12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening &#x0D;&lt;br&gt;7.Confirmed Mayo Stage IV as defined by:&#x0D;&lt;br&gt;-NT-proBNP =1800 pg/mL and &#x0D;&lt;br&gt;-Troponin-T &gt;0.03 ng/mL and&#x0D;&lt;br&gt;-dFLC =18 mg/dL&#x0D;&lt;br&gt;8.Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly&#x0D;&lt;br&gt;9.Adequate bone marrow reserve, hepatic function, and renal function, as demonstrated by:&#x0D;&lt;br&gt;-Absolute neutrophil count =1.0 × 10e9/L&#x0D;&lt;br&gt;-Platelet count =75 × 10e9/L&#x0D;&lt;br&gt;-Hemoglobin =9 g/dL&#x0D;&lt;br&gt;-Total bilirubin = 2 × the upper limit of normal (ULN)&#x0D;&lt;br&gt;-Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase =3 × ULN &#x0D;&lt;br&gt;-Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase =3 × ULN&#x0D;&lt;br&gt;-Alkaline phosphatase (ALP) =5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)&#x0D;&lt;br&gt;-Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration equation &#x0D;&lt;br&gt;10.Seated systolic blood pressure (BP) 90 to 180 mmHg&#x0D;&lt;br&gt;11.Distance walked during each Screening 6MWT is &gt;30 meters and &lt;550 meters&#x0D;&lt;br&gt;12.Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug, and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration &#x0D;&lt;br&gt;13.Male subjects must be surgically sterile or must agree to use highly effective physician approved contraception from Screening to 90 days following the last study drug administration&#x0D;&lt;br&gt;14.Ability to understand and willingness to sign a
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Non-AL amyloidosis&#x0D;&lt;br&gt;2.NT-proBNP &gt;8500 pg/mL&#x0D;&lt;br&gt;3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma &#x0D;&lt;br&gt;*Note that subjects who meet the IMWG definition of symptomatic multiple myeloma with signs and/or symptoms attributable only to associated amyloidosis are potentially eligible upon approval of the Sponsor.&#x0D;&lt;br&gt;4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study&#x0D;&lt;br&gt;5.Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with the subject’s ability to safely receive treatment or complete study assessments&#x0D;&lt;br&gt;6.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&#x0D;&lt;br&gt;7.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area &lt;1.0 cm2) or severe congenital heart disease&#x0D;&lt;br&gt;8.ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:&#x0D;&lt;br&gt;-First degree AV-block&#x0D;&lt;br&gt;-Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)&#x0D;&lt;br&gt;-Right or left bundle branch block&#x0D;&lt;br&gt;-Atrial fibrillation with a controlled ventricular rate (uncontrolled [&gt;110 bpm] ventricular rate is not allowed [determined by an average of 3 beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG])&#x0D;&lt;br&gt;9.Peripheral neuropathy assessed as National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 2 with pain, Grade 3, or Grade 4&#x0D;&lt;br&gt;10.Subject is receiving oral or intravenous antibiotics, antifungals, or antivirals within 1 week of Month 1-Day 1 with the exception of prophylactic oral agents&#x0D;&lt;br&gt;11.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1&#x0D;&lt;br&gt;12.Prior radiotherapy within 4 weeks of Month 1-Day 1&#x0D;&lt;br&gt;13.Major surgery within 4 weeks of Month 1-Day 1 or planned major surgery during the study&#x0D;&lt;br&gt;14.Active malignancy with the exception of any of the following:&#x0D;&lt;br&gt;-Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer&#x0D;&lt;br&gt;-Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for 2 years&#x0D;&lt;br&gt;-Low-risk prostate cancer with Gleason score &lt;7 and prostate specific antigen &lt;10 ng/mL&#x0D;&lt;br&gt;-Any other cancer from which the subject has been disease-free for =2 years&#x0D;&lt;br&gt;15.History of severe allergy to any of the components of birtamimab such as histidine/L histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 or history of Grade =3 infusion-related AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine (or an equivalent H1 antihistamine) or acetaminophen (or its equivalent, paracetamol)&#x0D;&lt;br&gt;16.Known or history of uncontrolled, active HIV, hepatitis B or hepatitis C, or SARS-CoV-2 infection&#x0D;&lt;br&gt;17.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11 1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid&#x0D;&lt;br&gt;18.Treatment with another investigational agent within 30 days of Month 1-Day 1&#x0D;&lt;br&gt;19.Women who are pregnant or lactating&#x0D;&lt;br&gt;20.Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject’s risk by particip
    </Exclusion_Criteria>
    <Condition>AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded  immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossia &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10036673
Term: Primary amyloidosis
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Birtamimab&lt;br&gt;Product Code: Birtamimab&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: BIRTAMIMAB&lt;br&gt;CAS Number: 1608108-91-3&lt;br&gt;Current Sponsor code: birtamimab&lt;br&gt;Other descriptive name: Humanized IgG1 kappa antiamyloid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care when administered intravenously in Mayo Stage IV subjects with AL amyloidosis by assessing time to all-cause mortality.;Secondary Objective: To evaluate birtamimab plus standard of care compared to placebo plus standard of care on the following:&lt;br&gt;• Change from baseline to Month 9 in health-related quality of life using the Short Form-36 questionnaire Version 2 (SF-36v2)&lt;br&gt;• Change from baseline to Month 9 in the 6-Minute Walk Test (6MWT) distance;Primary end point(s): Time to all-cause mortality;Timepoint(s) of evaluation of this end point: -Interim Efficacy Analysis will be conducted when approximately 50% (or 24) of the events have occurred&lt;br&gt;-Primary Analysis - for all-cause mortality, all deaths occurring after the first infusion of study drug (i.e., Study Day 1) through the study’s last subject last visit will be included.&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): •Change from baseline to Month 9 in the Physical Component Summary (PCS) score of the SF-36v2&#x0D;&lt;br&gt;•Change from baseline to Month 9 in the 6MWT distance (meters)&#x0D;&lt;br&gt;;Timepoint(s) of evaluation of this end point: from baseline until Month 9
    </Secondary_outcome>
    <Secondary_ID>NEOD001-301;146070
    </Secondary_ID>
    <Source_Support>Prothena Biosciences Limited
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>05/07/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11241443
    </Internal_Number>
    <TrialID>NCT04985734
    </TrialID>
    <Last_Refreshed_on>10 August 2021
    </Last_Refreshed_on>
    <Public_title>Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy
    </Public_title>
    <Scientific_title>Study on the Occurrence of Transthyretin Amyloidosis Cardiomyopathy in Patients With Idiopathic Peripheral Neuropathy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University Hospital, Antwerp
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210517
    </Date_registration3>
    <Date_registration>17/05/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04985734
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 1, 2021
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Belgium
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Victor S Issa
    </Contact_Lastname>
    <Contact_Email>victorsarli.issa@uza.br
    </Contact_Email>
    <Contact_Tel/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        - Adult patients (&gt; 18 years old) with diagnosis of idiopathic peripheral neuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with alternative established diagnosis of heart disease (ischemic heart&#x0D;&lt;br&gt;             disease, primary valvular heart disease, cardiomyopathies, pericardial disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with end stage renal disease undergoing dialysis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with other medical conditions recognized to impair the 1-year prognosis of&#x0D;&lt;br&gt;             patients&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloidosis Cardiac;Amyloid Polyneuropathy;Amyloidosis;Heart Failure;Cardiomyopathy Non-Dilated;Cardiomyopathies, Secondary
    </Condition>
    <Intervention>Diagnostic Test: Specific diagnostic work-up for ATTR-CM patients
    </Intervention>
    <Primary_outcome>Diagnosis yield
    </Primary_outcome>
    <Secondary_ID>EDGE1850
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10967846
    </Internal_Number>
    <TrialID>NCT04882735
    </TrialID>
    <Last_Refreshed_on>24 May 2021
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
    </Public_title>
    <Scientific_title>A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Acoramidis in Subjects With Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Eidos Therapeutics
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210429
    </Date_registration3>
    <Date_registration>29/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04882735
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2021
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Mark McGovern, RN, CCRN;Tammy McGraw
    </Contact_Lastname>
    <Contact_Email>;medinfo@eidostx.com
    </Contact_Email>
    <Contact_Tel>;+1 415-887-1471
    </Contact_Tel>
    <Contact_Affiliation>Eidos Therapeutics;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female =18 to =90 years of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have Stage I or II symptoms (polyneuropathy disability [PND] =IIIb) of ATTR-PN and an&#x0D;&lt;br&gt;             established diagnosis of ATTR-PN as defined by physical examination findings and/or&#x0D;&lt;br&gt;             neurophysiological test findings consistent with the diagnosis of ATTR-PN;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have an NIS of 5 to 130 (inclusive) during Screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a nerve conduction studies (NCS) score (sum of the sural sensory nerve action&#x0D;&lt;br&gt;             potential [SNAP], tibial compound muscle action potential (CMAP), ulnar SNAP, ulnar&#x0D;&lt;br&gt;             CMAP, and peroneal CMAP) of =2 points during Screening. NCS is a component of mNIS+7;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a mutation consistent with ATTR-PN either documented in medical history or&#x0D;&lt;br&gt;             confirmed by genotyping obtained at Screening prior to enrollment. No genetic testing&#x0D;&lt;br&gt;             is needed for subjects who are recipients of domino liver transplants;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have an anticipated survival of &gt;2 years in the opinion of the investigator;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have Karnofsky performance status =60 %.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had a prior liver transplantation or is planning to undergo liver transplantation with&#x0D;&lt;br&gt;             a wild-type organ graft as treatment for symptomatic ATTR-PN during the study period.&#x0D;&lt;br&gt;             Note: Recipients of a "domino" liver transplant from an ATTR-PN donor who have&#x0D;&lt;br&gt;             developed ATTR-PN mediated by their graft are allowed under this protocol, as long as&#x0D;&lt;br&gt;             re-transplantation to treat ATTR-PN is not planned during the study period and meets&#x0D;&lt;br&gt;             all other eligibility criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has sensorimotor or autonomic neuropathy not related to ATTR-PN; for example, due to&#x0D;&lt;br&gt;             autoimmune disease or monoclonal gammopathy, malignancy, or alcohol abuse;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has Vitamin B-12 levels below the lower limit of normal (LLN) at Screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has clinical evidence of untreated hyperthyroidism or hypothyroidism;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has leptomeningeal TTR amyloidosis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has Type 1 diabetes;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has had Type 2 diabetes for =5 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a documented case of hepatitis B or C at Screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known history of human immunodeficiency virus (HIV) infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has NYHA heart failure classification &gt;Class II;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had acute coronary syndrome, uncontrolled cardiac arrhythmia, or a stroke within 90&#x0D;&lt;br&gt;             days prior to Screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has estimated glomerular filtration rate (eGFR) by Modification of Diet for Renal&#x0D;&lt;br&gt;             Disease (MDRD) formula &lt;30 mL/min/1.73 m2 at Screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has abnormal liver function tests at Screening, defined as alanine aminotransferase&#x0D;&lt;br&gt;             (ALT) or aspartate aminotransferase (AST) &gt;3 × upper limit of normal (ULN) or total&#x0D;&lt;br&gt;             bilirubin &gt;3 × ULN;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the&#x0D;&lt;br&gt;             skin or carcinoma in situ of the cervix that has been successfully treated;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known hypersensitivity to acoramidis, its metabolites, or formulation excipients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is currently undergoing treatment for ATTR-PN with tafamidis, or patisiran, inotersen,&#x0D;&lt;br&gt;             or other knockdown agents, marketed drug products lacking a labeled indication for&#x0D;&lt;br&gt;             ATTR-PN (e.g., diflunisal, doxycycline), natural products or derivatives used as&#x0D;&lt;br&gt;             unproven therapies for ATTR-PN (e.g., green tea extract ,tauroursodeoxycholic acid&#x0D;&lt;br&gt;             [TUDCA]/ursodiol), within 14 days, or 14 days for tafamidis or 90days for patisiran&#x0D;&lt;br&gt;             and 180 days for inotersen prior to dosing.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
    </Condition>
    <Intervention>Drug: Acoramidis
    </Intervention>
    <Primary_outcome>Change from baseline to Month 18 in mNIS+7;Safety: TESAEs will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN);Safety: Adverse Events leading to treatment discontinuation will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN);Safety: Adverse Events will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN);Safety: Incidence of abnormal physical exam will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN);Safety: Incidence of abnormal vital signs will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN);Safety: Columbia-Suicide Severity Rating Scale (C-SSRS) will be used to evaluate the long-term safety and tolerability of acoramidis administered to subjects with symptomatic polyneuropathy (ATTR-PN)
    </Primary_outcome>
    <Secondary_outcome>Change from baseline to Month 18 in Norfolk QOL-DN;Change from baseline to Month 18 in mBMI;Change from baseline to Month 18 in COMPASS-31
    </Secondary_outcome>
    <Secondary_ID>AG10-334
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13700739
    </Internal_Number>
    <TrialID>EUCTR2021-000037-14-DK
    </TrialID>
    <Last_Refreshed_on>19 February 2024
    </Last_Refreshed_on>
    <Public_title>A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
    </Public_title>
    <Scientific_title>A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Prothena Biosciences Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210428
    </Date_registration3>
    <Date_registration>28/04/2021
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000037-14
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>01/09/2021
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2 
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Hungary;United States;Czechia;Japan;United Kingdom;Portugal;Spain;Greece;Canada;Austria;Netherlands;Belgium;Ireland;Taiwan;Denmark;Korea, Republic of;Poland;Italy;Israel;Australia;France;Türkiye;Germany
    </Countries>
    <Contact_Firstname>Regulatory Affairs
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>77 Sir John Rogerson’s Quay, Block C
    </Contact_Address>
    <Contact_Email>regaffairs@prothena.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Prothena Biosciences Limited
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.Aged =18 years and legal age of consent according to local regulations&lt;br&gt;2.Newly diagnosed and AL amyloidosis treatment naive with cardiac involvement&lt;br&gt;3.Confirmed diagnosis of AL amyloidosis&lt;br&gt;4.Confirmed Mayo Stage IV AL Amyloidosis as defined by NT-proBNP =1800 pg/mL and Troponin-T =0.025 ng/mL (mcg/L) or high sensitivity cardiac troponin T = 40 ng/L and dFLC =18 mg/dL&lt;br&gt;5.Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly&lt;br&gt;&lt;br&gt;A comprehensive list of inclusion criteria can be found in the protocol.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 75&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 75&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.Non-AL amyloidosis&lt;br&gt;2.NT-proBNP &gt;8500 pg/mL&lt;br&gt;3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma, except for malignancy biomarker of involved/and uninvolved serum free light chain ratio = 100&lt;br&gt;4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study&lt;br&gt;5.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&lt;br&gt;6.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area &lt;1.0 cm2) or severe congenital heart disease&lt;br&gt;7.ECG evidence of acute ischemia or active conduction system abnormalities&lt;br&gt;8.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1&lt;br&gt;9.Prior radiotherapy within 4 weeks of Month 1-Day 1&lt;br&gt;10.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11-1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid&lt;br&gt;11.Waldenström's macroglobulinemia and/or immunoglobulin M monoclonal gammopathy&lt;br&gt;&lt;br&gt;A comprehensive list of exclusion criteria can be found in the protocol.&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded  immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossia &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10036673
Term: Primary amyloidosis
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Birtamimab&lt;br&gt;Product Code: Birtamimab&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: BIRTAMIMAB&lt;br&gt;CAS Number: 1608108-91-3&lt;br&gt;Current Sponsor code: birtamimab&lt;br&gt;Other descriptive name: Humanized IgG1 kappa antiamyloid&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: Double-blind Phase&lt;br&gt;• To evaluate the efficacy of birtamimab plus standard of care  compared&lt;br&gt;to placebo plus standard of care when administered  intravenously in&lt;br&gt;Mayo Stage IV subjects with AL amyloidosis by assessing time to allcause&lt;br&gt;mortality.&lt;br&gt;&lt;br&gt;Open-label Extension Phase&lt;br&gt;• To evaluate the long-term safety of birtamimab plus standard of care&lt;br&gt;in Mayo Stage IV subjects with AL amyloidosis ;Secondary Objective: To evaluate birtamimab plus standard of care compared to placebo plus standard of care on the following:&lt;br&gt;• Change from baseline to Month 9 in the 6-Minute Walk Test (6MWT) distance&lt;br&gt;• Change from baseline to Month 9 in health-related quality of life using the Short Form-36 questionnaire Version 2 (SF-36v2);Primary end point(s): Time to all-cause mortality during the Double-blind Phase&lt;br&gt;;Timepoint(s) of evaluation of this end point: Time from the first dose of study drug until death or end of the Doubleblind Phase over 9&lt;br&gt;months&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): •Change from baseline to Month 9 of the Double-blind Phase in the&lt;br&gt;6MWT distance (meters)&lt;br&gt;•Change from baseline to Month 9 of the Double-blind Phase in the&lt;br&gt;Physical Component Summary (PCS) score of the SF-36v2&lt;br&gt;&lt;br&gt;;Timepoint(s) of evaluation of this end point: From baseline until Month 9 of the Double-blind Phase 
    </Secondary_outcome>
    <Secondary_ID>NEOD001-301;NCT04973137;146070
    </Secondary_ID>
    <Source_Support>Prothena Biosciences Limited
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/09/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13427031
    </Internal_Number>
    <TrialID>JPRN-jRCT2071210009
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>A Study to Evaluate the Efficacy and Safety of ION-682884 in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    </Public_title>
    <Scientific_title>A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Viney Nick
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210412
    </Date_registration3>
    <Date_registration>12/04/2021
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCT2071210009
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 20age old
    </Inclusion_agemin>
    <Inclusion_agemax>&lt;= 82age old
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/04/2021
    </Date_enrollement>
    <Target_size>14
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>randomized controlled trial, open(masking not used), historical control, parallel assignment, treatment purpose
    </Study_design>
    <Phase>3
    </Phase>
    <Countries>Brazil;Japan;Cyprus;Japan;France;Japan;Germany;Japan;Italy;Japan;New Zealand;Japan;Portugal;Japan;Spain;Japan;Sweden;Japan;Taiwan;Japan;United States;Japan
    </Countries>
    <Contact_Firstname>Clinical
    </Contact_Firstname>
    <Contact_Lastname>Contact
    </Contact_Lastname>
    <Contact_Address>Kyutaromachi 4-chome 1-3, Chuo-ku, Osaka
    </Contact_Address>
    <Contact_Email>PRJPN-Chiken@prahs.com
    </Contact_Email>
    <Contact_Tel>+81-6-4560-2001
    </Contact_Tel>
    <Contact_Affiliation>PRA Health Sciences K.K.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 20 to 82 years at the time of informed consent&lt;br&gt;2. Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal or abstinent&lt;br&gt;3. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential, the subject or the subject's non-pregnant female partner must be using a highly effective contraceptive method&lt;br&gt;4. Diagnosis of hereditary transthyretin-mediated polyneuropathy as defined by meeting all 3 of the following:&lt;br&gt;- Stage 1 or Stage 2 Familial Amyloid Polyneuropathy (FAP) or Coutinho Stage&lt;br&gt;- Documented genetic mutation in the TTR gene&lt;br&gt;- Symptoms and signs consistent with neuropathy associated with transthyretin amyloidosis, including NIS &gt;= 10 and &lt;= 130
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical examination that would render a subject unsuitable for inclusion, including but not limited to abnormal safety labs&lt;br&gt;2. Karnofsky performance status &lt;= 50&lt;br&gt;3. Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease), including uncontrolled diabetes&lt;br&gt;4. Prior liver transplant or anticipated liver transplant within 1-yr of Screening&lt;br&gt;5. New York Heart Association (NYHA) functional classification of &gt;= 3&lt;br&gt;6. Acute coronary syndrome within 6 months of screening or major surgery within 3 months of Screening&lt;br&gt;7. Other types of amyloidosis&lt;br&gt;8. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the Study&lt;br&gt;9. Current treatment with any approved drug for hereditary TTR amyloidosis such as Vyndaqel / Vyndamax (tafamidis), Tegsedi (inotersen), Onpattro (patisiran), off-label use of diflunisal or doxycycline, and tauroursodeoxycholic acid (TUDCA). If previously treated with Vyndaqel / Vyndamax, diflunisal or doxycycline, and TUDCA, must have discontinued treatment for at least 2 weeks prior to Study Day 1&lt;br&gt;10. Previous treatment with Tegsedi (Inotersen) or Onpattro (patisiran), or other oligonucleotide or RNA therapeutic (including siRNA)
    </Exclusion_Criteria>
    <Condition>Hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN)
    </Condition>
    <Intervention>Experimental: ION-682884&lt;br&gt;ION-682884 by subcutaneous injection once every 4 weeks&lt;br&gt;&lt;br&gt;Active Comparator: Inotersen&lt;br&gt;Inotersen by subcutaneous injection once weekly through week 34. Participants will then convert to ION-682884 administered subcutaneously once every 4 weeks until the end of study
    </Intervention>
    <Primary_outcome>- Change from baseline in mNIS+7 at Week 66&lt;br&gt;Note: The mNIS+7 composite score is a measure of neurologic impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function. The mNIS+7 composite score has a range of -22.32 to 346.32, and a higher score indicates lower function.&lt;br&gt;- Change from baseline in the Norfolk Quality of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66 &lt;br&gt;Note: The Norfolk QoL-DN score is a measure of physical function/large fiber neuropathy, symptoms,  activities of daily living, small fiber neuropathy, and autonomic neuropathy. The Norfolk QoL-DN total score has a range of -4 to 136, and a higher score indicates poorer quality of life.&lt;br&gt;- Percent change from baseline in serum TTR concentration at Week 66 &lt;br&gt;- Percent change from baseline in serum transthyretin (TTR) concentration at Week 35&lt;br&gt;- Change from baseline in modified neuropathy impairment score plus 7 (mNIS+7) at Week 35
    </Primary_outcome>
    <Secondary_outcome>- Change from baseline in Norfolk QOL-DN at Week 35&lt;br&gt;- Change from baseline in Neuropathy Symptom and Change (NSC) score at Weeks 35 and 66&lt;br&gt;Note: NSC score is a questionnaire composed of 38 questions that assess the presence and severity of these neuropathy symptoms (including weakness, loss of temperature and pain sensation, and manifestations associated with autonomic nervous system dysfunction).&lt;br&gt;- Change from baseline in the Physical Component Summary (PCS) score of the 36-Item Short Form Survey (SF-36) at Week 65&lt;br&gt;Note; The SF-36 is composed of 8 multi-item scales (35 items) assessing physical function (10 items), role limitations due to physical health problems (4 items), bodily pain (2 items), general health (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items) and emotional well-being (5 items). Each of the 8 scales is scored from 0 to 100 with higher scores indicating better health. The 8 scales can be aggregated into a PCS score, which is also scaled from 0 to 100 with higher scores indicating better health.&lt;br&gt;- Change from baseline in Polyneuropathy Disability (PND) score at Week 65&lt;br&gt;Note: The PND is a 6-stage scoring system: Stage 0: no impairment; Stage 1: sensory disturbances but preserved walking capabilities; Stage 2: impaired walking capacity, but ability to walk without a stick or crutches; Stage 3A/B: walking with help of 1 or 2 sticks or crutches; Stage 4: confined to wheel chair or bedridden.&lt;br&gt;- Change from baseline in modified body mass index (mBMI) at Week 65 &lt;br&gt;Note: mBMI is defined as body mass index in kilograms per square meter (kg/m^2) multiplied by serum albumin in grams per liter (g/L)
    </Secondary_outcome>
    <Secondary_ID>NCT04136184;2019-001698-10
    </Secondary_ID>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>chikenjimu@kuh.kumamoto-u.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Kumamoto Universiry Hospital IRB
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-96-344-2111
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>chikenjimu@kuh.kumamoto-u.ac.jp
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13898911
    </Internal_Number>
    <TrialID>NCT04850105
    </TrialID>
    <Last_Refreshed_on>22 April 2024
    </Last_Refreshed_on>
    <Public_title>A Non-interventional Cohort Safety Study of Patients With hATTR-PN
    </Public_title>
    <Scientific_title>A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (hATTR-PN)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Akcea Therapeutics
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210406
    </Date_registration3>
    <Date_registration>06/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04850105
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 21, 2021
    </Date_enrollement>
    <Target_size>240
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States;Canada;France;Germany;Greece;Italy;Portugal;Spain;Canada;France;Germany;Greece;Italy;Portugal;Spain;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ionis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email>ionisNCT04850105study@clinicaltrialmedia.com
    </Contact_Email>
    <Contact_Tel>(844) 915-5145
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Either:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. TEGSEDI Exposed Cohort: Patients diagnosed with hATTR-PN who have taken any dose&#x0D;&lt;br&gt;                  of TEGSEDI within 25 weeks prior to enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. TEGSEDI Unexposed Cohort: Patients diagnosed with hATTR-PN who have not taken any&#x0D;&lt;br&gt;                  dose of TEGSEDI within 25 weeks prior to enrollment and are eligible for TEGSEDI&#x0D;&lt;br&gt;                  treatment per applicable product label&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Clinically managed in Canada, Europe, or the US&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Have provided appropriate written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Transthyretin Amyloidosis With Polyneuropthy
    </Condition>
    <Intervention>Other: Data Collection
    </Intervention>
    <Primary_outcome>Further characterization of the long-term safety of TEGSEDI in patients with hATTR-PN under real-world conditions.
    </Primary_outcome>
    <Secondary_outcome>Description of the incidence rate of the Adverse Events of Special Interest (AESI) in the TEGSEDI-exposed and TEGSEDI-unexposed patients.;Description of the time to onset of Adverse Events of Special Interest (AESI) in the TEGSEDI-exposed and TEGSEDI-unexposed patients.
    </Secondary_outcome>
    <Secondary_ID>EUPAS37728;TEG4001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>United BioSource, LLC
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13397154
    </Internal_Number>
    <TrialID>NCT04828928
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)
    </Public_title>
    <Scientific_title>Prospective Study to Investigate Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)
    </Scientific_title>
    <Acronym>N-SAC
    </Acronym>
    <Primary_sponsor>University Hospital, Bordeaux
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210326
    </Date_registration3>
    <Date_registration>26/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04828928
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 23, 2021
    </Date_enrollement>
    <Target_size>65
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Guilhem SOLE, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Université Hospital, Bordeaux
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients of both gender, over 18 years old, with transthyretin amyloid cardiopathy&#x0D;&lt;br&gt;             according to one of the two American Heart Association definitions of 2016&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No mutation in the TTR gene&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients giving their free and informed consent to participate after information about&#x0D;&lt;br&gt;             the research&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients affiliated to or benefiting from a social security scheme&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with chronic neuropathy related to a known aetiology&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients under guardianship or curatorship&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Wild-type Amyloid Cardiopathy
    </Condition>
    <Intervention>Procedure: electromyogram
    </Intervention>
    <Primary_outcome>Presence of a clinical and/or electrophysiological neuropathy
    </Primary_outcome>
    <Secondary_outcome>Clinical data of patients with polyneuropathy with no identified etiology: Epidemiological characteristics;Clinical data of patients with polyneuropathy with no identified etiology: history characteristics;Clinical data of patients with polyneuropathy with no identified etiology: Heart attack;Clinical data of patients with polyneuropathy with no identified etiology: Clinical scores - KARNOFSKI index;Clinical data of patients with polyneuropathy with no identified etiology: Clinical scores - NIS-LL-;Clinical data of patients with polyneuropathy with no identified etiology: Clinical scores - ONLS-;Clinical data of patients with polyneuropathy with no identified etiology: Clinical scores - RODS-;Clinical data of patients with polyneuropathy with no identified etiology: Clinical scores - CADT-;Clinical data of patients with polyneuropathy with no identified etiology: Clinical scores -MoCA-;Clinical data of patients with polyneuropathy with no identified etiology: Electrophysiological data;Estimation of the frequency of the presence of neuropathy in our study population in order to compare it to a reference population
    </Secondary_outcome>
    <Secondary_ID>CHUBX 2020/27
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13035788
    </Internal_Number>
    <TrialID>NCT04828993
    </TrialID>
    <Last_Refreshed_on>8 May 2023
    </Last_Refreshed_on>
    <Public_title>The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
    </Public_title>
    <Scientific_title>A SINGLE ARM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF ORALLY ADMINISTERED TAFAMIDIS MEGLUMINE IN TRANSTHYRETIN AMYLOID POLYNEUROPATHY PARTICIPANTS IN CHINA
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Pfizer
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210317
    </Date_registration3>
    <Date_registration>17/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04828993
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 28, 2021
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Pfizer CT.gov Call Center
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Pfizer
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Male or female participants between the ages of 18 and 80 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Participants have amyloid documented by biopsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Participants must have a TTR mutation that is associated with ATTR-PN.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Participants have peripheral and/or autonomic neuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Stages of disease according to symptom severity-stage I.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other acute or chronic medical or psychiatric condition including recent or active&#x0D;&lt;br&gt;             suicidal ideation or behavior or laboratory abnormality, in the judgment of the&#x0D;&lt;br&gt;             investigator, would make the participant inappropriate for entry into this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Use of diflunisal, tauroursodeoxycholate, doxycycline, inotersen, patisiran or any&#x0D;&lt;br&gt;             other TTR stabilizing agent, or experimental interventions for familial amyloidosis&#x0D;&lt;br&gt;             within 30 days prior to the study entry and/or during study participation.&#x0D;&lt;br&gt;             Participants who are taking or who have previously taken tafamidis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             Prior/Concurrent Clinical Study Experience:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Previous administration with an investigational drug within 30 days or 5 half lives&#x0D;&lt;br&gt;             preceding the first dose of investigational product used in this study (whichever is&#x0D;&lt;br&gt;             longer).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Participant has primary (light chain) or secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. If female, participant is pregnant or breast feeding, or plans to be pregnant or&#x0D;&lt;br&gt;             breast feeding in the next 18 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Participant has received prior liver or any other organ except cornea transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Participant requires significant assistance with ambulation or is wheel chair bound.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Participants with cardiomyopathy specific TTR mutations.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Participant has other causes of sensorimotor neuropathy.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin Amyloid Polyneuropathy (ATTR-PN)
    </Condition>
    <Intervention>Drug: tafamidis meglumine
    </Intervention>
    <Primary_outcome>change from baseline in Neuropathy Impairment Score-lower limb (NIS-LL) at week 72
    </Primary_outcome>
    <Secondary_outcome>The incidence and severity of TEAE during the whole study;change from baseline in Norfolk QOL - Diabetic Neuropathy (Norfolk QOL-DN) at week 24, week 48, and week 72;change from baseline in Modified Body Mass Index (mBMI) at week 24, week 48 and week 72;Proportion of patients achieving transthyretin (TTR) stabilization at baseline, Week 8, Week 12 and Week 24, Week 48, week 72;TTR concentration at baseline, Week 8, Week 12, Week 24, Week 48 and week 72;The incidence of laboratory abnormalities during the whole study;Incidence of ECG abnormalities during the whole study;change from baseline in 36-item survey form (SF-36) at Week 24, Week 48 and week 72;change from baseline in EQ-5D-5L Index Score at week 24, week 48 and week 72;Incidence of vital sign abnormalities during the whole study;Incidence of clinically significant changes on Echocardiography during the whole study
    </Secondary_outcome>
    <Secondary_ID>B3461078
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13870647
    </Internal_Number>
    <TrialID>NL-OMON55279
    </TrialID>
    <Last_Refreshed_on>9 April 2024
    </Last_Refreshed_on>
    <Public_title>A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    </Public_title>
    <Scientific_title>A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy - NEURO-TTRANSFORM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210301
    </Date_registration3>
    <Date_registration>2021-03-01
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/55279
    </web_address>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>99
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement/>
    <Target_size>2
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized  controlled trial, Open (masking not used), Active, Parallel, Treatment
    </Study_design>
    <Phase>3
    </Phase>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Gazelle Court 2855
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Ionis Pharmaceuticals, Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;1. Must have given written informed consent (signed and dated) and any &lt;br&gt;authorizations required by local law and be able to comply with all study &lt;br&gt;requirements&lt;br&gt;2. Aged 18 to 82 years at the time of informed consent&lt;br&gt;3. Satisfy the following:&lt;br&gt;a. Females: must be non-pregnant and non-lactating and either: &lt;br&gt;i. Surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral &lt;br&gt;salpingectomy, bilateral oophorectomy)&lt;br&gt;ii. Post-menopausal (defined as 12 months of spontaneous amenorrhea in females &lt;br&gt;&gt; 55 years of age or, in females * 55 years, 12 months of spontaneous &lt;br&gt;amenorrhea without an alternative medical cause and FSH levels in the &lt;br&gt;postmenopausal range for the laboratory involved)&lt;br&gt;iii. Abstinent* or&lt;br&gt;iv. If engaged in sexual relations of child-bearing potential, agree to use &lt;br&gt;highly effective contraceptive methods (refer to Section 6.3.1) from the time &lt;br&gt;of signing the informed consent form until at least 24 weeks after the last &lt;br&gt;dose of ION*682884 or inotersen and agree to receive a monthly pregnancy test&lt;br&gt;b. Males: Surgically sterile (i.e., bilateral orchidectomy) or, if engaged in &lt;br&gt;sexual relations with a woman of child bearing potential (WOCBP), the patient &lt;br&gt;or the patient*s non-pregnant female partner must use a highly effective &lt;br&gt;contraceptive method (refer to Section 6.3.1) from the time of signing the &lt;br&gt;informed consent form until at least 24 weeks after the last dose of ION*682884 &lt;br&gt;or inotersen.&lt;br&gt;* Abstinence (i.e., refraining from heterosexual intercourse throughout the &lt;br&gt;duration of study participation) is only acceptable as true abstinence, i.e., &lt;br&gt;when this is in line with the preferred and usual lifestyle of the patient. &lt;br&gt;Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation &lt;br&gt;methods), declaration of abstinence for the duration of a trial and withdrawal &lt;br&gt;are not acceptable methods of contraception.&lt;br&gt;4. hATTR-PN as defined by meeting all 3 of the following criteria:&lt;br&gt;a. Stage 1 (ambulatory without assistance) or Stage 2 (ambulatory with &lt;br&gt;assistance) according to the Familial Amyloid Polyneuropathy (FAP) or Coutinho &lt;br&gt;Stage &lt;br&gt;b. Documented genetic mutation in the TTR gene&lt;br&gt;c. Symptoms and signs consistent with neuropathy associated with transthyretin &lt;br&gt;amyloidosis, including NIS * 10 and * 130&lt;br&gt;5. Willingness to adhere to vitamin A supplementation per protocol&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;1. Clinically significant abnormalities in medical history (e.g., previous &lt;br&gt;acute coronary syndrome within 6 months of Screening, major surgery within 3 &lt;br&gt;months of Screening) or physical examination&lt;br&gt;2. Screening laboratory results as follows, or any other clinically significant &lt;br&gt;abnormalities in screening laboratory values that would render a patient &lt;br&gt;unsuitable for inclusion:&lt;br&gt;a. Urine protein/creatinine ratio (UPCR) * 1000 mg/g. In the event of UPCR &lt;br&gt;above this threshold, eligibility may be confirmed by a repeat random urine &lt;br&gt;test with UPCR &lt; 1000 mg/g or a quantitative total urine protein measurement of &lt;br&gt;&lt; 1000 mg/24 hr&lt;br&gt;b. Renal insufficiency as defined by estimated glomerular filtration rate &lt;br&gt;(eGFRcreat-cys) &lt; 45 mL/min/1.73 m2 at Screening (eGFRcreat-cys is calculated &lt;br&gt;using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] &lt;br&gt;creatinine-cystatin C equation from 2012) (Inker et al. 2012)&lt;br&gt;c. Positive test (including trace) for blood on urinalysis. In the event of a &lt;br&gt;positive test, eligibility may be confirmed with urine microscopy showing * 5 &lt;br&gt;red blood cells per high power field&lt;br&gt;d. Alanine aminotransferase/ aspartate aminotransferase (ALT/AST) &gt; 2 × upper &lt;br&gt;limit of normal (ULN)&lt;br&gt;e. Bilirubin * 1.5 × ULN (patients with bilirubin * 1.5 × ULN may be allowed on &lt;br&gt;study if indirect bilirubin only is elevated, ALT/AST is not greater than the &lt;br&gt;ULN and genetic testing confirming Gilbert*s disease)&lt;br&gt;f. Platelets &lt; 125 × 109/L&lt;br&gt;g. HbA1C * 7%&lt;br&gt;h. Abnormal thyroid function tests with clinical significance per Investigator &lt;br&gt;judgement in consultation with the Sponsor Medical Monitor &lt;br&gt;i. Serum vitamin A (or retinol) level at Screening &lt; lower limit of normal &lt;br&gt;(LLN). For patients with a TTR mutation at position 84 (e.g., Ile84Ser or &lt;br&gt;Ile84Asn) and vitamin A &lt; LLN the exclusion criterion is signs or symptoms of &lt;br&gt;vitamin A deficiency (such as dry eye, Bitots* spot observed in the &lt;br&gt;ophthalmology exam, that in the opinion of the ophthalmologist is consistent &lt;br&gt;with vitamin A deficiency)&lt;br&gt;1. Active infection requiring systemic antiviral or antimicrobial therapy that &lt;br&gt;will not be completed prior to Study Day 1&lt;br&gt;2. Unwillingness to comply with study procedures, including follow up, as &lt;br&gt;specified by this protocol, or unwillingness to cooperate fully with the &lt;br&gt;Investigator&lt;br&gt;3. Known history of or positive test for human immunodeficiency virus (HIV), &lt;br&gt;hepatitis C (patients confirmed as cured from previous hepatitis C can be &lt;br&gt;included) or chronic hepatitis B&lt;br&gt;4. Uncontrolled hypertension (BP &gt; 160/100 mm Hg)&lt;br&gt;5. Malignancy within 5 years, except for basal or squamous cell carcinoma of &lt;br&gt;the skin or carcinoma in situ of the cervix that has been successfully &lt;br&gt;treated. Patients with a history of other malignancies that have been treated &lt;br&gt;with curative intent and which have no recurrence within 5 years may also be &lt;br&gt;eligible&lt;br&gt;6. Current treatment with any approved drug for hereditary TTR amyloidosis such &lt;br&gt;as Vyndaqel® / Vyndamax* (tafamidis), Tegsedi* (inotersen), Onpattro* &lt;br&gt;(patisiran), off-label use of diflunisal, doxycycline or tauroursodeoxycholic &lt;br&gt;acid (TUDCA). If previously treated with Vyndaqel® / Vyndamax*, diflunisal or &lt;br&gt;doxycycline, and TUDCA, must have discontinued treatment at least 2 weeks prior &lt;br&gt;to Study Day 1 &lt;br&gt;7. Previous treatment with Tegsedi* (inotersen) or Onpattro* (patisiran) or &lt;br&gt;other
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Familial amyloid polyneuropathy - Transthyretin (TTR) amyloid polyneuropathy;10034606
    </Condition>
    <Intervention>&lt;p&gt;Please refer to section E6 of the protocol. &lt;/p&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;p&gt;Week 35 Interim Analysis: Change from Baseline in serum TTR concentration and&lt;br /&gt;&lt;br&gt;the mNIS+7;&lt;br /&gt;&lt;br&gt;Week 66 Final Analysis: Change from Baseline in serum TTR concentration,&lt;br /&gt;&lt;br&gt;mNIS+7 and Norfolk QOL-DN&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Secondary endpoints:&lt;br /&gt;&#x0D;&lt;br&gt;Week 35 Interim Analysis:&lt;br /&gt;&#x0D;&lt;br&gt;* Change from Baseline in Norfolk QOL-DN&lt;br /&gt;&#x0D;&lt;br&gt;Week 66 Final Analysis:&lt;br /&gt;&#x0D;&lt;br&gt;* Change from Baseline in the NSC score at Weeks 35 and 66&lt;br /&gt;&#x0D;&lt;br&gt;* Change from Baseline in the PCS score of SF-36 at Week 65&lt;br /&gt;&#x0D;&lt;br&gt;* Change from Baseline in PND score at Week 65&lt;br /&gt;&#x0D;&lt;br&gt;* Change from Baseline in mBMI at Week 65&lt;br /&gt;&#x0D;&lt;br&gt;&lt;br /&gt;&#x0D;&lt;br&gt;Additional/Exploratory endpoints:&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in mNIS+7 at Week 85&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in Norfolk QOL-DN at Week 85&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in 10MWT at Weeks 37 and 81&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in R-ODS at Weeks 37 and 81&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in COMPASS-31 at Weeks 37 and 81&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in EQ-5D-5L at Weeks 37 and 81&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in the SF-36 at Week 35&lt;br /&gt;&#x0D;&lt;br&gt;Frequency of all cause hospitalizations in all patients by Week 66&lt;br /&gt;&#x0D;&lt;br&gt;Frequency of all cause hospitalizations in patients with cardiac involvement by&lt;br /&gt;&#x0D;&lt;br&gt;Week 66&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in ECHO parameters, including LV mass, LV wall thickness,&lt;br /&gt;&#x0D;&lt;br&gt;IVS thickness, and GLS, at Week 65 in patients with cardiac involvement&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in NT-proBNP at Week 65 in patients with cardiac&lt;br /&gt;&#x0D;&lt;br&gt;involvement&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in PGIS at Weeks 37 and 85&lt;br /&gt;&#x0D;&lt;br&gt;PGIC at Weeks 37 and 85&lt;br /&gt;&#x0D;&lt;br&gt;Plasma trough and post-treatment concentrations of ION-682884 or inotersen in&lt;br /&gt;&#x0D;&lt;br&gt;all patients, area under the curve (AUC), Cmax, and tmax in a subset of&lt;br /&gt;&#x0D;&lt;br&gt;patients, and t**z for patients who do not roll over to the OLE study.&lt;br /&gt;&#x0D;&lt;br&gt;&lt;br /&gt;&#x0D;&lt;br&gt;Safety endpoints:&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in platelet count per Common Terminology Criteria for&lt;br /&gt;&#x0D;&lt;br&gt;Adverse Events (CTCAE) grade.&lt;br /&gt;&#x0D;&lt;br&gt;Change from Baseline in renal function.&lt;br /&gt;&#x0D;&lt;br&gt;Additional safety endpoints include: adverse events, vital signs and weight,&lt;br /&gt;&#x0D;&lt;br&gt;physical examination, clinical laboratory tests, ECG, use of concomitant&lt;br /&gt;&#x0D;&lt;br&gt;medication, ophthalmology examination, thyroid panel, inflammatory panel,&lt;br /&gt;&#x0D;&lt;br&gt;coagulation, and immunogenicity&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>EUCTR2019-001698-10-NL;NCT04136184;NL73848.000.21
    </Secondary_ID>
    <Source_Support>industry
    </Source_Support>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/03/2021;06/05/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>;
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13347063
    </Internal_Number>
    <TrialID>NCT04601051
    </TrialID>
    <Last_Refreshed_on>18 September 2023
    </Last_Refreshed_on>
    <Public_title>Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
    </Public_title>
    <Scientific_title>Phase 1 Two-Part (Open-label, Single Ascending Dose (Part 1) and Open-label, Single Dose Expansion (Part 2)) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Intellia Therapeutics
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201019
    </Date_registration3>
    <Date_registration>19/10/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04601051
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 5, 2020
    </Date_enrollement>
    <Target_size>72
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>France;New Zealand;Sweden;United Kingdom;France;New Zealand;Sweden;United Kingdom
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Polyneuropathy Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male and/or female participants 18 to 80 years of age inclusive, at the time of&#x0D;&lt;br&gt;             signing the informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of polyneuropathy (PN) due to transthyretin (TTR) amyloidosis (ATTR)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have a body weight of at least 45 kilograms (kg) at Screening visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of access to approved treatments for ATTR and/or progression of hereditary&#x0D;&lt;br&gt;             transthyretin amyloidosis with polyneuropathy (ATTRv-PN) despite use of approved&#x0D;&lt;br&gt;             treatment for ATTRv-PN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Polyneuropathy Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Amyloidosis attributable to non-TTR protein, e.g., amyloid light-chain (AL)&#x0D;&lt;br&gt;             amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known leptomeningeal transthyretin amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of any of the following TTR-directed therapy for ATTR within certain timeframe:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Patisiran&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Inotersen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Vutrisiran&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Tafamidis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Diflunisal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Doxycycline and/or tauroursodeoxycholic acid&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               7. Any other investigational agent for the treatment of ATTRv-PN:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other protocol defined Inclusion/Exclusion criteria may apply&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Cardiomyopathy Inclusion Criteria (UK only):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male and/or female participants 18 to 90 years of age inclusive, at the time of&#x0D;&lt;br&gt;             signing the informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of transthyretin (ATTR) amyloidosis with cardiomyopathy, classified as&#x0D;&lt;br&gt;             hereditary ATTR amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy&#x0D;&lt;br&gt;             (ATTRwt-CM).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have a body weight of at least 45 kilograms (kg) at Screening visit&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  New York Heart Association (NYHA) Class I-III heart failure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 1 prior hospitalization for heart failure and/or clinical evidence of heart&#x0D;&lt;br&gt;             failure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to complete =150 meters on the 6-minute walk test (6-MWT) during the Screening&#x0D;&lt;br&gt;             period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Cardiomyopathy Exclusion Criteria (UK only):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Amyloidosis attributable to non-TTR protein, e.g., amyloid light-chain (AL)&#x0D;&lt;br&gt;             amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known leptomeningeal transthyretin amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of any of the following TTR-directed therapy for ATTR within certain timeframes:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Patisiran&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Inotersen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Vutrisiran&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Tafamidis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Diflunisal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Doxycycline and/or tauroursodeoxycholic acid&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               7. Investigational TTR stabilizer (e.g., AG-10)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with heart failure that in the opinion of the investigator is caused by&#x0D;&lt;br&gt;             ischemic heart disease, hypertension, or uncorrected valvular disease and not&#x0D;&lt;br&gt;             primarily due to transthyretin amyloid cardiomyopathy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants with a history of sustained ventricular tachycardia or aborted&#x0D;&lt;br&gt;             ventricular fibrillation or with a history of atrioventricular (AV) nodal or&#x0D;&lt;br&gt;             sinoatrial (SA) nodal dysfunction for which a pacemaker is indicated but will not be&#x0D;&lt;br&gt;             placed. Pacemaker or defibrillator placement, initiation of or change in&#x0D;&lt;br&gt;             anti-arrhythmic medication within 28 days prior to study drug administration.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other protocol defined Inclusion/Exclusion criteria may apply&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy;Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy;Wild-Type Transthyretin Cardiac Amyloidosis
    </Condition>
    <Intervention>Biological: NTLA-2001
    </Intervention>
    <Primary_outcome>Number of Participants with Treatment-Emergent Adverse Events;Number of Participants with Clinically Significant Clinical Laboratory Test Findings;Number of Participants with Clinically Significant Safety Measurements;Percent Change from Baseline in Serum TTR (enzyme-linked immunosorbent assay [ELISA]);Percent Change from Baseline in Serum Prealbumin;Mean Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUClast) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA;Mean Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA;Mean Maximum Concentration (Cmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA;Mean Time of the Maximum Concentration (Tmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA;Mean Terminal Half-Life (t½) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA;Mean Apparent Clearance (CL) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA;Mean Volume of Distribution (Vd) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA;Change from Baseline in Anti-Drug Antibody to NTLA-2001 and Anti-Cas9 Protein Antibody to Transgene Product Levels
    </Primary_outcome>
    <Secondary_outcome>Polyneuropathy only: Change from Baseline in Familial Amyloid Polyneuropathy (FAP) Stage.;Polyneuropathy only: Change from Baseline in Polyneuropathy Disability (PND) Score;Polyneuropathy only: Change from Baseline in Modified Body Mass Index (mBMI);Polyneuropathy only: Change from Screening in Neuropathy Impairment Score (NIS);Polyneuropathy only: Change from Baseline in Modified Neuropathy Impairment Score +7 (mNIS+7);Polyneuropathy only: Change from Screening in 10-Meter Walk Test (10-MWT);Polyneuropathy only: Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN);Polyneuropathy only: Change from Baseline in EuroQOL (EQ)-5D-5L;Cardiomyopathy only: Change from Baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP);Cardiomyopathy only: Change from Baseline in hs Troponin T;Cardiomyopathy only: Change from Baseline in Magnetic resonance imaging (MRI);Cardiomyopathy only: Change from Baseline in Echocardiogram;Cardiomyopathy only: Change from Baseline in Cardio-pulmonary exercise test;Cardiomyopathy only: Change from Baseline in 6-Minute Walk Test (6-MWT);Cardiomyopathy only: Change from Baseline in New York Heart Association (NYHA) Classification;Cardiomyopathy only: Change from Baseline in Patient-reported outcomes (KCCQ)
    </Secondary_outcome>
    <Secondary_ID>2020-002034-32;ITL-2001-CL-001
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14015944
    </Internal_Number>
    <TrialID>DRKS00018881
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Pathogenetic relevance of mutations in the Transthyretin gene in patients with polyneuropathy
    </Public_title>
    <Scientific_title>Pathogenetic relevance of mutations in the Transthyretin gene in patients with polyneuropathy - PARMITTYR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Uniklinik Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200630
    </Date_registration3>
    <Date_registration>30/06/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00018881
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>11/07/2020
    </Date_enrollement>
    <Target_size>300
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: diagnostic 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>H.C.
    </Contact_Firstname>
    <Contact_Lastname>Lehmann
    </Contact_Lastname>
    <Contact_Address>Kerpener Str. 62
    </Contact_Address>
    <Contact_Email>helmar.lehmann@uk-koeln.de
    </Contact_Email>
    <Contact_Tel>+49-221-478-87091
    </Contact_Tel>
    <Contact_Affiliation>Uniklinik Köln
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients over 18-years old with idiopathic polyneuropathy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pregnancy
    </Exclusion_Criteria>
    <Condition>Idiopathic polyneuropathy
    </Condition>
    <Intervention>Group 1: Patient with idiopathic polyneuropathy.&lt;br&gt;&lt;br&gt;2 Additional blood samples (EDTA) during routinely blood samples
    </Intervention>
    <Primary_outcome>Is there a mutation in the TTR gene?
    </Primary_outcome>
    <Secondary_outcome>Are there elecrtophysiologic or biochemic aberrations?
    </Secondary_outcome>
    <Source_Support>Alnylam Germany GmbH
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>20/11/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00018881#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11049606
    </Internal_Number>
    <TrialID>NCT04418024
    </TrialID>
    <Last_Refreshed_on>21 June 2021
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Polyneurophathy
    </Public_title>
    <Scientific_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)
    </Scientific_title>
    <Acronym>ATTRibute-PN
    </Acronym>
    <Primary_sponsor>Eidos Therapeutics, a BridgeBio company
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200522
    </Date_registration3>
    <Date_registration>22/05/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04418024
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 21, 2020
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Canada;Spain
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Mark McGovern, RN, CCRN
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Eidos Therapeutics, a BridgeBio company
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be male or female =18 to =90 years of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have Stage I or II symptoms (polyneuropathy disability [PND] =IIIa) of ATTR-PN and an&#x0D;&lt;br&gt;             established diagnosis of ATTR-PN as defined by physical exam findings and/or&#x0D;&lt;br&gt;             neurophysiological test findings consistent with the diagnosis of ATTR-PN;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have an NIS of 5 to 130 (inclusive) during screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a nerve conduction studies (NCS) score [sum of the sural sensory nerve action&#x0D;&lt;br&gt;             potential (SNAP), tibial compound muscle action potential (CMAP), ulnar SNAP, ulnar&#x0D;&lt;br&gt;             CMAP, and peroneal CMAP] of =2 points during screening. NCS is a component of mNIS+7;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a mutation consistent with ATTR-PN either documented in medical history or&#x0D;&lt;br&gt;             confirmed by genotyping obtained at Screening prior to randomization. *No genetic&#x0D;&lt;br&gt;             testing is needed for subjects who are recipients of domino liver transplants;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have an anticipated survival of =2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have Karnofsky performance status =60 %;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had a prior liver transplantation or is planning to undergo liver transplantation with&#x0D;&lt;br&gt;             a wild-type organ graft as treatment for symptomatic ATTR-PN during the study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Note: Recipients of a "domino" liver transplant from an ATTR-PN donor who have developed&#x0D;&lt;br&gt;        ATTR-PN mediated by their graft are allowed under this protocol, as long as&#x0D;&lt;br&gt;        re-transplantation to treat ATTR-PN is not planned during the study period and meets all&#x0D;&lt;br&gt;        other eligibility criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has sensorimotor or autonomic neuropathy not related to ATTR-PN; for example,&#x0D;&lt;br&gt;             autoimmune disease or monoclonal gammopathy, malignancy, or alcohol abuse;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has Vitamin B-12 levels below the lower limit of normal (LLN);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has clinical evidence of untreated hyper/hypothyroidism;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has leptomeningeal TTR amyloidosis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has Type 1 diabetes;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has had Type 2 diabetes for =5 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has active hepatitis B or C or known human immunodeficiency virus (HIV) infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has NYHA heart failure classification &gt;Class II&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had a malignancy within 2 years, except for basal or squamous cell carcinoma of&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is currently undergoing treatment for ATTR-PN with patisiran, inotersen, or other gene&#x0D;&lt;br&gt;             silencing agents, marketed drug products lacking a label indication for ATTR- PN&#x0D;&lt;br&gt;             (e.g., diflunisal, doxycycline), natural products or derivatives used as unproven&#x0D;&lt;br&gt;             therapies for ATTR-PN (e.g., green tea extract, tauroursodeoxycholic acid&#x0D;&lt;br&gt;             [TUDCA]/ursodiol), within 14 days, or 90 days for patisiran and 180 days for inotersen&#x0D;&lt;br&gt;             prior to dosing. Prior to screening, tafamidis, if already prescribed to potential&#x0D;&lt;br&gt;             subjects as part of their established background therapy, is allowed at the labeled&#x0D;&lt;br&gt;             dosage and administration of 20 mg/day for the treatment of ATTR-PN with, i in the&#x0D;&lt;br&gt;             opinion of the Investigator, evidence of disease progression while on tafamidis&#x0D;&lt;br&gt;             treatment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
    </Condition>
    <Intervention>Drug: AG10;Drug: Placebo
    </Intervention>
    <Primary_outcome>Change from baseline to Month 18 of treatment in Modified Neuropathy Impairment
    </Primary_outcome>
    <Secondary_ID>2018-004670-10;AG10-333
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14016957
    </Internal_Number>
    <TrialID>DRKS00021577
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Development of a screening tool for hATTR polyneuropathy (AmyloScan®)

    </Public_title>
    <Scientific_title>Development of a screening tool for hATTR polyneuropathy (AmyloScan®)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Universitätsklinikum Schleswig-Holstein Campus Kiel
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200504
    </Date_registration3>
    <Date_registration>04/05/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00021577
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>None
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>12/12/2019
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Juliane
    </Contact_Firstname>
    <Contact_Lastname>Sachau
    </Contact_Lastname>
    <Contact_Address>Arnold-Heller-Straße 3 (Haus D)
    </Contact_Address>
    <Contact_Email>juliane.sachau@uksh.de
    </Contact_Email>
    <Contact_Tel>+49 431 500 23921
    </Contact_Tel>
    <Contact_Affiliation>Sektion Neurologische Schmerzforschung und -therapie, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein Campus Kiel
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Study participants have to suffer from one of the following disease entities:&lt;br&gt;- ATTRv amlyoidosis with polyneuropathy (documented mutation)&lt;br&gt;- polyneuropathy of other etiology&lt;br&gt;- pain caused by knee osteoarthritis&lt;br&gt;&lt;br&gt;Study participants must have signed a consent form in which they declare that they understand the purpose of the study and the procedures used in it and that they consent to the study. Participants must be able to communicate adequately and be able to identify and differentiate the location and intensity of pain and complete the questionnaires used in this study. 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria are pain syndromes of other causes, which could possibly compete with the pain, and severe psychiatric disorders, e.g. severe depression.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;E85.1 &lt;br&gt;G63 &lt;br&gt;M17;Neuropathic heredofamilial amyloidosis;Polyneuropathy in diseases classified elsewhere;Gonarthrosis [arthrosis of knee];E85.1
    </Condition>
    <Intervention>Group 1: Patients with ATTRv amyloidosis will complete different questionnaires especially capturing pain and autonomic symptoms (PainDetect Questionnaire, PainPredict Questionnaire, Neuropathic Symptom Inventory, Compound Autonomic Dysfunction Test, FabryScan). In addition patients will complete a self-constructed questionnaire with open questions about their symptoms and the course of the disease. Patients will be examined once to detect nerve fiber dysfunctions using quantitative sensory testing (QST), a simple bedside testing procedure, Sudoscan, heart rate variability, tilt table test. In the second step, patients will be examined with the first version of the newly developed screening tool (AmyloScan®).&lt;br&gt;Group 2: Patients suffering from polyneuropathies of other etiology, e.g. diabetic neuropathy, will be examined with the above-mentioned testing procedures and the newly developed screening tool (AmyloScan®).&lt;br&gt;Group 3: Patients suffering from nociceptive pain due to knee osteoarthritis will be examined with the newly developed screening tool (AmyloScan®).
    </Intervention>
    <Primary_outcome>The aim of this study is to develop a simple screening tool (history questions and potentially a short sensory testing procedure) to detect ATTRv amyloidosis with polyneuropathy early in the disease course and to distinguish it from other painful neuropathies or diseases with pain in the extremities. For this purpose, cut-off scores with the best discriminative value for ATTRv amyloidosis will be identified by examining the patients with different questionnaires and testing procedures. 
    </Primary_outcome>
    <Secondary_outcome>See Primary Outcome
    </Secondary_outcome>
    <Source_Support>Alnylam Pharamceuticals, Inc.
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>22/10/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission der Medizinischen Fakultät der Christian-Albrechts-Universität zu Kiel
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-431-50014191
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkomm@email.uni-kiel.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00021577#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13523594
    </Internal_Number>
    <TrialID>NCT04306510
    </TrialID>
    <Last_Refreshed_on>13 November 2023
    </Last_Refreshed_on>
    <Public_title>A Clinical Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Patients With hATTR-PN
    </Public_title>
    <Scientific_title>A Phase 4 Safety Study Assessing the Adverse Events Occurring Within One Day of TEGSEDI Administration in Patients With Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Akcea Therapeutics
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200207
    </Date_registration3>
    <Date_registration>07/02/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04306510
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 21, 2021
    </Date_enrollement>
    <Target_size>75
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 4
    </Phase>
    <Countries>United States;Canada;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Ionis Pharmaceuticals
    </Contact_Lastname>
    <Contact_Email>ionisNCT04306510study@clinicaltrialmedia.com
    </Contact_Email>
    <Contact_Tel>(844) 742-0280
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Satisfy one of the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. US Patients: Adult patients (= 18 years old) diagnosed with hATTR-PN and&#x0D;&lt;br&gt;                  prescribed TEGSEDI according to the USPI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Canadian Patients: Adult patients (= 18 years old) diagnosed with stage 1 or&#x0D;&lt;br&gt;                  stage 2 hATTR PN and prescribed TEGSEDI according to the CPM&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Must have given written informed consent for participation in this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Must provide access to their previous medical records&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Are about to initiate or have recently initiated treatment with TEGSEDI and have not&#x0D;&lt;br&gt;             received more than 9 doses in total&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Be willing to complete required testing and report any AEs and/or changes in&#x0D;&lt;br&gt;             medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Satisfy one of the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Females: Non-pregnant and non-lactating; abstinent, or if engaged in sexual&#x0D;&lt;br&gt;                  relations of childbearing potential, patient is using an acceptable contraceptive&#x0D;&lt;br&gt;                  method from time of signing the informed consent form (ICF) until 13 weeks after&#x0D;&lt;br&gt;                  the last dose of TEGSEDI administration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Males: Abstinent or if engaged in sexual relations with a female of childbearing&#x0D;&lt;br&gt;                  potential, patient is utilizing an acceptable contraceptive method from the time&#x0D;&lt;br&gt;                  of signing the ICF until 13 weeks after the last dose of TEGSEDI administration&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Transthyretin Amyloidosis With Polyneuropthy
    </Condition>
    <Intervention>Procedure: Blood samples for immunoglobulins;Procedure: Blood samples for inflammatory markers;Procedure: Blood samples for anti-drug antibodies
    </Intervention>
    <Primary_outcome>To characterize AEs occurring within one day of TEGSEDI administration to adult patients with hATTR-PN.
    </Primary_outcome>
    <Secondary_ID>TEG4004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>12350942
    </Internal_Number>
    <TrialID>NCT04201418
    </TrialID>
    <Last_Refreshed_on>13 June 2022
    </Last_Refreshed_on>
    <Public_title>A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
    </Public_title>
    <Scientific_title>A Phase 4 Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of Hereditary Transthyretin-Mediated (ATTRv) Amyloidosis With a V122I or T60A Mutation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191213
    </Date_registration3>
    <Date_registration>13/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04201418
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 18, 2019
    </Date_enrollement>
    <Target_size>67
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Medical Director
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with ATTRv amyloidosis with polyneuropathy, with a documented V122I or T60A&#x0D;&lt;br&gt;             mutation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PND score of I-IIIB at baseline.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exposure to commercial patisiran in one of the 3 cohorts:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Prospective Cohort: Naive to patisiran treatment at the time of enrollment with&#x0D;&lt;br&gt;                  intention to initiate treatment with patisiran.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Mixed cohort: Currently on commercial patisiran therapy for less than 12 months&#x0D;&lt;br&gt;                  at study enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Retrospective cohort: Exposed to commercial patisiran treatment for at least 12&#x0D;&lt;br&gt;                  months prior to study enrollment, regardless of current treatment status at&#x0D;&lt;br&gt;                  enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  New York Heart Association (NYHA) heart failure classification =3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky Performance Status (KPS) &lt;60%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unstable congestive heart failure (CHF)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known primary amyloidosis (AL) or leptomeningeal amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior major organ transplant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previously received patisiran&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous treatment with a TTR silencing therapy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hereditary Transthyretin-mediated (ATTRv) Amyloidosis;Polyneuropathy
    </Condition>
    <Intervention>Drug: Patisiran
    </Intervention>
    <Primary_outcome>Percentage of Participants with Stable or Improved Polyneuropathy Disability (PND) Score at 12 Months Relative to Baseline
    </Primary_outcome>
    <Secondary_ID>ALN-TTR02-012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13844046
    </Internal_Number>
    <TrialID>EUCTR2019-001698-10-PT
    </TrialID>
    <Last_Refreshed_on>2 April 2024
    </Last_Refreshed_on>
    <Public_title>Study to determine the effectiveness and safety of ION-682884 in patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    </Public_title>
    <Scientific_title>A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy - NEURO – TTRANSFORM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191018
    </Date_registration3>
    <Date_registration>18/10/2019
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001698-10
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>19/03/2020
    </Date_enrollement>
    <Target_size>140
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: no Cross over: yes Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2 
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Argentina;Cyprus;Japan;United Kingdom;Portugal;Spain;Greece;New Zealand;Canada;Netherlands;Sweden;Turkey;Ireland;Taiwan;Brazil;Mexico;Italy;Australia;France;Germany
    </Countries>
    <Contact_Firstname>Ionis Clinical Trial Information
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>2855 Gazelle Court
    </Contact_Address>
    <Contact_Email>ClinicalTrials@ionisph.com
    </Contact_Email>
    <Contact_Tel>+1760931 9200
    </Contact_Tel>
    <Contact_Affiliation>Ionis Pharmaceuticals, Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Aged 18 to 82 years at the time of informed consent&#x0D;&lt;br&gt;2. Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal&#x0D;&lt;br&gt;3. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential, the subject or the subject's non-pregnant female partner must be using a highly effective contraceptive method&#x0D;&lt;br&gt;4. Diagnosis of hereditary transthyretin-mediated polyneuropathy as defined by meeting all 3 of the following:&#x0D;&lt;br&gt;• Stage 1 or Stage 2 FAP&#x0D;&lt;br&gt;• Documented genetic mutation in the TTR gene&#x0D;&lt;br&gt;• Symptoms and signs consistent with polyneuropathy as measured by NIS score = 10 and = 130&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 86&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 54&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Clinically-significant (CS) abnormalities in medical history, screening laboratory results, physical or physical examination that would render a subject unsuitable for inclusion, including but not limited to abnormal safety labs&#x0D;&lt;br&gt;2. Karnofsky performance status = 50&#x0D;&lt;br&gt;3. Other causes of sensorimotor or autonomic neuropathy (e.g., autoimmune disease), including uncontrolled diabetes&#x0D;&lt;br&gt;4. Prior liver transplant or anticipated liver transplant within 1-yr of Screening&#x0D;&lt;br&gt;5. New York Heart Association (NYHA) functional classification of = 3&#x0D;&lt;br&gt;6. Acute coronary syndrome within 6 months of Screening or major surgery within 3 months of Screening&#x0D;&lt;br&gt;7. Other types of amyloidosis&#x0D;&lt;br&gt;8. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the Study&#x0D;&lt;br&gt;9. Current treatment with any approved drug for hereditary TTR amyloidosis such as Vyndaqel® / Vyndamax™ (tafamidis), Tegsedi™ (inotersen), Onpattro™ (patisiran),off-label use of diflunisal or doxycycline, and tauroursodeoxycholic acid (TUDCA).If previously treated with Vyndaqel® / Vyndamax™, diflunisal or doxycycline, and TUDCA, must have discontinued treatment for 2 weeks prior to Study Day 1&#x0D;&lt;br&gt;10. Previous treatment with TegsediTM (Inotersen) or OnpattroTM (patisiran), or other oligonucleotide or RNA therapeutic (including siRNA)&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Hereditary Transthyretin-Mediated Amyloid Polyneuropathy &lt;br&gt;MedDRA version: 20.0
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 100000004850
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: ION-682884&lt;br&gt;Product Code: ION-682884&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ION-682884&lt;br&gt;CAS Number: 1637600-16-8&lt;br&gt;Current Sponsor code: ION-682884&lt;br&gt;Other descriptive name: ION-682884&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Product Name: inotersen&lt;br&gt;Product Code: ISIS 420915&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: INOTERSEN&lt;br&gt;CAS Number: 1432726-13-0&lt;br&gt;Current Sponsor code: ISIS 420915&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of ION-682884 after administration for 65 weeks, as compared to the historical control of the placebo cohort in the NEURO-TTR trial, based on the change from Baseline in serum TTR concentration, mNIS+7 and in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QOL-DN) in patients with hATTR.;Secondary Objective: To evaluate the efficacy of ION-682884, as compared to the placebo cohort in the NEURO-TTR trial, based on the change from Baseline in the following measures:&lt;br&gt;- Neuropathy Symptom and Change Score (NSC)&lt;br&gt;- Physical component summary (PCS) score of 36-Item Short Form Survey (SF-36)&lt;br&gt;- Polyneuropathy disability (PND) score&lt;br&gt;- Modified body mass index (mBMI);Primary end point(s): Interim Analysis Co-Primary Efficacy Endpoints  at Week 35 &lt;br&gt;- Percent change from Baseline in serum TTR concentration&lt;br&gt;- Change from Baseline in mNIS+7 &lt;br&gt;&lt;br&gt;Final Analysis Co-Primary Efficacy Endpoints &lt;br&gt;- Percent change from Baseline in serum TTR concentration &lt;br&gt;- Change from Baseline in mNIS+7 &lt;br&gt;- Change from Baseline in Norfolk QOL-DN &lt;br&gt;;Timepoint(s) of evaluation of this end point: Interim Analysis Co-Primary Efficacy Endpoints  at Week 35&lt;br&gt;Final Analysis Co-Primary Efficacy Endpoints &lt;br&gt;- Percent change from Baseline in serum TTR concentration at Week 65&lt;br&gt;- Change from Baseline in mNIS+7 at Week 66&lt;br&gt;- Change from Baseline in Norfolk QOL-DN at Week 66
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Interim Analysis Key Secondary Efficacy Endpoint at Week 35&#x0D;&lt;br&gt;- Change from Baseline in Norfolk QOL-DN&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Final Analysis Secondary Endpoint&#x0D;&lt;br&gt;- Change from Baseline in the NSC score&#x0D;&lt;br&gt;- Change from Baseline in the PCS score of SF-36 &#x0D;&lt;br&gt;- Change from Baseline in PND score &#x0D;&lt;br&gt;- Change from Baseline in mBMI ;Timepoint(s) of evaluation of this end point: Interim Analysis Key Secondary Efficacy Endpoint at Week 35&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Change from Baseline in NSC at Weeks 35 and 66&#x0D;&lt;br&gt;Change from Baseline in the PCS score of SF-36 at Week 65&#x0D;&lt;br&gt;Change from Baseline in PND score at Week 65&#x0D;&lt;br&gt;Change from Baseline in mBMI at Week 65
    </Secondary_outcome>
    <Secondary_ID>ION-682884-CS3;2019-001698-10-GB
    </Secondary_ID>
    <Source_Support>Ionis Pharmaceuticals, Inc.
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>02/03/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13430983
    </Internal_Number>
    <TrialID>JPRN-jRCT2080224769
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>HELIOS-A: A Phase 3 Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
    </Public_title>
    <Scientific_title>HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>CMIC Co., Ltd.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190705
    </Date_registration3>
    <Date_registration>05/07/2019
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCT2080224769
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 18age old
    </Inclusion_agemin>
    <Inclusion_agemax>&lt;= 85age old
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>31/07/2019
    </Date_enrollement>
    <Target_size>16
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>This is a global, Phase 3 randomized, open-label study designed to evaluate efficacy, safety, and pharmacokinetics (PK)/(pharmacodynamics (PD)  of ALN-TTRSC02 in adult patients with hATTR amyloidosis.  Patients will be randomized 3:1 to ALN TTRSC02 or patisiran, a reference comparator.
    </Study_design>
    <Phase>3
    </Phase>
    <Countries>Japan;Asia except Japan;North America;South America;Europe;Oceania
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Hamamatsucho Bldg., 1-1-1 Shibaura Minato-ku, Tokyo
    </Contact_Address>
    <Contact_Email>TTR02-006_SC02-002@cmic.co.jp
    </Contact_Email>
    <Contact_Tel>-
    </Contact_Tel>
    <Contact_Affiliation>CMIC Co., Ltd. (ICCC)
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: -Male or female of 18 to 85 years of age (inclusive)&lt;br&gt;-Has a diagnosis of hATTR amyloidosis with transthyretin (TTR) mutation&lt;br&gt;-Has adequate neurologic impairment score (NIS);&lt;br&gt;-Has adequate polyneuropathy disability (PND) score&lt;br&gt;-Has adequate Karnofsky Performance Status(KPS)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -Had a prior liver transplant or is likely to undergo liver transplantation during the study&lt;br&gt;-Has known other (non-hATTR) forms of amyloidosis or leptomeningeal amyloidosis&lt;br&gt;-Has New York Heart Association heart failure classification &gt;2&lt;br&gt;-Clinically significant liver function test abnormalities&lt;br&gt;-Has known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)infection&lt;br&gt;-Received an experimental drug within 30 days of dosing&lt;br&gt;-Received prior TTR-lowering treatment&lt;br&gt;-Has other known causes of neuropathy
    </Exclusion_Criteria>
    <Condition>Hereditary Transthyretin Amyloidosis with polyneuropathy
    </Condition>
    <Intervention>investigational material(s)&lt;br&gt;Generic name etc : ALN-TTRSC02&lt;br&gt;INN of investigational material : vutrisiran&lt;br&gt;Therapeutic category code : 129 Other agents affecting peripheral nervous system&lt;br&gt;Dosage and Administration for Investigational material : 25mg (0.5 mL) of ALN-TTRSC02 administered as a subcutaneous injection once every 3 months&lt;br&gt;&lt;br&gt;control material(s)&lt;br&gt;Generic name etc : Patisiran Sodium (JAN)&lt;br&gt;INN of investigational material : Patisiran&lt;br&gt;Therapeutic category code : 129 Other agents affecting peripheral nervous system&lt;br&gt;Dosage and Administration for Investigational material : 0.3mg/kg of Patisiran is administered by intravenous drip infusion once every 3 weeks
    </Intervention>
    <Primary_outcome>efficacy&lt;br&gt;-Change from Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 [Time Frame: Baseline, Month 9]&lt;br&gt;-Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score at Month 9 [Time Frame: Baseline, Month 9]
    </Primary_outcome>
    <Secondary_outcome>safety&lt;br&gt;efficacy&lt;br&gt;exploratory&lt;br&gt;pharmacokinetics&lt;br&gt;pharmacodynamics&lt;br&gt;-Change from Baseline in the Timed 10-Meter Walk Test (10-MWT) at Months 9 and 18 [ Time Frame: Baseline, Months 9 and 18]&lt;br&gt;-Change from Baseline in the Modified Body Mass Index (mBMI) at Months 9 and 18 [ Time Frame: Baseline, Months 9 and 18 ]&lt;br&gt;-Change from Baseline in the Rasch-Built Overall Disability Scale (R-ODS) at Months 9 and 18 [ Time Frame: Baseline, Months 9 and 18 ]&lt;br&gt;-Percentage Reduction in Serum Transthyretin (TTR) Levels at Months 9 and 18 [ Time Frame: Baseline, Months 9 and 18 ]&lt;br&gt;-Frequency of All-Cause Deaths and/or All-Cause Hospitalizations Up to Month 18 [ Time Frame: Up to Month 18 ]&lt;br&gt;-Frequency of All-Cause Deaths and/or All-Cause Hospitalizations in Participants with Cardiac Involvement Up to Month 18 [ Time Frame: Up to Month 18 ]
    </Secondary_outcome>
    <Secondary_ID>NCT03759379;JapicCTI-194846
    </Secondary_ID>
    <Source_Support>-
    </Source_Support>
    <Ethics_review_status>Approval;Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>24/04/2019;24/04/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>-;-
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Shinshu University Hospital Institutional Review Board;Kumamoto University Hospital Institutional Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>-;-
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13912524
    </Internal_Number>
    <TrialID>NCT03862807
    </TrialID>
    <Last_Refreshed_on>29 April 2024
    </Last_Refreshed_on>
    <Public_title>Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
    </Public_title>
    <Scientific_title>An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190228
    </Date_registration3>
    <Date_registration>28/02/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03862807
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 27, 2019
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>France;Germany;Italy;Portugal;Spain;Sweden;United Kingdom;France;Germany;Italy;Portugal;Spain;Sweden;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Medical Director
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Received liver transplant for treatment of hATTR amyloidosis =12 months before study&#x0D;&lt;br&gt;             start&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has increase in polyneuropathy disability (PND) score after liver transplant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has received stable immunosuppressive regimen with =10 mg/day of prednisone for at&#x0D;&lt;br&gt;             least 3 months before study start&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has Karnofsky Performance Status (KPS) of =70%&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has vitamin A level greater than or equal to lower limit of normal&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has previously received inotersen or patisiran&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has clinically significant liver function test abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known portal hypertension with ascites&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m^2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known leptomeningeal amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has New York Heart Association heart failure classification of &gt;2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is wheelchair bound or bedridden&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has received organ transplants other than liver transplant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Will be using another tetramer stabilizer during the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloidosis, Familial;Transthyretin Amyloidosis
    </Condition>
    <Intervention>Drug: Patisiran
    </Intervention>
    <Primary_outcome>Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR)
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in the Neuropathy Impairment Score (NIS) at Month 12;Change From Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Score at Month 12;Change From Baseline in the Rasch-Built Overall Disability Scale (R-ODS) at Month 12;Change From Baseline in the Composite Autonomic Symptom Score (COMPASS-31) at Month 12;Change From Baseline in the Modified Body Mass Index (mBMI) at Month 12;Percentage of Participants With Adverse Events
    </Secondary_outcome>
    <Secondary_ID>2018-003519-24;ALN-TTR02-008
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>21/12/2021
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT03862807
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13430753
    </Internal_Number>
    <TrialID>JPRN-jRCT2080224174
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>ALN-TTR02-006
    </Public_title>
    <Scientific_title>A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Alnylam Pharmaceuticals, Inc. / Medpace Japan KK
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20181206
    </Date_registration3>
    <Date_registration>06/12/2018
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCT2080224174
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 18age old
    </Inclusion_agemin>
    <Inclusion_agemax>&lt;= 85age old
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>02/09/2016
    </Date_enrollement>
    <Target_size>211
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Multicenter, open-label study
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Japan;Asia except Japan;North America;South America;Europe;Oceania
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email>RSJapan1@medpace.com
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Medpace Japan KK
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug&lt;br&gt;Be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Any new or uncontrolled condition that could make the patient unsuitable for participation
    </Exclusion_Criteria>
    <Condition>Hereditary transthyretin-mediated amyloidosis(hATTR amyloidosis)
    </Condition>
    <Intervention>investigational material(s)&lt;br&gt;Generic name etc : Patisiran (ALN-TTR02)&lt;br&gt;INN of investigational material : Patisiran&lt;br&gt;Therapeutic category code : 129 Other agents affecting peripheral nervous system&lt;br&gt;Dosage and Administration for Investigational material : 0.3 mg/kg(q3w) IV Infusion&lt;br&gt;&lt;br&gt;control material(s)&lt;br&gt;Generic name etc : -&lt;br&gt;INN of investigational material : -&lt;br&gt;Therapeutic category code : &lt;br&gt;Dosage and Administration for Investigational material : -
    </Intervention>
    <Primary_outcome>safety&lt;br&gt;Safety and tolerability of long-term dosing of patisiran as measured by the proportion of subjects with adverse events leading to discontinuation of study drug&lt;br&gt;5 years
    </Primary_outcome>
    <Secondary_outcome>safety&lt;br&gt;efficacy&lt;br&gt;Changes from baseline in the following items&lt;br&gt;Neurologic impairment score: NIS, mNIS+7, NIS+7&lt;br&gt;QOL: QOL-DN, EuroQOL(EQ-5D)&lt;br&gt;Others: R-ODS, COMPASS 31, serum TTR level, mBMI, NIS-Weakness(NIS-W), 10-Meter Walk Test  and grip strength test
    </Secondary_outcome>
    <Secondary_ID>JapicCTI-184235
    </Secondary_ID>
    <Source_Support>-
    </Source_Support>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>27/07/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Kumamoto University Hospital - IRB
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13823187
    </Internal_Number>
    <TrialID>NCT03759379
    </TrialID>
    <Last_Refreshed_on>1 April 2024
    </Last_Refreshed_on>
    <Public_title>HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
    </Public_title>
    <Scientific_title>HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181128
    </Date_registration3>
    <Date_registration>28/11/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03759379
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 14, 2019
    </Date_enrollement>
    <Target_size>164
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;United Kingdom;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Medical Director
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female of 18 to 85 years of age (inclusive);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a diagnosis of hATTR amyloidosis with transthyretin (TTR) mutation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has adequate neurologic impairment score (NIS);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has adequate polyneuropathy disability (PND) score;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has adequate Karnofsky Performance Status (KPS).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had a prior liver transplant or is likely to undergo liver transplantation during the&#x0D;&lt;br&gt;             study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known other (non-hATTR) forms of amyloidosis or leptomeningeal amyloidosis;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has New York Heart Association heart failure classification &gt;2;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant liver function test abnormalities;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B&#x0D;&lt;br&gt;             virus (HBV) infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Received an experimental drug within 30 days of dosing;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Received prior TTR-lowering treatment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has other known causes of neuropathy.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloidosis, Hereditary;Transthyretin Amyloidosis
    </Condition>
    <Intervention>Drug: Patisiran;Drug: Vutrisiran
    </Intervention>
    <Primary_outcome>Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)]
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)];Change From Baseline in the Timed 10-Meter Walk Test (10-MWT) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)];Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 18 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)];Change From Baseline in Norfolk QoL-DN Total Score at Month 18 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)];Change From Baseline in the 10-MWT at Month 18 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)];Change From Baseline in the Modified Body Mass Index (mBMI) at Month 18 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)];Change From Baseline in the Rasch-Built Overall Disability Scale (R-ODS) at Month 18 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)];Percent Reduction in Serum Transthyretin (TTR) Levels Through Month 18 Between the Vutrisiran Group (HELIOS-A) and the Patisiran Group (HELIOS-A)
    </Secondary_outcome>
    <Secondary_ID>2018-002098-23;ALN-TTRSC02-002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>11/08/2022
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT03759379
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10446894
    </Internal_Number>
    <TrialID>EUCTR2018-003519-24-GB
    </TrialID>
    <Last_Refreshed_on>5 January 2021
    </Last_Refreshed_on>
    <Public_title>Patisiran-LNP in Patients with hATTR Amyloidosis Disease Progression Post-Liver Transplant
    </Public_title>
    <Scientific_title>An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Alnylam Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181122
    </Date_registration3>
    <Date_registration>22/11/2018
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003519-24
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>12/03/2019
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Germany;Italy;United Kingdom;Sweden;Portugal;France;Spain;Netherlands
    </Countries>
    <Contact_Firstname>Clinical Trial Information Line
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>300 Third Street
    </Contact_Address>
    <Contact_Email>clinicaltrials@alnylam.com
    </Contact_Email>
    <Contact_Tel>0018772569526
    </Contact_Tel>
    <Contact_Affiliation>Alnylam Pharmaceuticals, Inc
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;-18 years of age or older&#x0D;&lt;br&gt;-Received an orthotopic liver transplant for treatment of hATTR amyloidosis at least 1 year prior&#x0D;&lt;br&gt;-Increase in polyneuropathy disability post-liver transplant as measured by polyneuropathy disability (PND) score.&#x0D;&lt;br&gt;-Karnofsky performance status of =70%&#x0D;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 10&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;-Currently taking tafamidis, doxycycline, diflunisal, or tauroursodeoxycholic acid&#x0D;&lt;br&gt;-Liver allograft rejection episodes or abnormal LFTs suggestive of possible allograft rejection in the past 6 months &#x0D;&lt;br&gt;-Abnormal liver function tests&#x0D;&lt;br&gt;-Known leptomeningeal amyloidosis&#x0D;&lt;br&gt;-New York Heart Association (NYHA) classification of &gt;2 &#x0D;&lt;br&gt;-PND score IV (wheelchair bound or bedridden)&#x0D;&lt;br&gt;- Prior organ transplant other than liver transplant&#x0D;&lt;br&gt;-Hospitalization for congestive heart failure or arrhythmia in the past 3 months   &lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10007509
Term: Cardiac amyloidosis
System Organ Class: 10007541 - Cardiac disorders
 &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10019889
Term: Hereditary neuropathic amyloidosis
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Trade Name: Onpattro&lt;br&gt;Product Name: patisiran-LNP&lt;br&gt;Product Code: ALN-TTR02&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: PATISIRAN&lt;br&gt;Current Sponsor code: ALN-TTR02&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the TTR reduction of patisiran-LNP in hATTR amyloidosis patients with disease progression after OLT ;Secondary Objective: - To evaluate the effect of patisiran-LNP on neuropathy &lt;br&gt;- To evaluate the effect of patisiran-LNP on patient reported outcomes including QoL, activities of daily living and autonomic neuropathy symptoms &lt;br&gt;- To characterize the effect on nutritional status  ;Primary end point(s): Percent change from baseline in serum TTR levels;Timepoint(s) of evaluation of this end point: Month 6, Month 12
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): -Change from baseline in Neuropathy Impairment Score (NIS)&#x0D;&lt;br&gt;-Change from baseline in quality of life and disability as assessed by Norfolk Quality of Life (QoL-DN), Rasch-built Overall Disability Scale (R-ODS), and Autonomic Symptoms Questionnaire (COMPASS 31)&#x0D;&lt;br&gt;-Change from baseline in modified Body Mass Index (mBMI);Timepoint(s) of evaluation of this end point: 12 months (this is applicable to all 3 of the secondary end points)
    </Secondary_outcome>
    <Secondary_ID>ALN-TTR02-008
    </Secondary_ID>
    <Source_Support>Alnylam Pharmaceuticals, Inc.
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>12/03/2019
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>14014767
    </Internal_Number>
    <TrialID>DRKS00015863
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Diagnosis of mitochondriopathies and familial Mediterranean fever using nanopore sequencing
    </Public_title>
    <Scientific_title>Diagnosis of mitochondriopathies and familial Mediterranean fever using nanopore sequencing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Laborärzte Singen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181116
    </Date_registration3>
    <Date_registration>16/11/2018
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00015863
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>None
    </Inclusion_agemin>
    <Inclusion_agemax>None
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>18/03/2019
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: diagnostic 
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Jonas
    </Contact_Firstname>
    <Contact_Lastname>Schmidt
    </Contact_Lastname>
    <Contact_Address>Virchowstraße 10c
    </Contact_Address>
    <Contact_Email>jonas.schmidt@labor-blessing.de
    </Contact_Email>
    <Contact_Tel>00497731/99560 
    </Contact_Tel>
    <Contact_Affiliation>Laborärzte Singen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Regarding the diagnosis of mitochondriopathies female patients with recurrent miscarriage should be included into the study.&lt;br&gt;To investigate the suitability of nanopore sequencing for the diagnosis of familial Mediterranean fever male and female patients with suspected familial Mediterranean fever should be included.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: There is no written consent regarding human genetics investigations according to the German Genetic Diagnostic Act.
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G31.81 &lt;br&gt;E85.0 &lt;br&gt;O03;Non-neuropathic heredofamilial amyloidosis;Spontaneous abortion;G31.81;E85.0
    </Condition>
    <Intervention>Group 1: In this study at first a method comparison between conventional Sanger sequencing and nanopore sequencing should be performed, to see whether nanopore sequencing is suitable for the laboratory diagnostic of familial Mediterranean fever. For this purpose, a single EDTA blood sample of patients which are suspected of familial Mediterranean fever should be used. &lt;br&gt;During the second part of this study a gene panel should be established which can be used for the laboratory diagnosis of mitochondriopathies by nanopore sequencing. Finally, this gene panel should be applied to investigate a possible relationship between mitochondriopathies and recurrent miscarriage. For this purpose, a single EDTA blood sample of the mother and as well as trophoblast tissue after an abortion should be used.  &lt;br&gt;
    </Intervention>
    <Primary_outcome>Is it possible to use nanopore sequencing for the diagnosis of mitochondriopathies and familial Mediterranean fever?
    </Primary_outcome>
    <Secondary_outcome>Is there a possible relationship between recurrent miscarriage and mitochondriopathies? 
    </Secondary_outcome>
    <Source_Support>Laborärzte Singen
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/10/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkommission@laek-bw.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission bei der Landesärztekammer Baden-Württemberg
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-711-7698919
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkommission@laek-bw.de
    </Ethics_review_contact_email>
    <results_yes_no/>
    <results_date_completed>01/12/2021
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00015863#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13395540
    </Internal_Number>
    <TrialID>NCT03720275
    </TrialID>
    <Last_Refreshed_on>16 October 2023
    </Last_Refreshed_on>
    <Public_title>Early and Systematic Screening in Chronic Neuropathy
    </Public_title>
    <Scientific_title>Evaluation of a New Diagnostic Approach to Familial Amyloid Neuropathy by Mutation of the TTR Gene in a Population of Idiopathic Chronic Neuropathies
    </Scientific_title>
    <Acronym>TTR-FAP
    </Acronym>
    <Primary_sponsor>University Hospital, Bordeaux
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181012
    </Date_registration3>
    <Date_registration>12/10/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03720275
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 27, 2018
    </Date_enrollement>
    <Target_size>130
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Guilhem Solé, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University Hospital Bordeaux, France
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients of both sexes presenting chronically (&gt; 3 months):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  neuropathy confirmed by an electroneuromyography&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  without obvious etiology (diabetes, alcohol consumption, renal insufficiency,&#x0D;&lt;br&gt;                  neurotoxic substances intake, family history of diagnosed hereditary neuropathy)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  without anomaly of the following biological examinations: fasting blood glucose,&#x0D;&lt;br&gt;                  blood count, gamma-glutamyl transferases, average cell volume, transaminases,&#x0D;&lt;br&gt;                  serum creatinine clearance, C-reactive protein, TSH&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged 18 to 90 years Patients giving their free and informed consent to participate,&#x0D;&lt;br&gt;             after research information&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  People placed under the protection of justice.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients who are not affiliated or who are not beneficiaries of a social security&#x0D;&lt;br&gt;             scheme&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with chronic neuropathy related to a known etiology&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloid Neuropathies, Familial
    </Condition>
    <Intervention>Genetic: Systematic screening of TTR mutations
    </Intervention>
    <Primary_outcome>Diagnosis of TTR-FAP
    </Primary_outcome>
    <Secondary_outcome>Age of patient at diagnosis;History of dysautonomias;Signs of dysautonomias;Weight of patient;Height of patient;Motor deficit of the lower limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS);Motor deficit of the upper limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS);Sensory deficit evaluated by a subscore of the Neuropathy Impairment Scale (NIS);Presence / Absence of reflexes osteo-tendinous evaluated by a subscore of the Neuropathy Impairment Scale (NIS);Presence of orthostatic hypotension;Dysautonomia score;Rasch-built Overall Disability Scale (RODS) score;Overall Neuropathy Limitations Scale (ONLS) score;Electroneuromyography findings (ENMG): axonal, demyelinating or mixed neuropathy).
    </Secondary_outcome>
    <Secondary_ID>CHUBX 2016/35
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Bordeaux
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>12573091
    </Internal_Number>
    <TrialID>NCT03588468
    </TrialID>
    <Last_Refreshed_on>10 October 2022
    </Last_Refreshed_on>
    <Public_title>Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study
    </Public_title>
    <Scientific_title>Expanding the Biomarkers in Familial Amyloid Neuropathy: Magnetic Resonance Imaging (MRI) and Motor Unit Estimation by Electrophysiological Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Assistance Publique Hopitaux De Marseille
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180704
    </Date_registration3>
    <Date_registration>04/07/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03588468
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 20, 2018
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>EMILIE GARRIDO PRADALIE
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>APHM
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        For a subject to be eligible, all of the inclusion criteria and none of the exclusion&#x0D;&lt;br&gt;        criteria must be met.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        3.1.1. TTR mutation gene carriers 3.1.1.a. Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subject must meet the following criteria to be included:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18 years and older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Men or women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Carrying TTR mutation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having social insurance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Given written informed consent after being informed of the purpose and potential risks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        3.1.1.b. Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects with the following criteria will be excluded:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with a contraindication for MRI explorations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject unable to understand the purpose and conditions of carrying out the study,&#x0D;&lt;br&gt;             unable to give consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        3.1.2. Healthy controls 3.1.2.a. Inclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subject must meet the following criteria to be included:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18 years and older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Men or women&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having social insurance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Given written informed consent after being informed of the purpose and potential risks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        3.1.2.b. Exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects with the following criteria will be excluded:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject with a contraindication for MRI explorations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject unable to understand the purpose and conditions of carrying out the study,&#x0D;&lt;br&gt;             unable to give consent&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloid Neuropathies;Transthyretin Amyloidosis
    </Condition>
    <Intervention>Other: Electrophysiological biomarkers;Other: MRI biomarkers
    </Intervention>
    <Primary_outcome>MRI neurography;MUNIX
    </Primary_outcome>
    <Secondary_ID>2017-37
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>7276349
    </Internal_Number>
    <TrialID>EUCTR2017-005115-13-FR
    </TrialID>
    <Last_Refreshed_on>20 August 2018
    </Last_Refreshed_on>
    <Public_title>A Non-Interventional Study to Monitor the Survival Status of&#x0D;
Patients that Discontinued from ISIS 420915-CS2 or&#x0D;
ISIS 420915-CS3
    </Public_title>
    <Scientific_title>A Non-Interventional Study to Monitor the Survival Status of&#x0D;
Patients that Discontinued from ISIS 420915-CS2 or&#x0D;
ISIS 420915-CS3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180227
    </Date_registration3>
    <Date_registration>27/02/2018
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-005115-13
    </web_address>
    <Recruitment_Status>Not Available
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement/>
    <Target_size>164
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Patient follow-up to determine survival status&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Portugal;United States;France;Argentina;Brazil;Spain;Germany;New Zealand;Italy;United Kingdom
    </Countries>
    <Contact_Firstname>Matthew Rael
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>2855 Gazelle Court
    </Contact_Address>
    <Contact_Email>mrael@ionisph.com
    </Contact_Email>
    <Contact_Tel>011 760603 2387
    </Contact_Tel>
    <Contact_Affiliation>Ionis Pharmaceuticals, Inc
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patient or representative must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;2. Patient must be part of the ISIS 420915-CS2 safety population (defined as all patients that received at least 1 dose of Study Drug (placebo or inotersen)) or representative(s) of patient in ISIS 420915-CS2 safety population&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 82&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 82&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;None&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy &lt;br&gt;MedDRA version: 20.0
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 100000004850
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Human Transthyretin Antisense Oligonucleotide&lt;br&gt;Product Code: ISIS 420915&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ISIS 420915&lt;br&gt;CAS Number: 1432726-13-0&lt;br&gt;Current Sponsor code: ISIS 420915&lt;br&gt;Other descriptive name: Inotersen&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To monitor the survival of patients who are no longer actively participating in ISIS 420915-CS2 or ISIS 420915-CS3 and were in the ISIS 420915-CS2 safety population (defined as all patients that received at least 1 dose of Study Drug (placebo or inotersen));Secondary Objective: To collect information about the cause of death and related circumstances;Primary end point(s): - Time to death from first dose of Study Drug in ISIS 420915-CS2 (inotersen or placebo)&lt;br&gt;- Time to death from first dose of inotersen&lt;br&gt;- Percentage of patients that died within 66 weeks, as well as 3 years, of first dose of Study Drug in ISIS 420915-CS2&lt;br&gt;- Percentage of patients whose survival status is unknown 66 weeks, as well as 3 years, after first dose of Study Drug in ISIS 420915-CS2;Timepoint(s) of evaluation of this end point: 2 years
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - Cause of death;Timepoint(s) of evaluation of this end point: 2 years
    </Secondary_outcome>
    <Secondary_ID>ISIS420915-CS4;2017-005115-13-ES
    </Secondary_ID>
    <Source_Support>Ionis Pharmaceuticals
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>7137397
    </Internal_Number>
    <TrialID>EUCTR2017-005115-13-ES
    </TrialID>
    <Last_Refreshed_on>11 June 2018
    </Last_Refreshed_on>
    <Public_title>A Non-Interventional Study to Monitor the Survival Status of
Patients that Discontinued from ISIS 420915-CS2 or
ISIS 420915-CS3
    </Public_title>
    <Scientific_title>A Non-Interventional Study to Monitor the Survival Status of
Patients that Discontinued from ISIS 420915-CS2 or
ISIS 420915-CS3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180219
    </Date_registration3>
    <Date_registration>19/02/2018
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-005115-13
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>25/04/2018
    </Date_enrollement>
    <Target_size>164
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Patient follow-up to determine survival status&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>United Kingdom;New Zealand;Italy;Portugal;France;United States;Argentina;Brazil;Spain;Germany
    </Countries>
    <Contact_Firstname>Matthew Rael
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>2855 Gazelle Court
    </Contact_Address>
    <Contact_Email>mrael@ionisph.com
    </Contact_Email>
    <Contact_Tel>011760603 2387
    </Contact_Tel>
    <Contact_Affiliation>Ionis Pharmaceuticals, Inc
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patient or representative must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.&lt;br&gt;&lt;br&gt;2. Patient must be part of the ISIS 420915-CS2 safety population (defined as all patients that received at least 1 dose of Study Drug (placebo or inotersen)) or representative(s) of patient in ISIS 420915-CS2 safety population&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 82&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 82&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;None&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy &lt;br&gt;MedDRA version: 20.0
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 100000004850
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Human Transthyretin Antisense Oligonucleotide&lt;br&gt;Product Code: ISIS 420915&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ISIS 420915&lt;br&gt;CAS Number: 1432726-13-0&lt;br&gt;Current Sponsor code: ISIS 420915&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To monitor the survival of patients who are no longer actively participating in ISIS 420915-CS2 or ISIS 420915-CS3 and were in the ISIS 420915-CS2 safety population (defined as all patients that received at least 1 dose of Study Drug (placebo or inotersen));Secondary Objective: To collect information about the cause of death and related circumstances;Primary end point(s): - Time to death from first dose of Study Drug in ISIS 420915-CS2 (inotersen or placebo)&lt;br&gt;- Time to death from first dose of inotersen&lt;br&gt;- Percentage of patients that died within 66 weeks, as well as 3 years, of first dose of Study Drug in ISIS 420915-CS2&lt;br&gt;- Percentage of patients whose survival status is unknown 66 weeks, as well as 3 years, after first dose of Study Drug in ISIS 420915-CS2;Timepoint(s) of evaluation of this end point: 2 years
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - Cause of death;Timepoint(s) of evaluation of this end point: 2 years
    </Secondary_outcome>
    <Secondary_ID>ISIS420915-CS4
    </Secondary_ID>
    <Source_Support>Ionis Pharmaceuticals
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13881347
    </Internal_Number>
    <TrialID>NCT03431896
    </TrialID>
    <Last_Refreshed_on>15 April 2024
    </Last_Refreshed_on>
    <Public_title>Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
    </Public_title>
    <Scientific_title>Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
    </Scientific_title>
    <Acronym>MED-hATTR
    </Acronym>
    <Primary_sponsor>The Cleveland Clinic
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180207
    </Date_registration3>
    <Date_registration>07/02/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03431896
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Mazen A Hanna, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Cleveland Clinic
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with known hereditary ATTR amyloidosis genetic mutations as identified by&#x0D;&lt;br&gt;             genetic testing.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with ATTR amyloidosis identified as wild-type.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloidosis;Amyloid;Amyloid Neuropathies, Familial;Amyloid Cardiomyopathy;Amyloid - Primary;Transthyretin Amyloidosis;AL Amyloidosis
    </Condition>
    <Primary_outcome>Average % change in oligomers in patients with new onset TTR amyloid symptoms
    </Primary_outcome>
    <Secondary_outcome>% change of oligomer levels relative to baseline level in patients with ATTR specific medication changes
    </Secondary_outcome>
    <Secondary_ID>17-1301
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13496567
    </Internal_Number>
    <TrialID>NCT03237494
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
    </Public_title>
    <Scientific_title>Genetic Screening of an At-risk Population for Hereditary TransthyRetin-related AMyloidosis and Longitudinal Monitoring of TTR Positive Subjects- A Multicenter Epidemiological Longitudinal Protocol
    </Scientific_title>
    <Acronym>TRAMmoniTTR
    </Acronym>
    <Primary_sponsor>CENTOGENE GmbH Rostock
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170731
    </Date_registration3>
    <Date_registration>31/07/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03237494
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 20, 2017
    </Date_enrollement>
    <Target_size>5000
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Austria;Germany;Switzerland;Austria;Germany;Switzerland
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Peter Bauer, Prof.;Sabine Roesner
    </Contact_Lastname>
    <Contact_Email>;sabine.roesner@centogene.com
    </Contact_Email>
    <Contact_Tel>;+49 381 80113657
    </Contact_Tel>
    <Contact_Affiliation>Centogene GmbH;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent is obtained from the participant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant is 18 years of age or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has no diagnosis of alcoholism according to international guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has not undergone chemotherapy for any carcinoma&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        AND&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        The participant is at risk for hATTR due to two or more the factors listed below:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cardiomyopathy or polyneuropathy with no obvious etiology atypical Chronic&#x0D;&lt;br&gt;             Inflammatory Demyelinating Polyneuropathy (CIDP) or Motor Neuron Disease (MND)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  autonomic dysfunction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  hypertrophic cardiomyopathy or heart failure with preserved ejection fraction Left&#x0D;&lt;br&gt;             Ventricular Hypertrophy (LVH)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  bilateral carpal tunnel syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  spinal stenosis or spinal radiculopathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  gait disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ocular changes involving vitreous opacities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unexplained weight loss &gt;5kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  renal abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  family history of hATTR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  based on imaging or biopsy suspected for the wild type TTR (ATTR) and not genetically&#x0D;&lt;br&gt;             tested for hATTR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        OR • The participant is diagnosed with hATTR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        OR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        • The participant is a 1st or 2nd degree relative of the TTR positive subject&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent is not obtained from the participant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant is younger than 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has a diagnosis of alcoholism according to International guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has undergone chemotherapy for any carcinoma&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant is not at risk for hATTR&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin Amyloidosis;Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy;Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy;Polyneuropathies;Cardiomyopathies
    </Condition>
    <Primary_outcome>Analysis of prevalance of hATTR mutations among a cohort of participants at risk for hATTR.;To monitor clinical status in TTR positive subjects.
    </Primary_outcome>
    <Secondary_outcome>Establishment of biomarker/s in TTR positive cohort.
    </Secondary_outcome>
    <Secondary_ID>TRAM2 analysis
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Alnylam Pharmaceuticals
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>12424157
    </Internal_Number>
    <TrialID>NCT03190577
    </TrialID>
    <Last_Refreshed_on>29 July 2022
    </Last_Refreshed_on>
    <Public_title>Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology
    </Public_title>
    <Scientific_title>Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology
    </Scientific_title>
    <Acronym>PRE-TRANS
    </Acronym>
    <Primary_sponsor>Nantes University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170614
    </Date_registration3>
    <Date_registration>14/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03190577
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 21, 2017
    </Date_enrollement>
    <Target_size>400
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France;France;France;France
    </Countries>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13461156
    </Internal_Number>
    <TrialID>JPRN-UMIN000027045
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Diagnosis and elucidation of small-fiber dysfunction using electrophysiological technique
    </Public_title>
    <Scientific_title>Diagnosis and elucidation of small-fiber dysfunction using electrophysiological technique - Diagnosis and elucidation of small-fiber dysfunction using electrophysiological technique                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170418
    </Date_registration3>
    <Date_registration>18/04/2017
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029068
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16years-old
    </Inclusion_agemin>
    <Inclusion_agemax>50years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2016/12/06
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Minori Kodaira
    </Contact_Lastname>
    <Contact_Address>3-1-1 Asahi, Matsumoto
    </Contact_Address>
    <Contact_Email>mkodaira@shinshu-u.ac.jp
    </Contact_Email>
    <Contact_Tel>0263-37-2673
    </Contact_Tel>
    <Contact_Affiliation>Shinshu University School of Medicine Department of Medicine (Neurology and Rheumatology)
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients or healthy subjects with other neuropathy
    </Exclusion_Criteria>
    <Condition>Familial amyloid polyneuropathy
    </Condition>
    <Intervention>Twice examinations using intraepidermal electrical stimulation
    </Intervention>
    <Primary_outcome>Correlation of sensory threshold and evoked potentials evaluated by intraepidermal electrical stimulation with sensory thresold assessed by quantitative sensory testing
    </Primary_outcome>
    <Source_Support>Japan Society for the Promotion of Science
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13996975
    </Internal_Number>
    <TrialID>NCT02939820
    </TrialID>
    <Last_Refreshed_on>27 May 2024
    </Last_Refreshed_on>
    <Public_title>Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
    </Public_title>
    <Scientific_title>Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20161018
    </Date_registration3>
    <Date_registration>18/10/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT02939820
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 24, 2017
    </Date_enrollement>
    <Target_size/>
    <Study_type>Expanded Access
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Medical Director
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female greater than or equal to 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a diagnosis of hATTR&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meet Karnofsky performance status and Polyneuropathy Disability (PND) score&#x0D;&lt;br&gt;             requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have adequate complete blood counts, liver function tests and coagulation tests&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participated in an interventional hATTR amyloidosis clinical trial involving RNA&#x0D;&lt;br&gt;             interference (RNAi) therapeutics within the last 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Are currently eligible to participate in or currently enrolled in an ongoing&#x0D;&lt;br&gt;             interventional hATTR amyloidosis clinical trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have inadequate cardiac function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known primary amyloidosis (AL amyloidosis) or leptomeningeal amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have known serious comorbidities or considered unfit for the program by the&#x0D;&lt;br&gt;             investigator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior or planned liver or heart transplantation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>TTR-mediated Amyloidosis;Amyloidosis, Hereditary;Amyloid Neuropathies, Familial;Familial Amyloid Polyneuropathies;Amyloid Neuropathies;Amyloidosis, Hereditary, Transthyretin-Related
    </Condition>
    <Intervention>Drug: patisiran (ALN-TTR02)
    </Intervention>
    <Secondary_ID>ALN-TTR02-007
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>12829847
    </Internal_Number>
    <TrialID>NCT02713880
    </TrialID>
    <Last_Refreshed_on>20 February 2023
    </Last_Refreshed_on>
    <Public_title>Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)
    </Public_title>
    <Scientific_title>Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy - An International, Multicenter, Epidemiological Protocol
    </Scientific_title>
    <Acronym>BioTRAP
    </Acronym>
    <Primary_sponsor>CENTOGENE GmbH Rostock
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160113
    </Date_registration3>
    <Date_registration>13/01/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02713880
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>2 Months
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 20, 2018
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Germany;India;Germany;India
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Arndt Rolfs, Prof.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>CENTOGENE GmbH Rostock
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent will be obtained from the parents before any study related&#x0D;&lt;br&gt;             procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients of both genders older than 2 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The patient has a diagnosis of Transthyretin-Related Familial Amyloidotic&#x0D;&lt;br&gt;             Polyneuropathy or a high-grade suspicion for Transthyretin-Related Familial&#x0D;&lt;br&gt;             Amyloidotic Polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High-grade suspicion present, if one or more inclusion criteria are valid:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Positive family anamnesis for Transthyretin-Related Familial Amyloidotic&#x0D;&lt;br&gt;                  -Polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Orthostatic dysregulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Acroparaesthesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Dysaesthesia and paraesthesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Muscle paresis and atrophy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No Informed consent from the parents before any study related procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients of both genders younger than 2 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy or no valid&#x0D;&lt;br&gt;             criteria for profound suspicion of Transthyretin-Related Familial Amyloidotic&#x0D;&lt;br&gt;             Polyneuropathy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin Amyloidosis;Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy;Transthyretin Amyloid Cardiopathy
    </Condition>
    <Primary_outcome>Development of a new MS-based biomarker for the early and sensitive diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood
    </Primary_outcome>
    <Secondary_outcome>Number of correctly identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy
    </Secondary_outcome>
    <Secondary_ID>BTR 06-2018
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10086342
    </Internal_Number>
    <TrialID>EUCTR2015-004318-14-DE
    </TrialID>
    <Last_Refreshed_on>16 November 2020
    </Last_Refreshed_on>
    <Public_title>A study to evaluate whether NEOD001 is safe and effective in subjects with light chain AL amyloidosis affecting the heart.
    </Public_title>
    <Scientific_title>A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Prothena Therapeutics Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20151126
    </Date_registration3>
    <Date_registration>26/11/2015
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004318-14
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>13/06/2016
    </Date_enrollement>
    <Target_size>129
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>United States;France;Greece;Spain;Austria;Australia;Israel;Germany;United Kingdom;Italy
    </Countries>
    <Contact_Firstname>Jay Soto
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>331 Oyster Point Boulevard
    </Contact_Address>
    <Contact_Email>jay.soto@prothena.com
    </Contact_Email>
    <Contact_Tel>+16506152131
    </Contact_Tel>
    <Contact_Affiliation>Prothena Biosciences Inc
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Age =18 years&lt;br&gt;&lt;br&gt;2. Confirmed diagnosis of systemic AL amyloidosis by the following:&lt;br&gt;o Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance &lt;br&gt;AND&lt;br&gt;o Confirmatory electron microscopy OR immunohistochemistry OR mass spectrometry of AL amyloidosis&lt;br&gt;&lt;br&gt;3. If the subject meets any of the following criteria, confirm diagnosis of AL amyloidosis by mass spectrometry OR immunoelectron microscopy of amyloid material in tissue biopsy: &lt;br&gt;o Is black or African American&lt;br&gt;o Is over 75 years of age (at time of diagnosis) with concurrent monoclonal gammopathy&lt;br&gt;o Has a history of familial amyloidosis and has concurrent monoclonal gammopathy&lt;br&gt;OR&lt;br&gt;o If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc DPD; Rapezzi et al, 2011), hydroxymethylenediphosphonate (99mTc HMDP; Galat et al, 2015), or pyrophosphate (99mTc PYP; Bokhari et al,  2013) scintigraphy&lt;br&gt;&lt;br&gt;4. Cardiac involvement as defined by BOTH of the following:&lt;br&gt;o Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure&lt;br&gt;o Either an endomyocardial biopsy demonstrating AL amyloidosis OR an echocardiogram demonstrating a mean left ventricular wall thickness at diastole &gt;12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening&lt;br&gt;&lt;br&gt;5. NT-proBNP =650 pg/mL and =5000 pg/mL (i.e., =76.7 pmol/L and =590 pmol/L)&lt;br&gt;&lt;br&gt;6. Received at least one prior systemic chemotherapeutic regimen, which may include stem cell transplant, for AL amyloidosis&lt;br&gt;&lt;br&gt;7. Achieved at least a partial hematologic response to a first-line therapy resulting in a stable hematologic condition not currently requiring additional active treatment against the plasma cell dyscrasia component of their AL disease&lt;br&gt;&lt;br&gt;8. Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:  &lt;br&gt;o Absolute neutrophil count (ANC) =1.0 × 109/L&lt;br&gt;o Platelet count =75 × 109/L&lt;br&gt;o Hemoglobin =9 g/dL&lt;br&gt;o Total bilirubin =2 × upper limit of normal (ULN)&lt;br&gt;o Aspartate aminotransferase (AST) =3 × ULN &lt;br&gt;o Alanine aminotransferase (ALT) =3 × ULN&lt;br&gt;o Alkaline phosphatase (ALP) =5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)&lt;br&gt;o Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation&lt;br&gt;&lt;br&gt;9. Systolic blood pressure 90-180 mmHg&lt;br&gt;&lt;br&gt;10. Distance walked during each of the two Screening 6-minute walk tests (6MWTs) is &gt;100 meters and &lt;600 meters&lt;br&gt;&lt;br&gt;11. Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration&lt;br&gt; &lt;br&gt;12. Male subjects must be surgica
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Subjects must not meet any of the following criteria:&lt;br&gt;&lt;br&gt;1. Diagnosis of non-AL amyloidosis&lt;br&gt;&lt;br&gt;2. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma &lt;br&gt;&lt;br&gt;3. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject's ability to safely receive treatment or complete study assessments&lt;br&gt;&lt;br&gt;4. Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&lt;br&gt;&lt;br&gt;5. Severe valvular stenosis (e.g. aortic or mitral stenosis with a valve area &lt;1.0 cm2) or severe congenital heart disease&lt;br&gt;&lt;br&gt;6. ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:&lt;br&gt;o First degree atrioventricular (AV) block&lt;br&gt;o Second degree AV block Type 1 (Mobitz Type 1/Wenckebach type)&lt;br&gt;o Right or left bundle branch block&lt;br&gt;o Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., &gt;110 bpm] ventricular rate is not allowed [determined by an average of three beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG])&lt;br&gt;&lt;br&gt;7. Has not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse Events [CTCAE] =Grade 2) from the clinically significant toxic effects of prior anticancer therapy. Exception: subjects with prior bortezomib treatment may have CTCAE Grade 2 neuropathy.&lt;br&gt;&lt;br&gt;8. Received any of the following within the specified time frame prior to the Month 1-Day 1 Visit:&lt;br&gt;o Oral or intravenous antibiotics, antifungals, or antivirals within 1 week, with the exception of prophylactic oral agents. Note:  In the event that a subject requires the chronic use of antivirals, Medical Monitor permission is required for entry into the study.&lt;br&gt;o Hematopoietic growth factors, transfusions of blood or blood products within 1 week&lt;br&gt;o Chemotherapy, radiotherapy, or other plasma cell directed therapy within 6 months&lt;br&gt;o ASCT within 12 months&lt;br&gt;o Major surgery within 4 weeks&lt;br&gt;o Planned major surgery or organ transplant during the study&lt;br&gt;o Any other investigational agent within 4 weeks&lt;br&gt;o Prior treatment with NEOD001, 11-1F4, anti-serum amyloid P (SAP) antibody (exception: allowed as part of established diagnostic procedures such as SAP scintigraphy), or other investigational treatment directed at amyloid &lt;br&gt;o Doxycycline within 6 weeks&lt;br&gt;&lt;br&gt;9. Active malignancy with the exception of any of the following:&lt;br&gt;o Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer&lt;br&gt;o Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for =2 years&lt;br&gt;o Low-risk prostate cancer with Gleason score &lt;7 and prostate-specific antigen &lt;10 mg/mL&lt;br&gt;o Any other cancer from which the subject has been disease-free for =2 years&lt;br&gt;&lt;br&gt;10. History of Grade =3 infusion-related adverse events (AEs) or hypersensitivity to another monoclonal antibody&lt;br&gt;&lt;br&gt;11. History of severe allergy to any of the components of NEOD001 such as histidine/L-histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20&lt;br&gt;&lt;br&gt;12. Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infection&lt;br&gt;&lt;br&gt;13. Women who are breastfeeding&lt;br&gt;&lt;br&gt;14. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject’s risk by p
    </Exclusion_Criteria>
    <Condition>Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble,fibrillar deposits of abnormal AL protein (amyloid),in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac,renal,and hepatic dysfunction,gastrointestinal involvement and neuropathy and macroglossia &lt;br&gt;MedDRA version: 20.0
Level: PT
Classification code 10036673
Term: Primary amyloidosis
System Organ Class: 10021428 - Immune system disorders
;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: NEOD001&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: N/A&lt;br&gt;CAS Number: N/A&lt;br&gt;Current Sponsor code: NEOD001&lt;br&gt;Other descriptive name: Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous drip use (Noncurrent)&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: The objective of this study is to determine the efficacy and safety of NEOD001 versus placebo in subjects with AL amyloidosis who have persistent cardiac dysfunction.;Secondary Objective: • Change from baseline to 12 months of treatment in the Physical Component Score (PCS) of the Short Form-36 Version 2 (SF-36v2)&lt;br&gt;• Change from baseline to 12 months of treatment in the 6MWT distance (meters)&lt;br&gt;• NT-proBNP Slope over 12 months of treatment&lt;br&gt;• Renal evaluable subjects: renal best response from baseline through 12 months of treatment&lt;br&gt;• Peripheral neuropathy evaluable subjects: change from baseline to 12 months of treatment in NIS-LL total score&lt;br&gt;• Hepatic evaluable subjects: hepatic best response from baseline through 12 months of treatment&lt;br&gt;;Primary end point(s): NT-proBNP best response;Timepoint(s) of evaluation of this end point: NT-proBNP best response from baseline through 12 months of treatment
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - SF-36v2&lt;br&gt;- 6MWT&lt;br&gt;-NT proBNP Slope&lt;br&gt;- Renal best response&lt;br&gt;- Peripheral neuropathy score&lt;br&gt;- Hepatic Best Response&lt;br&gt;;Timepoint(s) of evaluation of this end point: •Change from baseline to 12 months of treatment in the Physical Component Score (PCS) of the Short Form-36 Version 2 (SF-36v2) &lt;br&gt;•Change from baseline to 12 months of treatment in the 6MWT distance (meters) &lt;br&gt;•NT proBNP Slope over 12 months of treatment&lt;br&gt;•Renal evaluable subjects: renal best response from baseline through 12 months of treatment &lt;br&gt;•Peripheral neuropathy evaluable subjects: change from baseline to 12 months of treatment in NIS-LL total score &lt;br&gt;•Hepatic evaluable subjects: hepatic best response from baseline through 12 months of treatment &lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NEOD001-201
    </Secondary_ID>
    <Source_Support>Prothena Therapeutics Limited
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>13/06/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>03/09/2018
    </results_date_posted>
    <results_date_completed>05/03/2018
    </results_date_completed>
    <results_url_link>https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004318-14/results
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10248140
    </Internal_Number>
    <TrialID>NCT02595983
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
    </Public_title>
    <Scientific_title>An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20151030
    </Date_registration3>
    <Date_registration>30/10/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02595983
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2015
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>France;Germany;Portugal;Spain;Sweden;United Kingdom;France;Germany;Portugal;Spain;Sweden;United Kingdom
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>John Vest, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of FAP (familial amyloidotic polyneuropathy) with documented TTR mutation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Received an orthotopic liver transplant =12 months before the date of informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An increase in polyneuropathy disability (PND) score post-transplant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Polyneuropathy Disability score of =3b&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  New York Heart Association (NYHA) classification of &gt;2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other known causes of sensorimotor or autonomic neuropathy (eg, autoimmune disease)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin (TTR)-Mediated Amyloidosis;Familial Amyloidotic Polyneuropathy (FAP);ATTR Amyloidosis;Familial Amyloid Neuropathies
    </Condition>
    <Intervention>Drug: Revusiran
    </Intervention>
    <Primary_outcome>Percentage Change From Baseline in Serum TTR at Month 6
    </Primary_outcome>
    <Secondary_outcome>Percentage Change From Baseline in Serum TTR Over 18 Months;Change From Baseline in Modified Neurological Impairment Score (mNIS +7) Composite Score Over 18 Months;Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) Questionnaire Score;Number of Participants in Each Polyneuropathy Disability (PND) Stage Based on Worst Post-Baseline Score
    </Secondary_outcome>
    <Secondary_ID>ALN-TTRSC-005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>28/03/2019
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02595983
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13581956
    </Internal_Number>
    <TrialID>NCT02510261
    </TrialID>
    <Last_Refreshed_on>19 December 2023
    </Last_Refreshed_on>
    <Public_title>The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
    </Public_title>
    <Scientific_title>A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150716
    </Date_registration3>
    <Date_registration>16/07/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT02510261
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 16, 2015
    </Date_enrollement>
    <Target_size>211
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Argentina;Australia;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;Argentina;Australia;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Medical Director
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have completed a patisiran study (i.e., completed the last efficacy visit in the&#x0D;&lt;br&gt;             parent study) and, in the opinion of the investigator, tolerated study drug&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be willing and able to comply with the protocol-required visit schedule and visit&#x0D;&lt;br&gt;             requirements and provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any new or uncontrolled condition that could make the participant unsuitable for&#x0D;&lt;br&gt;             participation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloidosis
    </Condition>
    <Intervention>Drug: Patisiran
    </Intervention>
    <Primary_outcome>Percentage of Participants With Adverse Events (AEs) Leading to Study Discontinuation
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in the Total Neuropathy Impairment Score (NIS) at Year 5;Change From Baseline in the Total Modified NIS (mNIS +7) Composite Score At Year 3;Change From Baseline in the NIS+7 Total Score at Week 52;Change From Baseline in the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) Questionnaire Total Score at Year 5;Change From Baseline in the EuroQOL-5 Dimensions-5 Levels (EQ-5D-5L) Index Score at Year 5;Change From Baseline in the EuroQoL Visual Analogue Scale (EQ-VAS) Score at Year 5;Change From Baseline in the Composite Autonomic Symptom Score (COMPASS 31) Total Score at Week 52;Change From Baseline in the Modified Body Mass Index (mBMI) at Year 5;Change From Baseline in the Rasch-built Overall Disability Scale (R-ODS) at Year 5;Change From Baseline in the NIS+7 Component: NIS-Weakness (NIS-W) Score at Year 5;Change From Baseline in the 10-meter Walk Test (10-MWT) Speed at Year 5;Change From Baseline in the Hand Grip Strength at Week 52;Number of Participants With Change From Baseline in the Polyneuropathy Disability (PND) Stage;Number of Participants With Change From Baseline in the Familial Amyloidotic Polyneuropathy (FAP) Stage;Number of Participants With Change From Baseline in the New York Heart Association (NYHA) Classification;Change From Baseline in the Intraepidermal Nerve Fiber Density (IENFD) at Year 5;Change From Baseline in the Sweat Gland Nerve Fiber Density (SGNFD) at Year 5;Change From Baseline in the Dermal Amyloid Burden at Year 5;Change From Baseline in the Cardiac Biomarker: Serum Troponin I at Year 5;Change From Baseline in the Cardiac Biomarker: N-terminal Prohormone of B-type Natriuretic Peptide (NT-proBNP) at Year 5;Change From Baseline in the Echocardiogram Parameter: Average Peak Longitudinal Strain at Year 5;Change From Baseline in the Echocardiogram Parameter: Left Ventricular (LV) Mass at Year 5;Change From Baseline in the Echocardiogram Parameter: LV End-diastolic Volume at Year 5;Change From Baseline in the Echocardiogram Parameter: LV Relative Wall Thickness at Year 5;Change From Baseline in the Echocardiogram Parameter: Mean LV Wall Thickness at Year 5;Change From Baseline in the Echocardiogram Parameter: Cardiac Output at Year 5;Percent Change From Baseline in Serum TTR Levels at Year 5
    </Secondary_outcome>
    <Secondary_ID>2014-003877-40;ALN-TTR02-006
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>06/12/2023
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02510261
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6585708
    </Internal_Number>
    <TrialID>EUCTR2015-002603-29-SE
    </TrialID>
    <Last_Refreshed_on>11 December 2017
    </Last_Refreshed_on>
    <Public_title>A study to look at the efficacy and safety of an investigational drug, revusiran, in the treatment of patients with Transthyretin-Mediated amyloidosis, whose disease has continued to worsen following liver transplantation
    </Public_title>
    <Scientific_title>An Open-Label Study To Evaluate The Efficacy And Safety Of Revusiran In Patients With Transthyretin-Mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post Orthotopic Liver Transplant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Alnylam Pharmaceuticals, Inc
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150710
    </Date_registration3>
    <Date_registration>10/07/2015
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002603-29
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>01/12/2015
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Portugal;Spain;Sweden
    </Countries>
    <Contact_Firstname>Clinical Trial Hotline
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>300 Third Street
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel>0018663300326
    </Contact_Tel>
    <Contact_Affiliation>Alnylam Pharmaceuticals Inc
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Male or female =18 years of age&lt;br&gt;2. Diagnosis of FAP with documented TTR mutation&lt;br&gt;3. Received an OLT =12 months before the date of informed consent&lt;br&gt;4. An increase in polyneuropathy disability (PND) score compared to a preliver transplant assessment OR increase in PND score between any 2 assessments postliver transplant, which in the opinion of the Investigator is due to underlying FAP progression &lt;br&gt;5. On stable immunosuppressive regimen with =10 mg/day of prednisone for at least 3 months before the date of informed consent &lt;br&gt;6. Neurological impairment score (NIS) of 5 to 130 (inclusive)&lt;br&gt;7. Polyneuropathy Disability score of =3b&lt;br&gt;8. Karnofsky Performance Status =60%&lt;br&gt;9. No liver allograft rejection episodes (chronic, acute, or subacute) in the past 6 months before the date of informed consent&lt;br&gt;10. Normal liver function, including aspartate transaminase, alanine transaminase,  and total bilirubin, unless elevation in total bilirubin is due to Gilbert’s syndrome based on central laboratory evaluation&lt;br&gt;11. Adequate renal function demonstrated by estimated glomerular filtration rate  =45 mL/min/1.73 m2 (calculated by a central laboratory using the Modification of Diet in Renal Disease formula)&lt;br&gt;12. Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use 1 highly effective method of contraception throughout study participation and for 28 days after last dose administration&lt;br&gt;13. Males who agree to use appropriate means of contraception throughout study participation until 28 days after last dose administration&lt;br&gt;14. Patient, or patient’s legal representative, is able and willing to provide written informed consent and the patient is willing to comply with the study requirements&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 12&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Untreated hypo- or hyperthyroidism&lt;br&gt;2. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed before the first dose of study drug administration&lt;br&gt;3. Active infection with hepatitis B or hepatitis C (based on serology) &lt;br&gt;4. Known human immunodeficiency virus infection&lt;br&gt;5. New York Heart Association (NYHA) classification of &gt;2&lt;br&gt;6. Known leptomeningeal amyloidosis&lt;br&gt;7. Other known causes of sensorimotor or autonomic neuropathy (eg, autoimmune disease)&lt;br&gt;8. Known type I diabetes &lt;br&gt;9. Type II diabetes mellitus for =5 years from the time of informed consent&lt;br&gt;10. Vitamin B12 levels below the lower limit of normal&lt;br&gt;11. Known history of alcohol abuse within the last 2 years from the time of informed consent&lt;br&gt;12. Received an investigational agent or device within 30 days of anticipated study drug administration or 5 half-lives of the study drug, whichever is longer&lt;br&gt;13. Currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid; if previously on any of these agents, must have completed a 14-day washout before start of study drug administration in this study&lt;br&gt;14. Malignancy within the last 2 years from the time of informed consent, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated&lt;br&gt;15. History of allergic reaction to an oligonucleotide or N-acetylgalactosamine (GalNAc)&lt;br&gt;16. History of intolerance to subcutaneous (SC) injection&lt;br&gt;17. Other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin (TTR)-mediated Familial Amyloidotic Polyneuropathy (FAP) &lt;br&gt;MedDRA version: 18.0
Level: PT
Classification code 10019889
Term: Hereditary neuropathic amyloidosis
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Revusiran&lt;br&gt;Product Code: ALN-TTRSC&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ALN-51547&lt;br&gt;Current Sponsor code: ALN-51547&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: Assess the efficacy of revusiran in patients with Transthyretin (TTR) -mediated Familial Amyloidotic Polyneuropathy (FAP) with disease progression post-orthotopic liver transplant (OLT) by evaluating the reduction in serum TTR level compared to baseline;Secondary Objective: • Evaluate the safety and tolerability of revusiran when administered to TTR-mediated FAP patients with disease progression post-OLT&lt;br&gt;• Characterize the pharmacokinetics (PK) of revusiran &lt;br&gt;• Describe the effect of revusiran on neurologic impairment &lt;br&gt;;Primary end point(s): The primary endpoint is the percent reduction from baseline in serum TTR level at 6 months.;Timepoint(s) of evaluation of this end point: 6 months
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): The secondary endpoints of the study are the change from baseline over 18 months for the following:&lt;br&gt;• Serum TTR&lt;br&gt;• Modified (m)NIS+7 &lt;br&gt;• Norfolk Quality of Life-Diabetic Neuropathy questionnaire&lt;br&gt;• PND Score&lt;br&gt;;Timepoint(s) of evaluation of this end point: 18 months
    </Secondary_outcome>
    <Secondary_ID>ALN-TTRSC-005
    </Secondary_ID>
    <Source_Support>Alnylam Pharmaceuticals, Inc
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>11052921
    </Internal_Number>
    <TrialID>EUCTR2014-001957-17-SE
    </TrialID>
    <Last_Refreshed_on>21 June 2021
    </Last_Refreshed_on>
    <Public_title>THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS (Buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues).&#x0D;
An open follow-up study of  the diflunisal trials (IND 68092 and DFNS01), and an open label observational study on previously untreated patients with familial transthyretin amyloidosis complicated by cardiomyopathy (diseases of the heart muscle).?&#x0D;

    </Public_title>
    <Scientific_title>THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS:&#x0D;
An open label phase III extension study of  the diflunisal trials (IND 68092 and DFNS01), and an open label observational study on previously untreated patients with familial transthyretin amyloidosis complicated by cardiomyopathy.?&#x0D;
 - DFNS02                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Umeå University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150706
    </Date_registration3>
    <Date_registration>06/07/2015
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001957-17
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>21/10/2015
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Sweden
    </Countries>
    <Contact_Firstname>Intissar Anan
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Umeå University Hospital
    </Contact_Address>
    <Contact_Email>intissar.anan@umu.se
    </Contact_Email>
    <Contact_Tel>469078550000
    </Contact_Tel>
    <Contact_Affiliation>Umeå University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Open to patients that have been participating in the DFNS01 study. All patients will have a biopsy and genetically proven systemic transthyretin amyloidosis caused by a TTR gene mutation. The amyloid shall be proven to be of transthyretin type, and the fibril composition settled.&#x0D;&lt;br&gt;For patients not previously participating in the DFNS01 trial, the diagnosis shall be proven by biopsy and identification of a TTR-gene mutation. The amyloid shall be proven to be of transthyretin type, and the fibril composition settled. TTTR-amyloid cardiomyopathy shall be confirmed by DPD-scintigraphy, and an increased intra-ventricular septal thickness of &gt; 12 mm and a pro-BNP blood concentration above the normal limit.&#x0D;&lt;br&gt;2. Age = 18 years.&#x0D;&lt;br&gt;3. Negative pregnancy test for sexually active women of child bearing potential and willing to comply with effective contraception methods during the course of the trial. Acceptable methods are such as oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double-barrier methods (for example, condom and spermicide), intrauterine device (IUD), hormonal IUD.&#x0D;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 10&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 30&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Concomitant use of non-study NSAIDs&#x0D;&lt;br&gt;2. Heart failure with symptoms at daily activities (NYHA class =III)&#x0D;&lt;br&gt;3. Renal insufficiency (creatinine clearence &lt; 30 ml calculated from the Cockcroft-Gault formula)&#x0D;&lt;br&gt;4. Active non-haemorrhoidal bleeding within the last 18 month.&#x0D;&lt;br&gt;5. Non-treated peptic ulcer disease.&#x0D;&lt;br&gt;6. Anticoagulation therapy, low dose ASA permitted (=160 mg).&#x0D;&lt;br&gt;7. Non-steroidal or aspirin allergy/hypersensitivity&#x0D;&lt;br&gt;8. Thrombocytopenia (&lt; 100,000 platelets/mm3)&#x0D;&lt;br&gt;9. Inability or unwillingness of subject to give written informed consent&#x0D;&lt;br&gt;10. By the investigator regarded as unable to follow the study guidelines and scheduled controls.&#x0D;&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Familial transthyretin amyloidosis complicated by cardiomyopathy &lt;br&gt;MedDRA version: 18.0
Level: LLT
Classification code 10019893
Term: Hereditary neuropathic amyloidosis, Swedish type
System Organ Class: 100000004850
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To follow the development of neurological, nutritional and cardiac manifestations of transthyretin amyloidosis in patients treated by Diflunisal 250 mg twice daily.&lt;br&gt;Primary end-points&lt;br&gt;1. changes in the Kumamoto scale&lt;br&gt;2. cardiac impairment measured by echocardiographic assessment of global systolic strain&lt;br&gt;;Secondary Objective: Secondary end points&lt;br&gt;1. changes in nutritional status measured by the modified body mass index (mBMI)&lt;br&gt;2. changes in neurological impairment measured by the PND-score.&lt;br&gt;3. cardiac impairment measured by echocardiographic measurement of septal thickness and blood pro-BNP concentration.&lt;br&gt;4. Karnofsky performance scale&lt;br&gt;5. drug safety&lt;br&gt;;Primary end point(s): Primary endpoints will be:&lt;br&gt;1. changes in the Kumamoto scale&lt;br&gt;2. cardiac impairment measured by echocardiographic assessment of global systolic strain&lt;br&gt;;Timepoint(s) of evaluation of this end point: Primary and secondary end-points will be evaluated at 12 months and the end of the 24 months study period by descriptive statistical methods. &lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Secondary end points will be:&#x0D;&lt;br&gt;1. changes in nutritional status measured by the modified body mass index (mBMI)&#x0D;&lt;br&gt;2. changes in neurological impairment measured by the PND-score.&#x0D;&lt;br&gt;3. cardiac impairment measured by echocardiographic measurement of septal thickness and blood pro-BNP concentration.&#x0D;&lt;br&gt;4. Karnofsky performance scale&#x0D;&lt;br&gt;5. drug safety&#x0D;&lt;br&gt;;Timepoint(s) of evaluation of this end point: Secondary endpoints for effect parameters will be evaluated at 12 months and the end of the 24 months study period by descriptive statistical methods. Safety parameters will be measured at 1 month (± 1 week), 3 months (±2 weeks), 6 months (± 1 month), 9 months (±1 month), 12 months (±1 month) and thereafter every 6 months (± 1month).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>DFNS02
    </Secondary_ID>
    <Source_Support>Västerbotten county counsil;Umeå University
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>21/10/2015
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>8474057
    </Internal_Number>
    <TrialID>EUCTR2014-003865-11-NL
    </TrialID>
    <Last_Refreshed_on>28 February 2019
    </Last_Refreshed_on>
    <Public_title>A study to see how effective and safe NEO001 is when given together with the standard treatment  in comparison to placebo together with the standard treatment  in people with Light Chain (AL) Amyloidosis.
    </Public_title>
    <Scientific_title>A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Prothena Therapeutics Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150619
    </Date_registration3>
    <Date_registration>19/06/2015
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003865-11
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt; Female: yes&lt;br&gt; Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>21/03/2016
    </Date_enrollement>
    <Target_size>236
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>
                Controlled: yes
                Randomised: yes
                Open: no
                Single blind: no
                Double blind: yes
                Parallel group: no
                Cross over: no
                Other: no
                If controlled, specify comparator, Other Medicinial Product: no
                Placebo: yes
                Other: no
                Number of treatment arms in the trial: 2

    </Study_design>
    <Phase>
                Human pharmacology (Phase I): no
                Therapeutic exploratory (Phase II): no
                Therapeutic confirmatory - (Phase III): yes
                Therapeutic use (Phase IV): no

    </Phase>
    <Countries>United States;Greece;Spain;Austria;Israel;Italy;United Kingdom;France;Canada;Poland;Belgium;Australia;Denmark;Netherlands;Germany
    </Countries>
    <Contact_Firstname>Jay Soto
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>331 Oyster Point Blvd
    </Contact_Address>
    <Contact_Email>Jay.soto@prothena.com
    </Contact_Email>
    <Contact_Tel>+1 (650) 615-2131
    </Contact_Tel>
    <Contact_Affiliation>Prothena Biosciences Inc
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;                Subjects must meet all of the following criteria:&lt;br&gt;                1. Aged = 18 years&lt;br&gt;                2. Newly diagnosed and AL amyloidosis treatment naïve&lt;br&gt;                3. Bone marrow demonstrating clonal plasma cells&lt;br&gt;                4. Confirmed diagnosis of AL amyloidosis by the following:&lt;br&gt;                • Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance AND&lt;br&gt;                • Confirmatory immunohistochemistry OR mass spectroscopy of AL amyloidosis&lt;br&gt;                5. Confirmed diagnosis of AL amyloidosis by mass spectrometry or immunoelectron microscopy of amyloid material in tissue biopsy if the subject meets any of the following:&lt;br&gt;                • is black or African American&lt;br&gt;                • is over 75 years of age with concurrent monoclonal gammopathy&lt;br&gt;                • has a history of familial amyloidosis and has concurrent monoclonal gammopathy&lt;br&gt;                OR&lt;br&gt;                • If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have&lt;br&gt;                gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc-DPD; Rapezzi 2011), hydroxymethylenediphosphonate (99mTc-HMDP; Galat 2015), or pyrophosphate (99mTc-PYP; Bokhari 2013) scintigraphy&lt;br&gt;                6. Cardiac involvement as defined by all of the following:&lt;br&gt;                • Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure&lt;br&gt;                • Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole &gt; 12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening&lt;br&gt;                • NT-proBNP = 650 pg/mL and = 8500 pg/mL&lt;br&gt;                7. Planned first-line chemotherapy contains bortezomib administered weekly and SC&lt;br&gt;                8. Adequate bone marrow reserve, hepatic function and renal function, as demonstrated by: absolute neutrophil count (ANC) = 1.0 x10^9/L&lt;br&gt;                • platelet count = 75 x 10^9/L&lt;br&gt;                • hemoglobin = 9 g/dL&lt;br&gt;                • total bilirubin = 2 times the upper limit of normal (x ULN)&lt;br&gt;                • aspartate aminotransferase (AST) / serum glutamic oxaloacetic transaminase (SGOT) = 3 x ULN&lt;br&gt;                • alanine aminotransferase (ALT) / serum glutamic pyruvic transaminase (SGPT) = 3 x ULN&lt;br&gt;                • alkaline phosphatase (ALP) = 5 x ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)&lt;br&gt;                • estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73 m^2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation&lt;br&gt;                9. Seated systolic blood pressure (BP) 90-180 mmHg&lt;br&gt;                10. Distance walked during each Screening 6MWT is =30 meters and = 550 meters&lt;br&gt;                11. Women of childbearing potenti
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;                Subjects must meet none of the following criteria:&lt;br&gt;                1. Non-AL amyloidosis&lt;br&gt;                2. NT-proBNP &lt; 650 pg/mL or &gt; 8,500 pg/mL&lt;br&gt;                3. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma (see Appendix 5)&lt;br&gt;                *Note that subjects who meet the IMWG definition of symptomatic multiple myeloma with signs and/or symptoms attributable only to associated amyloidosis and who do not otherwise meet the criteria for diagnosis of smoldering myeloma are potentially eligible upon approval of the Sponsor.&lt;br&gt;                4. Subject is eligible for and plans to undergo ASCT or organ transplant&lt;br&gt;                5. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject’s ability to safely receive treatment or complete study assessments&lt;br&gt;                6. Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit&lt;br&gt;                7. Severe valvular stenosis (e.g. aortic or mitral stenosis with a valve area &lt;1.0 cm2) or severe congenital heart disease&lt;br&gt;                8. ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:&lt;br&gt;                • First degree AV-block&lt;br&gt;                • Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)&lt;br&gt;                • Right or left bundle branch block&lt;br&gt;                • Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., &gt;110 bpm] ventricular rate is not allowed [determined by an average of three beats in Lead II or three representative beats if Lead II is not representative of the overall ECG])&lt;br&gt;                9. Peripheral neuropathy assessed as National Cancer Institute-Common Terminology Criteria for Adverse Events ( NCI-CTCAE) Grade 2 with pain, Grade 3 or Grade 4&lt;br&gt;                10. Subject is receiving oral or IV antibiotics, antifungals or antivirals within 1 week of Month 1-Day 1 with the exception of prophylactic oral agents&lt;br&gt;                11. Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1&lt;br&gt;                12. Prior radiotherapy within 4 weeks of Month 1-Day 1&lt;br&gt;                13. Major surgery within 4 weeks of Month 1-Day 1 or planned major surgery during the study&lt;br&gt;                14. Active malignancy with the exception of any of the following:&lt;br&gt;                • Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer&lt;br&gt;                • Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for 2 years&lt;br&gt;                • Low-risk prostate cancer with Gleason score &lt; 7 and prostate-specific antigen &lt; 10 mg/mL&lt;br&gt;                • Any other cancer from which the subject has been disease-free for = 2 years&lt;br&gt;                15. History of severe allergy to any of the components of NEOD001 such as histidine/L histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 or History of Grade = 3 infusion-related AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine (or an equivalent H1 antihistamine) or acetaminophen (or its equivalent, paracetamol)&lt;br&gt;                16. Known or history of uncontrolled, active human immunodeficiency virus (HIV), Hepatiti
    </Exclusion_Criteria>
    <Condition>Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble,fibrillar deposits of abnormal AL protein (amyloid),in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac,renal,and hepatic dysfunction,gastrointestinal involvement and neuropathy and macroglossia &lt;br&gt;
                MedDRA version: 20.0
                Level: PT
                Classification code 10036673
                Term: Primary amyloidosis
                System Organ Class: 10021428 - Immune system disorders
            ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
    </Condition>
    <Intervention>&lt;br&gt;                Product Name: NEOD001&lt;br&gt;                Product Code: NEOD001&lt;br&gt;                Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;                INN or Proposed INN: N/A&lt;br&gt;                CAS Number: N/A&lt;br&gt;                Current Sponsor code: NEOD001&lt;br&gt;                Other descriptive name: Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody&lt;br&gt;                Concentration unit: mg milligram(s)&lt;br&gt;                Concentration type: equal&lt;br&gt;                Concentration number: 500-&lt;br&gt;                Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;                Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of NEOD001 plus standard of care vs. placebo plus standard of care when administered intravenously in subjects with AL amyloidosis by assessing time to all- cause mortality or cardiac hospitalization;&lt;br&gt;                Secondary Objective: In subjects with AL amyloidosis, comparing NEOD001 plus standard of care vs. placebo plus standard of care:&lt;br&gt;                • To evaluate the safety of NEOD001&lt;br&gt;                • To evaluate the cardiac response rate as assessed by NT-proBNP&lt;br&gt;                • To evaluate health-related quality of life using the Short Form 36 questionnaire (SF-36)&lt;br&gt;                • To evaluate cardiac functional response using the 6 Minute Walk Test (6MWT)&lt;br&gt;                • To evaluate the renal response rate using established criteria&lt;br&gt;                • To evaluate peripheral neuropathy using the Neuropathy Impairment Scale – Lower Limbs (NIS-LL)&lt;br&gt;                • To evaluate the hepatic response rate according to consensus criteria&lt;br&gt;                • To evaluate cardiac-specific quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ)&lt;br&gt;                • To evaluate time to cardiac mortality or cardiac hospitalization&lt;br&gt;                • To evaluate time to all-cause mortality&lt;br&gt;            ;Primary end point(s): Time to all-cause mortality or cardiac hospitalization;Timepoint(s) of evaluation of this end point: As adjudicated by the CEC
    </Primary_outcome>
    <Secondary_outcome>&lt;br&gt;                Secondary end point(s): • NT-proBNP best response from baseline to Month 9&lt;br&gt;                • Change from baseline to Month 9 in the Physical Component Score of the SF-36&lt;br&gt;                • Change from baseline to Month 9 in the 6MWT&lt;br&gt;                • For renal-evaluable subjects, renal best response from baseline to Month 9&lt;br&gt;                • For subjects with peripheral neuropathy due to AL amyloidosis, change from baseline to Month 9 in the NIS-LL score&lt;br&gt;                • For hepatic-evaluable subjects, hepatic best response from baseline to Month 9&lt;br&gt;                • Change from baseline to Month 9 in the KCCQ&lt;br&gt;                • Time to cardiac mortality or cardiac hospitalization as adjudicated by the CEC&lt;br&gt;                • Time to all-cause mortality&lt;br&gt;            ;&lt;br&gt;                Timepoint(s) of evaluation of this end point: • NT-proBNP best response from baseline to Month 9&lt;br&gt;                • Change from baseline to Month 9 in the SF-36&lt;br&gt;                • Change from baseline to Month 9 in the 6MWT&lt;br&gt;                • Renal best response from baseline to Month 9 (Palladini 2014)&lt;br&gt;                • Change from baseline to Month 9 in the NIS-LL score&lt;br&gt;                • Hepatic best response from baseline to Month 9 (Comenzo 2012)&lt;br&gt;                • Change from baseline to Month 9 in the KCCQ&lt;br&gt;                • Time to cardiac mortality or cardiac hospitalization as adjudicated by the CEC&lt;br&gt;                • Time to all-cause mortality&lt;br&gt;            
    </Secondary_outcome>
    <Secondary_ID>NEOD001-CL002;NCT02312206;2014-003865-11-DE
    </Secondary_ID>
    <Source_Support>Prothena Therapeutics Limited
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>28/03/2019
    </results_date_posted>
    <results_date_completed>08/06/2018
    </results_date_completed>
    <results_url_link>https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003865-11/results
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>5077992
    </Internal_Number>
    <TrialID>EUCTR2014-003877-40-ES
    </TrialID>
    <Last_Refreshed_on>24 August 2015
    </Last_Refreshed_on>
    <Public_title>Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)
    </Public_title>
    <Scientific_title>A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Alnylam Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150303
    </Date_registration3>
    <Date_registration>03/03/2015
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003877-40
    </web_address>
    <Recruitment_Status>Authorised
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>11/05/2015
    </Date_enrollement>
    <Target_size>228
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1

    </Study_design>
    <Countries>Portugal;United States;Taiwan;Spain;Turkey;United Kingdom;Italy;France;Mexico;Canada;Argentina;Brazil;Bulgaria;Netherlands;Germany;Japan;Korea, Republic of;Sweden
    </Countries>
    <Contact_Firstname>Monica Bermejo
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Antonio Maura 16, 5 izquierda
    </Contact_Address>
    <Contact_Email>m.bermejo@medpace.com
    </Contact_Email>
    <Contact_Tel>0034918534105
    </Contact_Tel>
    <Contact_Affiliation>Medpace Spain, S.L
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Have completed a patisiran study &lt;br&gt;2. Adequate liver function and renal function&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 114&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 114&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pregnant or nursing&lt;br&gt;2. Have uncontrolled clinically significant cardiac arrhythmia or unstable angina&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin mediated amyloidosis (ATTR) &lt;br&gt;MedDRA version: 17.1
Level: PT
Classification code 10007509
Term: Cardiac amyloidosis
System Organ Class: 10007541 - Cardiac disorders
 &lt;br&gt;MedDRA version: 17.1
Level: PT
Classification code 10019889
Term: Hereditary neuropathic amyloidosis
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Patisiran&lt;br&gt;Product Code: ALN-TTR02&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Patisiran&lt;br&gt;Current Sponsor code: Patisiran&lt;br&gt;Other descriptive name: ALN-TTR02&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To assess the safety and efficacy of long-term dosing with patisiran in transthyretin-mediated amyloidosis (ATTR) patients with familial amyloidotic polyneuropathy (FAP);Secondary Objective: None;Primary end point(s): To assess the safety and efficacy of long-term dosing with patisiran;Timepoint(s) of evaluation of this end point: The review of AEs will be done at each visit from Day 0 through 28 days post last dose.  Efficacy assessments will be performed at Day 0, annually and 28 days post last dose
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): None;Timepoint(s) of evaluation of this end point: None
    </Secondary_outcome>
    <Secondary_ID>ALN-TTR02-006
    </Secondary_ID>
    <Source_Support>Alnylam Pharmaceuticals, Inc
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10237530
    </Internal_Number>
    <TrialID>NCT02319005
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
    </Public_title>
    <Scientific_title>A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20141212
    </Date_registration3>
    <Date_registration>12/12/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02319005
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2014
    </Date_enrollement>
    <Target_size>206
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Belgium;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;Belgium;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jared Gollob, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Documented TTR mutation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Amyloid deposits in cardiac or non-cardiac tissue&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical history of heart failure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of cardiac involvement by echocardiogram&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known primary amyloidosis (AL), leptomeningeal amyloidosis, non-FAC hereditary&#x0D;&lt;br&gt;             cardiomyopathy, hypertensive cardiomyopathy, or cardiomyopathy due to valvular heart&#x0D;&lt;br&gt;             disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known peripheral vascular disease affecting ambulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a Polyneuropathy Disability score &gt;2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has a New York Heart Association (NYHA) classification of IV&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC);Amyloidosis, Hereditary;Amyloid Neuropathies, Familial;Amyloid Neuropathies;Amyloidosis, Hereditary, Transthyretin-Related;Familial Transthyretin Cardiac Amyloidosis
    </Condition>
    <Intervention>Drug: Revusiran (ALN-TTRSC);Drug: Sterile Normal Saline (0.9% NaCl)
    </Intervention>
    <Primary_outcome>6 Minute Walk Distance (6-MWD);Serum TTR Levels
    </Primary_outcome>
    <Secondary_outcome>Composite Cardiovascular (CV) Mortality and Cardiovascular (CV) Hospitalization;New York Heart Association (NYHA) Class;Kansas City Cardiomyopathy Questionnaire (KCCQ);Cardiovascular (CV) Mortality;Cardiovascular (CV) Hospitalization;All-cause Mortality
    </Secondary_outcome>
    <Secondary_ID>ALN-TTRSC-004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>18/07/2018
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02319005
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10237296
    </Internal_Number>
    <TrialID>NCT02312206
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
    </Public_title>
    <Scientific_title>A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
    </Scientific_title>
    <Acronym>VITAL
    </Acronym>
    <Primary_sponsor>Prothena Therapeutics Ltd.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20141202
    </Date_registration3>
    <Date_registration>02/12/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02312206
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 2015
    </Date_enrollement>
    <Target_size>260
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Key Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Age = 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Newly diagnosed, AL amyloidosis treatment naïve&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Bone marrow consistent with plasma cell dyscrasia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Confirmed diagnosis of AL amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Cardiac involvement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Planned first-line chemotherapy contains a proteasome-inhibiting agent administered&#x0D;&lt;br&gt;             weekly&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Adequate bone marrow reserve, hepatic and renal function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Key Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Non-AL amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Meets diagnostic criteria for symptomatic multiple myeloma&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subject is eligible for and plans to undergo ASCT&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. History of Grade = 3 infusion-associated AEs or hypersensitivity to another monoclonal&#x0D;&lt;br&gt;             antibody, or known hypersensitivity to diphenhydramine or acetaminophen&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Primary Systemic (AL) Amyloidosis
    </Condition>
    <Intervention>Drug: NEOD001;Other: Placebo
    </Intervention>
    <Primary_outcome>Time to Composite of All-cause Mortality or Cardiac Hospitalization
    </Primary_outcome>
    <Secondary_ID>NEOD001-CL002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>29/05/2019
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02312206
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13554564
    </Internal_Number>
    <TrialID>NCT02175004
    </TrialID>
    <Last_Refreshed_on>27 November 2023
    </Last_Refreshed_on>
    <Public_title>Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
    </Public_title>
    <Scientific_title>An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140612
    </Date_registration3>
    <Date_registration>12/06/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT02175004
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 26, 2014
    </Date_enrollement>
    <Target_size>135
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States;New Zealand
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Satisfactory completion of dosing &amp; efficacy assessments in ISIS 420915-CS2&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any new condition or worsening of existing condition that could make the patient&#x0D;&lt;br&gt;             unsuitable for participation, or interfere with the patient participating in and/or&#x0D;&lt;br&gt;             completing the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>FAP;Familial Amyloid Polyneuropathy;TTR;Transthyretin;Amyloidosis
    </Condition>
    <Intervention>Drug: Inotersen
    </Intervention>
    <Primary_outcome>Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Related to Study Drug;Percentage of Participants With Change From Baseline in Vital Signs;Percentage of Participants With Change From Baseline in Weight;Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Test Values;Percentage of Participants With Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) as Determined by Electrocardiogram (ECG);Percentage of Participants Using Concomitant Medication for Nervous and Cardiovascular System Disorders;Percentage of Participants With Change From Baseline in Ophthalmic Examination as Assessed by Visual Acuity Changes;Percentage of Participants With Change From Baseline in Light Detection Ability Measured by Electroretinography
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in the Modified Neuropathy Impairment Score (mNIS)+7 Composite Score at Weeks 78 and 156;Change From Baseline in the mNIS +7 Component: Heart Rate to Deep Breathing Score at Weeks 78 and 156;Change From Baseline in the mNIS +7 Component: Nerve Conduction Score at Weeks 78 and 156;Change From Baseline in the mNIS +7 Component: Heat-Pain Sensory Score at Weeks 78 and 156;Change From Baseline in the mNIS +7 Component: Touch-Pressure Sensory Score at Weeks 78 and 156;Change From Baseline in the Neuropathy Impairment (NIS) Composite Score at Week 52 of Years 4 and 5;Change From Baseline in the NIS Component: Cranial Nerves Score at Week 52 of Years 4 and 5;Change From Baseline in the NIS Component: Muscle Weakness Score at Week 52 of Years 4 and 5;Change From Baseline in the NIS Component: Reflexes Score at Week 52 of Years 4 and 5;Change From Baseline in the NIS Component: Sensory Score at Week 52 of Years 4 and 5;Change From Baseline in the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) Questionnaire Total Score at Weeks 78 and 156;Change From Baseline in the Norfolk QoL-DN Physical Functioning/Large Fiber Neuropathy Domain Score;Change From Baseline in the Modified Body Mass Index (mBMI) at Weeks 78 and 156;Change From Baseline in the Body Mass Index (BMI) at Weeks 78 and 156;Percentage of Participants With Change From Baseline in the Polyneuropathy Disability (PND) Score;Percent Change From Baseline in Global Longitudinal Strain (GLS) by Echocardiogram (ECHO) in the Cardiomyopathy-ECHO (CM-ECHO) Set;Percent Change From Baseline in GLS by ECHO in the CS3 ECHO Subgroup;Change From Baseline in Transthyretin (TTR) Level;Change From Baseline in Retinol Binding Protein 4 (RBP4) Level;Ctrough: Trough Plasma Concentration of ISIS 420915
    </Secondary_outcome>
    <Secondary_ID>2013-004561-13;ISIS 420915-CS3
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>09/02/2023
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02175004
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>5250819
    </Internal_Number>
    <TrialID>EUCTR2014-001586-27-ES
    </TrialID>
    <Last_Refreshed_on>7 December 2015
    </Last_Refreshed_on>
    <Public_title>Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity
    </Public_title>
    <Scientific_title>Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>SOM Innovation Biotech SL (SOM Biotech)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140602
    </Date_registration3>
    <Date_registration>02/06/2014
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001586-27
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>25/07/2014
    </Date_enrollement>
    <Target_size/>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no

    </Study_design>
    <Countries>Spain
    </Countries>
    <Contact_Firstname>Miriam García Diez
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Passeig de la Vall d?Hebron, 119-129
    </Contact_Address>
    <Contact_Email>miriam.garcia@vhir.org
    </Contact_Email>
    <Contact_Tel>+349348930002703
    </Contact_Tel>
    <Contact_Affiliation>ARO-VHIR
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Participant is willing and able to give informed consent for participation in the study.&lt;br&gt;- Male or Female, aged 18 years or above at time of consent.&lt;br&gt;- Two cohorts defined by TTR variant:&lt;br&gt;            Wild type TTR: healthy patients&lt;br&gt;            V30M TTR mutant: Asymptomatic carriers with documented &lt;br&gt;            mutation V30M TTR or diagnosed TTR-FAP patients (stage 1 or &lt;br&gt;            2) not undergoing pharmacological treatment with Vyndaqel®.&lt;br&gt;- Body Mass Index (BMI) &gt; 17.5 kg/m2&lt;br&gt;- Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 2 month thereafter. &lt;br&gt;- Able (in the Investigators opinion) and willing to comply with all study requirements.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 20&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;The participant may not enter the study if ANY of the following apply:&lt;br&gt;- Female participants who is pregnant, lactating or planning pregnancy during the course of the study.&lt;br&gt;- Evidence of history of clinically significant hepatic disease.&lt;br&gt;- An ALT or AST measurement &gt; 2 times the ULN (Upper Limit of Normal).&lt;br&gt;- Scheduled elective surgery or other procedures requiring general anaesthesia during the study. &lt;br&gt;- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant?s ability to participate in the study.&lt;br&gt;- Donation of blood during the study or within the past 4 weeks.&lt;br&gt;- Treatment (during the study or within the past 4 weeks) with a prescription or investigational drug for the treatment of TTR amyloidosis.&lt;br&gt;- Treatment with NSAIDs during the study or within the past 4 weeks.  The following NSAID are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam and sulindac&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Patients with familial amyloid polyneuropathy (FAP), asymptomatic carriers and healthy volunteers &lt;br&gt;MedDRA version: 17.0
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 100000004850
;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
    </Condition>
    <Intervention>&lt;br&gt;Trade Name: Tasmar&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: TOLCAPONE&lt;br&gt;CAS Number: 134308-13-7&lt;br&gt;Current Sponsor code: SOM0226&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: Determine whether SOM0226 induces TTR stabilization by evaluating whether treatment with SOM0226 prevents urea-induced denaturation of tetrameric TTR.;Secondary Objective: - The secondary objective is to determine the plasma concentration of SOM0226 needed to induce a maximal stabilization of TTR in healthy volunteers, patients and asymptomatic carriers.&lt;br&gt;- A pharmacodynamics assessment will be used to determine an effective dose of SOM0226 to confer TTR stabilization, by determining the molar ratio SOM0226:TTR that must be reached in plasma to induce maximal stabilization of TTR in healthy individuals, patients and asymptomatic carriers.;Primary end point(s): TTR stabilization will be measured by determining the concentration of tetrameric TTR after denaturation. The ratio of TTR tetramer after denaturation / TTR tetramer before denaturation of plasma samples from treated subjects will be compared to their baseline ratio. TTR stabilization will be determined as percentage of the baseline ratio.&lt;br&gt;&lt;br&gt;TTR stabilization will be measured in plasma samples obtained from each participant before first dose and at different times during each treatment period.  In terms of assessing efficacy, a positive result will be a TTR stabilization value superior to 20%.;Timepoint(s) of evaluation of this end point: Phase A (24 hours) and  Phase B (32 hours). Between these two phases there is a washout period of 6 weeks (+-2 weeks)
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): - The pharmacodynamics characteristics of SOM0226 will be assessed to determine which plasma SOM0226:TTR molar ratio is needed to reach a plateau of TTR stabilization. &lt;br&gt;                    - The concentration of SOM0226 will be determined in all &lt;br&gt;                      plasma samples obtained at different times during each &lt;br&gt;                      treatment period.&lt;br&gt;                    - The concentration of TTR will be determined in all &lt;br&gt;                        plasma samples, and the molar ratio SOM0226:TTR in &lt;br&gt;                        each sample will be calculated.&lt;br&gt;- Safety will be assessed by ALT and AST liver function measures in samples obtained at the end of each treatment phase (24 hours in Phase A and 32 hours in Phase B).;Timepoint(s) of evaluation of this end point: Phase A (24 hours) and  Phase B (32 hours). Between these two phases there is a washout period of 6 weeks (+-2 weeks)
    </Secondary_outcome>
    <Secondary_ID>SOMCT01-C
    </Secondary_ID>
    <Source_Support>Fundació Vall d'Hebron-Institut de Recerca
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10822131
    </Internal_Number>
    <TrialID>EUCTR2013-004561-13-PT
    </TrialID>
    <Last_Refreshed_on>12 April 2021
    </Last_Refreshed_on>
    <Public_title>Not available
    </Public_title>
    <Scientific_title>An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) - ISIS 420915-CS3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140507
    </Date_registration3>
    <Date_registration>07/05/2014
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004561-13
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>04/07/2014
    </Date_enrollement>
    <Target_size>135
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;
    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>United States;France;Portugal;Argentina;Spain;Brazil;Germany;United Kingdom;New Zealand;Italy
    </Countries>
    <Contact_Firstname>Matt R. Buck
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>2855 Gazelle Court
    </Contact_Address>
    <Contact_Email>mbuck@ionisph.com
    </Contact_Email>
    <Contact_Tel>0117606032684
    </Contact_Tel>
    <Contact_Affiliation>Ionis Pharmaceuticals, Inc
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Completion of ISIS 420915-CS2 with the following as judged by the Investigator and Sponsor:&lt;br&gt;a. Satisfactory completion of dosing and end of treatment (EOT) efficacy assessments&lt;br&gt;b. No significant tolerability issues&lt;br&gt;c. Satisfactory compliance to the ISIS 420915-CS2 protocol requirements&lt;br&gt;2. Willingness to take vitamin A supplements&lt;br&gt;3. Satisfy one of the following:&lt;br&gt;a. Females: Non-pregnant and non-lactating; surgically sterile, postmenopausal, abstinent, or if engaged in sexual relations of childbearing potential, patient is using an acceptable contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until at least 3 months after the last dose of ISIS 420915.&lt;br&gt;b. Males: Surgically sterile, abstinent, or if engaged in sexual relations with a female of childbearing potential, patient is utilizing an acceptable contraceptive method (refer to Section 6.3.1) during and for 3 months after the last dose of ISIS 420915.&lt;br&gt;4. Must have given written informed consent (signed and dated) and any authorization required by local law and be able to comply with all study requirements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 70&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 65&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Have any new condition or worsening of existing condition that in the opinion of the Investigator or Sponsor would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy &lt;br&gt;MedDRA version: 20.0
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 100000004850
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Human Transthyretin Antisense Oligonucleotide&lt;br&gt;Product Code: ISIS 420915&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ISIS 420915&lt;br&gt;CAS Number: 1432726-13-0&lt;br&gt;Current Sponsor code: ISIS 420915&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the safety and tolerability of extended dosing with ISIS 420915 in patients with Familial Amyloid Polyneuropathy.;Secondary Objective: To evaluate the efficacy of extended dosing with ISIS 420915 based on change from baseline and progression rate, if applicable, in the following measures:&lt;br&gt;• Modified Neuropathy Impairment Score +7 (mNIS+7)&lt;br&gt;• Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire:&lt;br&gt;o total score (all patients)&lt;br&gt;o symptoms domain score (Stage 1 patients)&lt;br&gt;o physical functioning/large fiber neuropathy domain score (Stage 2 patients)&lt;br&gt;• Modified body mass index (mBMI) and body mass index (BMI) • NIS, heat-pain sensory, touch-pressure sensory, nerve conduction, and heart rate to deep breathing tests (components of mNIS+7)&lt;br&gt;• Polyneuropathy disability score (PND score)&lt;br&gt;• To evaluate the pharmacodynamic (PD) effect of extended dosing with ISIS 420915 based on change from baseline in transthyretin (TTR) and retinol binding protein 4 (RBP4)&lt;br&gt;• Global longitudinal strain (GLS) by echocardiogram (ECHO) &lt;br&gt;To evaluate the plasma trough levels of ISIS 420915.;Primary end point(s): Safety Endpoints&lt;br&gt;• Adverse events&lt;br&gt;• Vital signs and weight&lt;br&gt;• Physical examination&lt;br&gt;• Clinical laboratory tests&lt;br&gt;• ECG&lt;br&gt;• Use of concomitant medication&lt;br&gt;• Ophthalmology and ERG examinations;Timepoint(s) of evaluation of this end point: Through the course of the study.
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): Efficacy Endpoints&lt;br&gt;• Change in the mNIS+7 score and components from baseline to Week 78 and Week 156&lt;br&gt;• Change in the NIS score and components from baseline to Y5-W52 and Y4-W52&lt;br&gt;• Change in the Norfolk QOL-DN questionnaire scores from baseline to Week 78 Week 156 and Week 52 of each subsequent year&lt;br&gt;• Change in the mBMI and BMI from baseline to Week 78 and Week 156 &lt;br&gt;• Change in PND score from baseline to Week 78 Week 156 and at Week 52 of each subsequent year.&lt;br&gt;• Changes in Global longitudinal strain (GLS) by echocardiogram (ECHO)from baseline to Week 78 , Week 156 and at Week 52 of each subsequent year in the ISIS 420915-CS2 ECHO subgroup and in the Cardiomyopathy-ECHO (CM-ECHO) Set;Timepoint(s) of evaluation of this end point: Week 78 and Week 156 and at Week 52 of each subsequent year 
    </Secondary_outcome>
    <Secondary_ID>ISIS420915-CS3
    </Secondary_ID>
    <Source_Support>Ionis Pharmaceuticals
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>04/07/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10232291
    </Internal_Number>
    <TrialID>NCT02152644
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Prevalence of Amyloidosis and Carpal Tunnel
    </Public_title>
    <Scientific_title>Prevalence of Amyloidosis in Carpal Tunnel Surgery
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Hospital Italiano de Buenos Aires
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140401
    </Date_registration3>
    <Date_registration>01/04/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02152644
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2017
    </Date_enrollement>
    <Target_size>0
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Argentina
    </Countries>
    <Contact_Firstname> ; ; ; ; ; ; ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Adela Aguirre, MD;Lourdes Posadas-Martínez, MD;Dorotea Fantl, MD;María S. Saez, BCH;Gustavo Greloni, MD;Federico Varela, MD;Patricia Sorroche, BCH;Gabriel Waisman, MD;Fernán G. De Quiros, MD;Jorge Boretto, MD;Elsa Nucifora, MD;Diego Giunta, MD
    </Contact_Lastname>
    <Contact_Email>;;;;;;;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;;;;;;;
    </Contact_Tel>
    <Contact_Affiliation>Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires;Hospital Italiano de Buenos Aires
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adult patients older than 21 years with carpal tunnel syndrome with surgical&#x0D;&lt;br&gt;             indication (moderate to severe symptoms that do not respond to conservative treatment&#x0D;&lt;br&gt;             physiotherapy, splinting, activity modification) for more than 6 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Refusal to participate or to the process of informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Secondary acute carpal tunnel syndrome (eg ganglion).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Formal contraindication surgical treatment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Amyloid Neuropathy, Carpal Tunnel
    </Condition>
    <Primary_outcome>presence of amyloid deposits
    </Primary_outcome>
    <Secondary_ID>1589
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>5074952
    </Internal_Number>
    <TrialID>NCT02061878
    </TrialID>
    <Last_Refreshed_on>24 August 2015
    </Last_Refreshed_on>
    <Public_title>A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
    </Public_title>
    <Scientific_title>A Randomized Controlled Study to Evaluate the Effect of Bexarotene - an RXR Agonist - on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>ReXceptor, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140205
    </Date_registration3>
    <Date_registration>05/02/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02061878
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>21 Years
    </Inclusion_agemin>
    <Inclusion_agemax>50 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>August 2014
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
    </Study_design>
    <Phase>Phase 1
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Craig T Curtis, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Compass Research
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Young healthy adults (age 21-50)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  APOE3/3 genotype&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications for blood or CSF sampling&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Bleeding disorder or taking anticoagulants/antiplatelets&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic active infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Blood donation within the past month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active drug/alcohol dependence or abuse history with in the last 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Thyroid dysfunction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High triglycerides (&gt;3.5 mmol/L)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High cholesterol (&gt;4.0 mmoL/L)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Leukopenia, including low neutrophil count (&lt;3 x 10^9/L)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological or psychiatric disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Homeless or prisoner&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Incapable of self-informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Blood borne disease (HIV, Hepatitis)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Actively smoking and incapable of using nicotine patches&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known drug allergy to pain medication or local anesthetic&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects that have participated in another study in the last 30 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abnormalities in lumbar spine previously known within 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  APOE2 or APOE4 allele&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abnormal EKG&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Alzheimer's Disease
    </Condition>
    <Intervention>Drug: Bexarotene;Drug: Placebo
    </Intervention>
    <Primary_outcome>Area under the effect curve for newly generated beta-Amyloid (clearance phase),
    </Primary_outcome>
    <Secondary_outcome>Fractional clearance rate of beta-Amyloid peptide in CNS
    </Secondary_outcome>
    <Secondary_ID>REXCEPTOR-101
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13911502
    </Internal_Number>
    <TrialID>NCT01960348
    </TrialID>
    <Last_Refreshed_on>29 April 2024
    </Last_Refreshed_on>
    <Public_title>APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
    </Public_title>
    <Scientific_title>APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alnylam Pharmaceuticals
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20131009
    </Date_registration3>
    <Date_registration>09/10/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT01960348
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2013
    </Date_enrollement>
    <Target_size>225
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>United States;Argentina;Australia;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;Argentina;Australia;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jared Gollob
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Alnylam Pharmaceuticals
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Male or female of 18 to 85 years of age (inclusive);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a diagnosis of FAP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neuropathy Impairment Score requirement of 5-130&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meet Karnofsky performance status requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have adequate complete blood counts and liver function tests&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have adequate cardiac function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had a prior liver transplant or is planned to undergo liver transplant during the&#x0D;&lt;br&gt;             study period;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has untreated hypo- or hyperthyroidism;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has known human immunodeficiency virus (HIV) infection;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the&#x0D;&lt;br&gt;             skin or carcinoma in situ of the cervix that has been successfully treated;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Recently received an investigational agent or device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>TTR-mediated Amyloidosis;Amyloidosis, Hereditary;Amyloid Neuropathies, Familial;Familial Amyloid Polyneuropathies;Amyloid Neuropathies;Amyloidosis, Hereditary, Transthyretin-Related
    </Condition>
    <Intervention>Drug: patisiran (ALN-TTR02);Drug: Sterile Normal Saline (0.9% NaCl)
    </Intervention>
    <Primary_outcome>Modified Neuropathy Impairment Score +7 (mNIS+7)
    </Primary_outcome>
    <Secondary_outcome>Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Questionnaire;Neurological Impairment Score-Weakness (NIS-W) Score;Rasch-built Overall Disability Scale (R-ODS) Score;Timed 10-meter Walk Test (10-MWT, Gait Speed);Modified Body Mass Index (mBMI);Autonomic Symptoms Questionnaire (Composite Autonomic Symptom Score [COMPASS 31])
    </Secondary_outcome>
    <Secondary_ID>2013-002987-17;ALN-TTR02-004
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>06/09/2018
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01960348
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6526736
    </Internal_Number>
    <TrialID>EUCTR2013-002987-17-SE
    </TrialID>
    <Last_Refreshed_on>30 October 2017
    </Last_Refreshed_on>
    <Public_title>The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis.
    </Public_title>
    <Scientific_title>APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Alnylam Pharmaceuticals, Inc
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130913
    </Date_registration3>
    <Date_registration>13/09/2013
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002987-17
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>25/11/2013
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Portugal;United States;Taiwan;Spain;Turkey;United Kingdom;Italy;France;Mexico;Argentina;Brazil;Bulgaria;Netherlands;Germany;Sweden;Korea, Republic of
    </Countries>
    <Contact_Firstname>Clinical Trials Information
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Karjalankatu 2, 4 Krs
    </Contact_Address>
    <Contact_Email>regsubmissions@medpace.com
    </Contact_Email>
    <Contact_Tel>+46 702524055
    </Contact_Tel>
    <Contact_Affiliation>Medpace Finland OY
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;• Male or female of 18 to 85 years of age (inclusive);&#x0D;&lt;br&gt;• Have a diagnosis of FAP&#x0D;&lt;br&gt;• Meet Neuropathy Impairment Score requirements and Karnofsky performance status requirements&#x0D;&lt;br&gt;• Have adequate complete blood counts and liver function tests&#x0D;&lt;br&gt;• Have adequate cardiac function&#x0D;&lt;br&gt;• No active infection with hepatitis B or hepatitis C&#x0D;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 100&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 100&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;• Had a prior liver transplant or is planned to undergo liver transplant during the study period; &#x0D;&lt;br&gt;• Has untreated hypo- or hyperthyroidism;&#x0D;&lt;br&gt;• Has known human immunodeficiency virus (HIV) infection;&#x0D;&lt;br&gt;• Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;&#x0D;&lt;br&gt;• Recently received an investigational agent or device &#x0D;&lt;br&gt;• Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid&#x0D;&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin mediated amyloidosis (ATTR) &lt;br&gt;MedDRA version: 19.0
Level: PT
Classification code 10007509
Term: Cardiac amyloidosis
System Organ Class: 10007541 - Cardiac disorders
 &lt;br&gt;MedDRA version: 19.0
Level: PT
Classification code 10019889
Term: Hereditary neuropathic amyloidosis
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: ALN-TTR02 &lt;br&gt;Product Code: ALN-TTR02 &lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Patisiran&lt;br&gt;Current Sponsor code: Patisiran&lt;br&gt;Other descriptive name: ALN-TTR02&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To determine the efficacy of ALN-TTR02;Secondary Objective: To determine the effect of ALN-TTR02 on various clinical parameters;Primary end point(s): The difference between the ALN TTR02 and placebo groups in the change from baseline of modified Neuropathy Impairment Score+7 (mNIS+7);Timepoint(s) of evaluation of this end point: The difference between the ALN TTR02 and placebo groups in the change from baseline of modified NIS+7 (mNIS+7) at 18 months
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): The difference between ALN-TTR02 and placebo in the change from baseline in the following measurements:&#x0D;&lt;br&gt;• Quality of Life&#x0D;&lt;br&gt;• Modified Body Mass Index&#x0D;&lt;br&gt;• Autonomic function&#x0D;&lt;br&gt;• Muscle weakness as assessed by walking test&#x0D;&lt;br&gt;;Timepoint(s) of evaluation of this end point: The difference between ALN-TTR02 and placebo in the change from baseline in the various clinical parameters at 18 months
    </Secondary_outcome>
    <Secondary_ID>ALN-TTR02-004
    </Secondary_ID>
    <Source_Support>Alnylam Pharmaceuticals, Inc
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6113737
    </Internal_Number>
    <TrialID>EUCTR2013-001644-65-PT
    </TrialID>
    <Last_Refreshed_on>18 April 2017
    </Last_Refreshed_on>
    <Public_title>The Study of an Investigational Drug, ALN-TTR02, for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02.

    </Public_title>
    <Scientific_title>A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of  ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Alnylam Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130530
    </Date_registration3>
    <Date_registration>30/05/2013
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001644-65
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>19/07/2013
    </Date_enrollement>
    <Target_size>28
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>France;United States;Portugal;Brazil;Spain;Germany;Sweden
    </Countries>
    <Contact_Firstname>Clinical Trials Information
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Pormestarinrinne 8
    </Contact_Address>
    <Contact_Email>regsubmissions@medpace.com
    </Contact_Email>
    <Contact_Tel>49896737916
    </Contact_Tel>
    <Contact_Affiliation>Medpace Finland OY
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Previously received and tolerated ALN-TTR02 in Study ALN-TTR02-002.&lt;br&gt;2. Adequate Karnofsky performance status, liver function, and renal function.&lt;br&gt;&lt;br&gt;Additional inclusion criteria are utilized to assess entry in PK subgroup and for the cardiac subgroup.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 14&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 14&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pregnant or nursing.&lt;br&gt;2. Has had a liver transplant.&lt;br&gt;3. Has a New York Heart Association heart failure classification &gt;2.&lt;br&gt;4. Has unstable angina.&lt;br&gt;5. Has uncontrolled clinically significant cardiac arrhythmia.&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin mediated amyloidosis (ATTR) &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10007509
Term: Cardiac amyloidosis
System Organ Class: 10007541 - Cardiac disorders
 &lt;br&gt;MedDRA version: 14.1
Level: PT
Classification code 10019889
Term: Hereditary neuropathic amyloidosis
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: ALN-TTR02&lt;br&gt;Product Code: ALN-TTR02&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ALN-18328&lt;br&gt;Current Sponsor code: ALN-18328&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the safety and tolerability of long-term dosing with ALN-TTR02.;Secondary Objective: To assess the PD effect associated with long-term dosing of ALN-TTR02 on serum TTR.&lt;br&gt;&lt;br&gt;To assess changes from baseline in:&lt;br&gt;• Neurologic impairment, quality of life and disability, motor function impacting activities of daily living, and nutritional status.;Primary end point(s): To evaluate the safety and tolerability of long-term dosing with ALN-TTR02:&lt;br&gt;•assessment of adverse events (AEs),&lt;br&gt;•12 lead electrocardiograms (ECGs),&lt;br&gt;•vital signs (blood pressure, pulse rate, oral body temperature and respiratory rate),&lt;br&gt;•clinical laboratory safety tests (hematology, serum chemistry, thyroid function, coagulation, and urinalysis), &lt;br&gt;•ophthalmology examinations, and&lt;br&gt;•physical examinations.;Timepoint(s) of evaluation of this end point: The review of AEs will be done at each visit from Day 0 through through 56 days post last dose. The other assessments will be carried out at specific timepoints between screening and 56 days post last dose, as descibed in the study schedule.
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): To assess the PD effect associated with long-term dosing of ALN-TTR02 on serum TTR.&lt;br&gt;&lt;br&gt;To assess changes from baseline in:&lt;br&gt;• Neurologic impairment, quality of life and disability, motor function impacting activities of daily living, and nutritional status.;Timepoint(s) of evaluation of this end point: An assessment of the concentrations of serum TTR, RBP, and Vitamin A will be determined at specified time points between screening and 56 days post last dose, as described in the study schedule.&lt;br&gt;&lt;br&gt;Other assessments of neurologic impairment and QOL will be performed approximately every six months for approximately two years.
    </Secondary_outcome>
    <Secondary_ID>ALN-TTR02-003
    </Secondary_ID>
    <Source_Support>Alnylam Pharmaceuticals, Inc.
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6628862
    </Internal_Number>
    <TrialID>NCT01821118
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
    </Public_title>
    <Scientific_title>A Phase 2, Randomized, Double Blind Placebo Controlled Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Efficacy Of Pf-04360365 (Ponezumab) In Adult Subjects With Probable Cerebral Amyloid Angiopathy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Pfizer
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130304
    </Date_registration3>
    <Date_registration>04/03/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01821118
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2013
    </Date_enrollement>
    <Target_size>36
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>United States;Canada;France;Netherlands;United Kingdom;Canada;France;Netherlands;United Kingdom;United States;United States;Canada;France;Netherlands;United Kingdom;Canada;France;Netherlands;United Kingdom;United States;United States;Canada;France;Netherlands;United Kingdom;Canada;France;Netherlands;United Kingdom;United States;United States;Canada;France;Netherlands;United Kingdom;Canada;France;Netherlands;United Kingdom;United States;United States;Canada;France;Netherlands;United Kingdom;Canada;France;Netherlands;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Pfizer CT.gov Call Center;Pfizer CT.gov Call Center;Pfizer CT.gov Call Center;Pfizer CT.gov Call Center;Pfizer CT.gov Call Center
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Pfizer;Pfizer;Pfizer;Pfizer;Pfizer
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients diagnosed with probable CAA using the Boston criteria; with no clinical&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In general good health&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Co-morbid diagnosis of clinically documented Alzheimer's disease or significant&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant syncope, epilepsy, head trauma or clinically significant&#x0D;&lt;br&gt;             unexplained loss of consciousness within the last 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject's body weight exceeding 100kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of childbearing potential.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients diagnosed with probable CAA using the Boston criteria; with no clinical&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In general good health&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Co-morbid diagnosis of clinically documented Alzheimer's disease or significant&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant syncope, epilepsy, head trauma or clinically significant&#x0D;&lt;br&gt;             unexplained loss of consciousness within the last 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject's body weight exceeding 100kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of childbearing potential.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients diagnosed with probable CAA using the Boston criteria; with no clinical&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In general good health&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Co-morbid diagnosis of clinically documented Alzheimer's disease or significant&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant syncope, epilepsy, head trauma or clinically significant&#x0D;&lt;br&gt;             unexplained loss of consciousness within the last 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject's body weight exceeding 100kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of childbearing potential.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients diagnosed with probable CAA using the Boston criteria; with no clinical&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  In general good health&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Co-morbid diagnosis of clinically documented Alzheimer's disease or significant&#x0D;&lt;br&gt;             cognitive impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically significant syncope, epilepsy, head trauma or clinically significant&#x0D;&lt;br&gt;             unexplained loss of consciousness within the last 5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject's body weight exceeding 100kg&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of childbearing potential.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy
    </Condition>
    <Intervention>Biological: Ponezumab;Other: placebo;Biological: Ponezumab;Other: placebo;Biological: Ponezumab;Other: placebo;Biological: Ponezumab;Other: placebo
    </Intervention>
    <Primary_outcome>Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance Imaging (fMRI);Change From Baseline to Day 90 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked fMRI;Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance Imaging (fMRI);Change From Baseline to Day 90 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked fMRI;Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance Imaging (fMRI);Change From Baseline to Day 90 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked fMRI
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline to Day 2 and Day 90 in Cerebrovascular Reactivity as Measured by the Time to Peak From Visual Task-evoked fMRI;Change From Baseline to Day 2 and Day 90 in Cerebrovascular Reactivity as Measured by the Amplitude From Visual Task-evoked fMRI;Change From Baseline to Day 2 and Day 90 in Cerebrovascular Reactivity as Measured by the Time to Return to Baseline From Visual Task-evoked fMRI;Change From Baseline in Concentration of Total Plasma Amyloid Beta (AB);Number of Participants With Brain Structural Magnetic Resonance Imaging (sMRI) Abnormalities;Mean Montreal Cognitive Assessment (MoCA) Total Score Over Time;Number of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs);Number of Participants With Laboratory Abnormalities;Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria;Overall Number of Participants With Positive Responses to Questions on the Columbia Suicide Severity Rating Scale (C-SSRS);Number of Participants With Significant Changes From Baseline in Physical Examination at Final Visit;Number of Participants With Significant Changes in Neurological Examination Results;Number of Participants With Anti-PF-04360365 Antibodies
    </Secondary_outcome>
    <Secondary_ID>2013-001557-27;A9951024
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>03/11/2016
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01821118
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>10221402
    </Internal_Number>
    <TrialID>NCT01737398
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
    </Public_title>
    <Scientific_title>A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121127
    </Date_registration3>
    <Date_registration>27/11/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01737398
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>82 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 15, 2013
    </Date_enrollement>
    <Target_size>173
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>United States;Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States;Bulgaria
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stage 1 and Stage 2 FAP participants with the following:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. NIS score within protocol criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Documented transthyretin variant by genotyping&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Documented amyloid deposit by biopsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Females of child-bearing potential must use appropriate contraception and be&#x0D;&lt;br&gt;             non-pregnant and non-lactating. Males engaging in relations of child-bearing potential&#x0D;&lt;br&gt;             are to use appropriate contraception&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Low Retinol level at screen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Karnofsky performance status =50&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Poor Renal function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known type 1 or type 2 diabetes mellitus&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other causes of sensorimotor or autonomic neuropathy (for example, autoimmune disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If previously treated with Vyndaqel®, will need to have discontinued treatment for 2&#x0D;&lt;br&gt;             weeks prior to Study Day 1. If previously treated with Diflunisal, will need to have&#x0D;&lt;br&gt;             discontinued treatment for 3 days prior to Study Day 1&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous treatment with any oligonucleotide or siRNA within 12 months of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior liver transplant or anticipated liver transplant within 1 year of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  New York Heart Association (NYHA) functional classification of =3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute Coronary Syndrome or major surgery within 3 months of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known Primary or Leptomeningeal Amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anticipated survival less than 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other conditions in the opinion of the investigator which interfere with the&#x0D;&lt;br&gt;             participant participating in or completing the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>FAP;Familial Amyloid Polyneuropathy;TTR;Transthyretin;Amyloidosis
    </Condition>
    <Intervention>Drug: Inotersen;Drug: Placebo
    </Intervention>
    <Primary_outcome>Change From Baseline In The Modified Neuropathy Impairment Score (mNIS) +7 Composite Score at Week 66;Change From Baseline In The Norfolk Quality Of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline In The Norfolk QoL-DN Questionnaire Symptoms Domain Score at Week 66;Change From Baseline In The Norfolk QoL-DN Questionnaire Physical Functioning/Large Fiber Neuropathy Domain Score at Week 66;Change From Baseline In Modified Body Mass Index (mBMI) at Week 65;Change From Baseline In Body Mass Index (BMI) at Week 65;Change From Baseline in Neuropathy Impairment Score (NIS) at Week 66;Change From Baseline in Modified +7 at Week 66;Change From Baseline in NIS+7 at Week 66;Change From Baseline in Global Longitudinal Strain (GLS) by Echocardiogram (ECHO) at Week 65 in the CM-ECHO Set;Change From Baseline in Global Longitudinal Strain (GLS) by Echocardiogram ECHO at Week 65 in the ECHO Subgroup;Change From Baseline in Transthyretin (TTR) Level at Week 65;Change From Baseline in Retinol Binding Protein 4 (RBP4) Level at Week 65;Maximum Measured Plasma Concentration (Cmax) Of Inotersen At Week 65;Time To The Maximum Plasma Concentration (Tmax) Of Inotersen At Week 65;Area Under The Plasma Concentration-time Curve From 0 To 24 Hours (AUC[0-24hr]) Of Inotersen At Week 65;Area Under The Plasma Concentration-time Curve From 0 To 168 Hours (AUC[0-168hr]) Of Inotersen At Week 65;Plasma Clearance From 0 To 24 Hours (CL[0-24hr]/F) Of Inotersen At Week 65;Inotersen Plasma Clearance At Steady State (CLss/F) At Week 65
    </Secondary_outcome>
    <Secondary_ID>ISIS 420915-CS2
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>23/01/2019
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01737398
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>7325225
    </Internal_Number>
    <TrialID>EUCTR2012-001831-30-GB
    </TrialID>
    <Last_Refreshed_on>10 September 2018
    </Last_Refreshed_on>
    <Public_title>A controlled study to assess the effectiveness and safety of study drug, ISIS 420915, in patients with Familial Amyloid Polyneuropathy
    </Public_title>
    <Scientific_title>A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy - ISIS 420915-CS2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Ionis Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121116
    </Date_registration3>
    <Date_registration>16/11/2012
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001831-30
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>22/04/2013
    </Date_enrollement>
    <Target_size>135
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Portugal;France;United States;Argentina;Brazil;Spain;Bulgaria;Germany;New Zealand;Italy;United Kingdom
    </Countries>
    <Contact_Firstname>Matt R. Buck
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>2855 Gazelle Ct.
    </Contact_Address>
    <Contact_Email>mbuck@ionisph.com
    </Contact_Email>
    <Contact_Tel>011760603-2684
    </Contact_Tel>
    <Contact_Affiliation>Ionis Pharmaceuticals, Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;•  Diagnosed Stage 1 or Stage 2 FAP patient&#x0D;&lt;br&gt;•  Meets NIS requirements&#x0D;&lt;br&gt;•  Male or female aged 18 to 82 years old at the time of informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 70&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 65&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;•	Has inadequate liver, renal or heart function&#x0D;&lt;br&gt;•  Has retinol levels at screen &lt; LLN&#x0D;&lt;br&gt;•  Has human immunodeficiency virus (HIV), hepatitis B or hepatitis C&#x0D;&lt;br&gt;•  Has type 1 or type 2 diabetes mellitus or other cause of sensorimotor or autonomic neuropathy&#x0D;&lt;br&gt;•  Recently treated with another investigational drug, biological agent or device&#x0D;&lt;br&gt;•  Is currently taking Vyndaqel® or diflunisal&#x0D;&lt;br&gt;•  Prior liver transplant or anticipated liver transplant within 1 year of screening&#x0D;&lt;br&gt;•  Anticipated survival less than 2 years&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy &lt;br&gt;MedDRA version: 19.0
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 100000004850
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Human Transthyretin Antisense Oligonucleotide&lt;br&gt;Product Code: ISIS 420915&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ISIS 420915&lt;br&gt;Current Sponsor code: ISIS 420915&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Subcutaneous use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of ISIS 420915 as compared to placebo, given for 65 weeks, as measured by the change from baseline in the modified Neuropathy Impairment Score +7 (mNIS+7) and in the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire total score, in patients with Familial Amyloid Polyneuropathy (FAP).;Secondary Objective: To evaluate the efficacy of ISIS 420915 as compared to placebo based on the change from baseline in the following measures:&lt;br&gt;•	Norfolk QOL-DN questionnaire symptoms domain score in Stage 1 patients and Norfolk QOL-DN questionnaire physical functioning/large fiber neuropathy domain score in Stage 2 patients&lt;br&gt;•	Modified body mass index (mBMI) and body mass index (BMI)&lt;br&gt;•	NIS and modified +7&lt;br&gt;•	NIS+7&lt;br&gt;•	Global longitudinal strain (GLS) by echocardiogram (ECHO) in the ECHO subgroup and in the Cardiomyopathy-ECHO (CM-ECHO) Set&lt;br&gt;&lt;br&gt;To evaluate the pharmacodynamic (PD) effect of ISIS 420915 as compared to placebo, based on the change from baseline in transthyretin (TTR) and retinol binding protein 4 (RBP4).&lt;br&gt;&lt;br&gt;To evaluate the safety and tolerability of ISIS 420915.&lt;br&gt;&lt;br&gt;To evaluate the plasma trough levels of ISIS 420915 in all patients and to evaluate the plasma pharmacokinetic parameters of ISIS 420915 in a subset of patients.;Primary end point(s): Change in mNIS+7 score from baseline to Week 66 and the change in the Norfolk QOL-DN questionnaire total score from baseline to Week 66;Timepoint(s) of evaluation of this end point: 66 Weeks
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): •	Change in the Norfolk QOL-DN questionnaire symptoms domain score (Stage 1 patients only) and Norfolk QOL-DN questionnaire physical functioning/large fiber neuropathy domain score (Stage 2 patients only) from baseline to Week 66&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;•	Change in the mBMI and BMI from baseline to Week 65&#x0D;&lt;br&gt;	&#x0D;&lt;br&gt;•	Change in NIS and modified +7 from baseline to Week 66&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;•	Change in NIS+7 score from baseline to Week 66&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;•                   Changes in Global longitudinal strain (GLS) by echocardiogram (ECHO) in the ECHO subgroup and in the Cardiomyopathy-ECHO (CM-ECHO) Set&#x0D;&lt;br&gt;;Timepoint(s) of evaluation of this end point: 66 Weeks
    </Secondary_outcome>
    <Secondary_ID>ISIS420915-CS2
    </Secondary_ID>
    <Source_Support>Ionis Pharmaceuticals
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>12348667
    </Internal_Number>
    <TrialID>NCT01705626
    </TrialID>
    <Last_Refreshed_on>13 June 2022
    </Last_Refreshed_on>
    <Public_title>Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)
    </Public_title>
    <Scientific_title>Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR-FAP): An International, Multicenter, Epidemiological Protocol
    </Scientific_title>
    <Acronym>TRAP2-1
    </Acronym>
    <Primary_sponsor>CENTOGENE GmbH Rostock
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20121009
    </Date_registration3>
    <Date_registration>09/10/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01705626
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2016
    </Date_enrollement>
    <Target_size>500
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Austria;Hungary;North Macedonia;Poland;Serbia;Spain;Austria;Hungary;North Macedonia;Poland;Serbia;Spain;Germany
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Peter Bauer, Prof.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Centogene GmgH
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent is obtained from the participant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant is aged between 18 and 85 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant is diagnosed with small fiber polyneuropathy of no obvious etiology&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has no diagnosis of alcoholism, according to International Guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has not undergone chemotherapy for carcinoma&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant is younger than 18 years or older than 85 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The etiology of the small fiber polyneuropathy is clearly determined&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has a diagnosis of alcoholism, according to International Guidelines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The participant has undergone chemotherapy for carcinoma&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Polyneuropathy, Amyloid;Neuropathic Pain;Cardiac Failure;Orthostatic Hypotension;Gastrointestinal Disorders
    </Condition>
    <Primary_outcome>Epidemiological analysis of prevalence of the TTR FAP in participants with small fiber polyneuropathy of no obvious etiology.
    </Primary_outcome>
    <Secondary_outcome>Establishment of a biomarker in TTR-positive cohort
    </Secondary_outcome>
    <Secondary_ID>TRAP 08-2012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13442559
    </Internal_Number>
    <TrialID>JPRN-UMIN000008396
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>A randomized, double-blind, placebo-controlled trial of diflunisal on familial amyloid polyneuropathy
    </Public_title>
    <Scientific_title>A randomized, double-blind, placebo-controlled trial of diflunisal on familial amyloid polyneuropathy - A trial of diflunisal on familial amyloid polyneuropathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Department of Neurology, Faculty of Life Sciences, Kumamoto University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120710
    </Date_registration3>
    <Date_registration>10/07/2012
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009874
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18years-old
    </Inclusion_agemin>
    <Inclusion_agemax>65years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2012/08/01
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Randomized
    </Study_design>
    <Phase>Phase III
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Taro Yamashita
    </Contact_Lastname>
    <Contact_Address>1-1-1, Honjo, Kumamoto
    </Contact_Address>
    <Contact_Email>taro-yamashita@fc.kuh.kumamoto-u.ac.jp
    </Contact_Email>
    <Contact_Tel>096-373-5893
    </Contact_Tel>
    <Contact_Affiliation>Faculty of Life Sciences, Kumamoto University Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: patients after liver transplantation
    </Exclusion_Criteria>
    <Condition>patients of familial amyloid polyneuropathy
    </Condition>
    <Intervention>Diflunisal, 500mg / day, PO, 1 year&lt;br&gt;Parse, 500mg / day, PO, 1 year
    </Intervention>
    <Primary_outcome>clinical manifestation
    </Primary_outcome>
    <Secondary_outcome>nerve conduction study data
    </Secondary_outcome>
    <Source_Support>Department of Neurology, Faculty of Life Sciences, Kumamoto University
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_completed>31/12/2012
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>12967547
    </Internal_Number>
    <TrialID>NCT01604122
    </TrialID>
    <Last_Refreshed_on>17 April 2023
    </Last_Refreshed_on>
    <Public_title>Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
    </Public_title>
    <Scientific_title>Cross-sectional, Non-interventional Burden Of Disease (Bod) Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (Ttr-fap) Or Transthyretin Cardiomyopathy (ttr-cm) And Caregivers
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Pfizer
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20120521
    </Date_registration3>
    <Date_registration>21/05/2012
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01604122
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 18, 2012
    </Date_enrollement>
    <Target_size>1
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Pfizer CT.gov Call Center
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Pfizer
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults (ages 18-85 years inclusive) diagnosed with TTR-FAP or TTR-CM and experiencing&#x0D;&lt;br&gt;             symptoms or currently providing care for a patient with TTR-FAP or TTR-FAP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Caregivers who formally care for a TTR-FAP or TTR-CM patient as part of their job&#x0D;&lt;br&gt;             description and receive payment for their services.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP);Transthyretin Cardiomyopathy (TTR-CM);Familial Amyloid Cardiomyopathy;Senile Systemic Amyloidosis (SSA)
    </Condition>
    <Intervention>Other: No drug;Other: No drug
    </Intervention>
    <Primary_outcome>Demographical Characteristics of Participants;Disease Characteristics of Participants: Disease Duration;Disease Characteristics of Participants: Mutation Type;Disease Characteristics of Participants: Liver Transplantation Status;Disease Characteristics of Participants: Number of Participants With Family History of ATTR;Disease Characteristics of Participants: Mobility Status;12-Item Short-Form Health Survey (SF-12) Scores;Hospital Anxiety and Depression Scale (HADS): Depression and Anxiety Subscale Scores;Euro Quality of Life (EQ-5D-3L)- Health State Profile Utility Score;Euro Quality of Life (EQ-5D-3L)- Visual Analog Scale (VAS) Score;Work Productivity and Activity Impairment- Specific Health Version (WPAI-SH): Percent of Work Time Missed;Work Productivity and Activity Impairment- Specific Health Version: Percent Impairment While Working;Work Productivity and Activity Impairment- Specific Health Version: Percent Overall Work Impairment;Work Productivity and Activity Impairment- Specific Health Version: Percent Activity Impairment;Healthcare Resource Use Survey: Number of Outpatient Visits to Healthcare Providers;Healthcare Resource Use Survey: Number of Hospitalizations;Healthcare Resource Use Survey: Number of Emergency Care Visits;Healthcare and Resource Use Survey: Symptomatic Treatment of Participants;Healthcare Resource Use Survey: Number of Symptomatic Treatment Visits;Healthcare Resource Use Survey: Out-of-Pocket Costs;Participants Pain Score;Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL): Total Scores;Norfolk Quality of Life-Diabetic Neuropathy Total Quality of Life: Subscale Scores;Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores;Zarit Burden Interview (ZBI): Total Scores;Zarit Burden Interview: Subscale Scores;Caregiver Burden Items Assessment: Number of Hours Per Week Spent in Care of the Participants With ATTR;Caregiver Burden Items Assessment: Work Time Lost;Caregiver Burden Items Assessment: Total Cost
    </Primary_outcome>
    <Secondary_ID>B3461036
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>12/04/2017
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01604122
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>7766617
    </Internal_Number>
    <TrialID>KCT0000379
    </TrialID>
    <Last_Refreshed_on>11 March 2019
    </Last_Refreshed_on>
    <Public_title>Neuropathologic and Neurochemical Imaging Technologies and Their Clinical Applications in Alzheimer's Disease
    </Public_title>
    <Scientific_title>Phase 1 and Phase 2 clinical trials for the evaluation of pharmacokinetics, safety, and efficacy of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical for PET imaging of amyloid plaques, in Alzheimer's disease patients and healthy volunteers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Seoul National University Bundang Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20120312
    </Date_registration3>
    <Date_registration>2012-03-12
    </Date_registration>
    <Source_Register>CRIS
    </Source_Register>
    <web_address>http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1897
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>60(Year)
    </Inclusion_agemin>
    <Inclusion_agemax>80(Year)
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2010-10-25
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional Study
    </Study_type>
    <Study_design>Primary Purpose : Diagnosis, Intervention Model : Others, Blinding/Masking : Open, Allocation : Not Applicable
    </Study_design>
    <Phase>Phase1/Phase2
    </Phase>
    <Countries>Korea, Republic of
    </Countries>
    <Contact_Firstname>Ji 
    </Contact_Firstname>
    <Contact_Lastname>Shin
    </Contact_Lastname>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Seoul National University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Clinical Dementia Rating: over 0.5&lt;br&gt;NINCDS/ADRDA criteria probable Alzheimer's disease&lt;br&gt;DSM-IV criteria Alzheimer's Disease
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Evidence of delirium or confusion, other consciousness disorder&lt;br&gt;Nuerologic disease that causes cognitive fuction decline(parkinson's disease, stroke, brain hemorrhage, cancer, normal pressure hydrocephalus etc.)
    </Exclusion_Criteria>
    <Condition>;Mental and behavioral disorders
    </Condition>
    <Intervention>Radiation : radiopharmaceutical: SNUBH-NM-333(18F)&lt;br&gt;volume: 5~10CC&lt;br&gt;number: 1&lt;br&gt;period: once&lt;br&gt;injection route: intra vein&lt;br&gt;subject: Alzheimer's disease patients, healthy volunteers
    </Intervention>
    <Primary_outcome>Pharmacokinetics of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical ;Safety of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical 
    </Primary_outcome>
    <Secondary_outcome>Evaluation of adverse event after SNUBH-NM-333(18F) injection  
    </Secondary_outcome>
    <Source_Support>Ministry of Health &amp; Welfare
    </Source_Support>
    <Ethics_review_status>Submitted approval
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Seoul National University Hospital Institutional Review Board 
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>5000854
    </Internal_Number>
    <TrialID>EUCTR2012-000467-24-SE
    </TrialID>
    <Last_Refreshed_on>10 July 2015
    </Last_Refreshed_on>
    <Public_title>The Study of an Investigational Drug, ALN-TTR02, for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
    </Public_title>
    <Scientific_title>A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients with TTR Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Alnylam Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120221
    </Date_registration3>
    <Date_registration>21/02/2012
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-000467-24
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>08/05/2012
    </Date_enrollement>
    <Target_size>27
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: 
Open: 
Single blind: 
Double blind: 
Parallel group: 
Cross over: 
Other: 
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no

    </Study_design>
    <Countries>France;Portugal;Brazil;Spain;Germany;Sweden
    </Countries>
    <Contact_Firstname>Clinical Trials Information
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Pormestarinrinne 8
    </Contact_Address>
    <Contact_Email>regsubmissions@medpace.com
    </Contact_Email>
    <Contact_Tel>49896737916
    </Contact_Tel>
    <Contact_Affiliation>Medpace Finland OY
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Male or female aged 18 years or older.&#x0D;&lt;br&gt;2. Patients has a biopsy-proven diagnosis of TTR amyloidosis with documented signs/symptoms of the disease (e.g., sensory, motor, or autonomic neuropathy) that are at least mild to moderate in severity.&#x0D;&lt;br&gt;3. Body mass index (BMI) of 17–33 kg/m2.&#x0D;&lt;br&gt;4. Karnofsky performance status of 60% or greater.&#x0D;&lt;br&gt;5. Absolute neutrophil count (ANC) =1500 cells/mm³,&#x0D;&lt;br&gt;platelet count =100,000 cells/mm³, and hemoglobin =10 g/dL.&#x0D;&lt;br&gt;6. Adequate liver function, demonstrated by an aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 x the upper limit of normal (ULN), total bilirubin within normal limits, albumin &gt;3 g/dL, international normalized ratio (INR) =1.2.&#x0D;&lt;br&gt;7. Adequate renal function: serum creatinine =1.5 x ULN.&#x0D;&lt;br&gt;8. Seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV).&#x0D;&lt;br&gt;9. Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must be using two highly effective methods of contraception ( hormonal - oral, implantable, injectable, or transdermal contraceptives in conjunction with spermicide, condom, or diaphragm; mechanical - spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD) in conjunction with spermicide or condom; or surgical sterilization of partner in conjunction with spermicide, condom, or diaphragm) prior to screening, throughout study participation, and for 1 month after ending study participation.&#x0D;&lt;br&gt;10. Males agree to use appropriate contraception throughout study participation and for 1 month after ending study participation.&#x0D;&lt;br&gt;11. Patient is willing and able to comply with protocol required visit schedule and visit requirements and provide written informed consent.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 24&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 3&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pregnant or nursing.&#x0D;&lt;br&gt;2. Has had a liver transplant.&#x0D;&lt;br&gt;3. Has a known surgery planned during any point of the study period.&#x0D;&lt;br&gt;4. Has known human immunodeficiency virus (HIV) positive status.&#x0D;&lt;br&gt;5. Has a known or suspected systemic bacterial, viral, parasitic, or fungal infection.&#x0D;&lt;br&gt;6. Received an investigational agent, other than tafamidis or diflunisal, within 30 days prior to study drug administration.&#x0D;&lt;br&gt;7. Has a New York Heart Association heart failure classification &gt;2.&#x0D;&lt;br&gt;8. Has unstable angina.&#x0D;&lt;br&gt;9. Has uncontrolled clinically significant cardiac arrhythmia.&#x0D;&lt;br&gt;10. Is considered unfit for the study by the Principal Investigator.&#x0D;&lt;br&gt;11. Had a prior severe reaction to a liposomal product.&#x0D;&lt;br&gt;12. Has known hypersensitivity to oligonucleotides.&#x0D;&lt;br&gt;13. Is an employee or family member of Alnylam, the CRO, or the clinical study site personnel.&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin mediated amyloidosis (ATTR) &lt;br&gt;MedDRA version: 15.1
Level: PT
Classification code 10007509
Term: Cardiac amyloidosis
System Organ Class: 10007541 - Cardiac disorders
 &lt;br&gt;MedDRA version: 15.1
Level: PT
Classification code 10019889
Term: Hereditary neuropathic amyloidosis
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: ALN-TTR02&lt;br&gt;Product Code: ALN-TTR02&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: ALN-18328&lt;br&gt;Current Sponsor code: ALN-18328&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: • To evaluate the safety and tolerability of multiple doses of ALN-TTR02.;Secondary Objective: • To characterize the plasma and urine PK of ALN-TTR02.&lt;br&gt;• To assess preliminary evidence of the PD effect of ALN-TTR02 on serum total TTR levels.;Primary end point(s): To evaluate the safety and tolerability of multiple doses of ALN-TTR02 including:&lt;br&gt;•assessment of adverse events (AEs),&lt;br&gt;•12 lead electrocardiograms (ECGs),&lt;br&gt;• cardiac monitoring (telemetry)&lt;br&gt;•arterial oxygen saturation (SaO2) using pulse oximetry,&lt;br&gt;•vital signs (blood pressure, pulse rate, oral body temperature and&lt;br&gt;respiratory rate),&lt;br&gt;•clinical laboratory safety tests (hematology, serum chemistry,&lt;br&gt;coagulation, urinalysis, liver function, lipid panel, thyroid function, complement factor Bb, cytokines, and&lt;br&gt;•physical examinations.;Timepoint(s) of evaluation of this end point: The review of AEs will be done at each visit from Day 0 through Day 56.  The other assessments will be carried out at specific timepoints between screening and D208, as described in the study schedule.
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): PK profile of ALN-TTR02, including:&#x0D;&lt;br&gt;•plasma-concentration time profiles for ALN-18328 and the novel lipid components DLin-MC3-DMA and PEG2000-C-DMG.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;PD effect of ALN-TTR02 on serum TTR, RBP and Vitamin A, including:&#x0D;&lt;br&gt;•serial assessment of serum concentrations of TTR, TTR mRNA, RBP and Vitamin A.;Timepoint(s) of evaluation of this end point: ALN-18328, PEG2000-C-DMG and DLin-MC3-DMA concentrations will be determined at specified time points between D0 and D208, as described in the study schedule.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;An assessment of the concentrations of serum TTR, TTR mRNA, RBP and Vitamin A will be determined at specified time points between screening and D208, as described in the study schedule.
    </Secondary_outcome>
    <Secondary_ID>ALN-TTR02-002
    </Secondary_ID>
    <Source_Support>Alnylam Pharmaceuticals, Inc.
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13428738
    </Internal_Number>
    <TrialID>JPRN-jRCT2080221636
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
    </Public_title>
    <Scientific_title>The Effect Of Transthyretin Stabilization, Safety, Tolerability, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin: A Phase 3, Open-Label(B3461010)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Pfizer Japan Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20111102
    </Date_registration3>
    <Date_registration>02/11/2011
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCT2080221636
    </web_address>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 20age old
    </Inclusion_agemin>
    <Inclusion_agemax>&lt;= 75age old
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>02/11/2011
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Nonrandomized Trial, Open, Single Group
    </Study_design>
    <Phase>3
    </Phase>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>clinical-trials@pfizer.com
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Pfizer Japan Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -Primary amyloidosis and secondary amyloidosis.&lt;br&gt;-History of liver transplant.
    </Exclusion_Criteria>
    <Condition>Transthyretin Familial Amyloid Polyneuropathy
    </Condition>
    <Intervention>investigational material(s)&lt;br&gt;Generic name etc : tafamidis meglumine&lt;br&gt;INN of investigational material : tafamidis meglumine&lt;br&gt;Therapeutic category code : 129 Other agents affecting peripheral nervous system&lt;br&gt;Dosage and Administration for Investigational material : 20 mg QD
    </Intervention>
    <Primary_outcome>TTR stabilization at Week 8 compared with Baseline, as measured by a validated immunoturbidimetric assay.&lt;br&gt;Same as above
    </Primary_outcome>
    <Secondary_outcome>Change from baseline on the following scales:Neuropathy Impairment Score;QOL;"Sigma 7 NTs NDS"as measured by nerve conduction studies(NCS),vibration detection threshold(VDT) and heart rate response to deep breathing(HRDB);&lt;br&gt;Change from baseline on the following scales:"Sigma 3 NTSF NDS"as measured by cooling and heat pain thresholds utilizing CASE IV and heart rate response to deep breathing (HRDB);mBMI;Ambulatory status.&lt;br&gt;Transthyretin(TTR)stabilization at each follow up visit after Week 8.&lt;br&gt;Blood samples for determination of plasma levels of tafamidis will be collected at Baseline and during the visits at Week 2.&lt;br&gt;lood samples for determination of plasma levels of tafamidis will be collected at Week 4.&lt;br&gt;Blood samples for determination of plasma levels of tafamidis will be collected Week 8.&lt;br&gt;Blood samples for determination of plasma levels of tafamidis will be collected at Week 26.&lt;br&gt;Blood samples for determination of plasma levels of tafamidis will be collected at Week 52.&lt;br&gt;Blood samples for determination of plasma levels of tafamidis will be collected at Week 78.&lt;br&gt;Blood samples for determination of plasma levels of tafamidis will be collected at End of study.&lt;br&gt;Same as above
    </Secondary_outcome>
    <Secondary_ID>JapicCTI-111678
    </Secondary_ID>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>5530032
    </Internal_Number>
    <TrialID>EUCTR2011-005236-25-SE
    </TrialID>
    <Last_Refreshed_on>23 May 2016
    </Last_Refreshed_on>
    <Public_title>A phase II multicenter pilot study of the safety and efficacy of Doxycycline/UrsoDeoxyCholicAcid on disease progression in ATTR amyloidosis
    </Public_title>
    <Scientific_title>A phase II multicenter pilot study of the safety and efficacy of Doxycycline/UrsoDeoxyCholicAcid on disease progression in ATTR amyloidosis - Dox/Urso                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Umeå University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20111101
    </Date_registration3>
    <Date_registration>01/11/2011
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-005236-25
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>21/12/2011
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no

    </Study_design>
    <Phase>Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no

    </Phase>
    <Countries>Sweden
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1)	Cardiomyopahty with septal thickness &gt;/= 15 mm and/or S-NT-ProBNP &gt;/=300 ng/L&#x0D;&lt;br&gt;2)	Age &gt;/=50 years&#x0D;&lt;br&gt;3)	Male and females after menopause&#x0D;&lt;br&gt;4)	Written informed consent to be obtained prior to any study procedure&#x0D;&lt;br&gt;5)	Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy of green birefringent material in Congo red-stained tissue specimens, and typing of amyloid deposits as TTR and identification of amyloid fibril type.&#x0D;&lt;br&gt;6)	Molecular definition of the TTR mutation or immunohistochemical staining of amyloid fibrils with anti TTR antibody &#x0D;&lt;br&gt;7)	NYHA class &lt;/=III&#x0D;&lt;br&gt;8)	Systolic blood pressure &gt;/=100 mmHg (standing)&#x0D;&lt;br&gt;9)	Must have symptomatic organ involvement with amyloid to justify therapy&#x0D;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 15&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 15&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Liver transplantation in the previous 6 months or liver transplantation anticipated in less than 6 months;&#x0D;&lt;br&gt;	2) ALT and/or AST &gt;/= 2 x UNL;&#x0D;&lt;br&gt;	3) Creatinine clearance &lt; 30 ml/min (Cocroft-Gault Formula) &#x0D;&lt;br&gt;4) Any other lab values, illness or condition that in the opinion of the investigator might place the subject at unacceptable risk for participation in the study;&#x0D;&lt;br&gt;	5) History of hypersensitivity to any of the ingredients of the study therapies;&#x0D;&lt;br&gt;	6) Use of any investigational drug, device (or biologic) within 4 weeks prior to study entry or during the study.&#x0D;&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin amyloidosis &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10019893
Term: Hereditary neuropathic amyloidosis, Swedish type
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Trade Name: Ursofalk&lt;br&gt;Product Name: Ursofalk&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 128-13-2 &lt;br&gt;Other descriptive name: URSODESOXYCHOLIC ACID&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Doxyferm&lt;br&gt;Product Name: Doxyferm&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 17086-28-1&lt;br&gt;Other descriptive name: DOXYCYCLINE MONOHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To evaluate the efficacy of doxycycline + UDCA on disease progression in ATTR subjects with cardiomyopathy with or without neuropathy.;Secondary Objective: 1.  To evaluate the safety and tolerability of doxycyclin + UDCA in ATTR subjects over 12 months.&lt;br&gt;2. To evaluate symptoms and signs of peripheral sensorimotor neuropathy when present (Kumamoto Scale).&lt;br&gt;3. To evaluate disease evolution (maintenance of response, occurrence of disease progression) over 18 months.&lt;br&gt;4. To evaluate the outcome of the treatment with regard to type of amyloid fibrills&lt;br&gt;;Primary end point(s): Response rate to doxycycline + UDCA treatment at month 12. A responder is an ATTR subject with:&lt;br&gt;		&lt;br&gt;- a reduction of, or an  increase in serum NT-proBNP concentration of less than 30% of pre-treatment level will be regarded as consistent with treatment efficacy.&lt;br&gt;;Timepoint(s) of evaluation of this end point: After 12 month of treatment
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): -mBMI-reduction of less than 10% after 12 months of treatment&#x0D;&lt;br&gt;- increase of septum thickness = 2 mm during 12 months of treatment.&#x0D;&lt;br&gt;- to assess the change from baseline in the neurologic Kumamoto Scale at months 6, 12 and 18; &#x0D;&lt;br&gt;- to assess the tolerability and safety of the treatment, i.e. monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), and the regularly scheduled monitoring of hematology, blood chemistry, physical examinations, and blood pressure over 12 months and 18 months.&#x0D;&lt;br&gt;;Timepoint(s) of evaluation of this end point: At 6, 12 and 18 month 
    </Secondary_outcome>
    <Secondary_ID>Dox/Urso
    </Secondary_ID>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6501560
    </Internal_Number>
    <TrialID>NCT01435655
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
    </Public_title>
    <Scientific_title>The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Pfizer
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110913
    </Date_registration3>
    <Date_registration>13/09/2011
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01435655
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2011
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 3
    </Phase>
    <Countries>Japan;Japan;Japan;Japan
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Pfizer CT.gov Call Center;Pfizer CT.gov Call Center;Pfizer CT.gov Call Center;Pfizer CT.gov Call Center
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Pfizer;Pfizer;Pfizer;Pfizer
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject had amyloid documented by biopsy in accordance with institutional site&#x0D;&lt;br&gt;             standard of care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary amyloidosis and secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of liver transplant.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject had amyloid documented by biopsy in accordance with institutional site&#x0D;&lt;br&gt;             standard of care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary amyloidosis and secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of liver transplant.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject had amyloid documented by biopsy in accordance with institutional site&#x0D;&lt;br&gt;             standard of care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary amyloidosis and secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of liver transplant.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subject had amyloid documented by biopsy in accordance with institutional site&#x0D;&lt;br&gt;             standard of care.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary amyloidosis and secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of liver transplant.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin Familial Amyloid Polyneuropathy;Transthyretin Familial Amyloid Polyneuropathy;Transthyretin Familial Amyloid Polyneuropathy;Transthyretin Familial Amyloid Polyneuropathy
    </Condition>
    <Intervention>Drug: tafamidis;Drug: tafamidis;Drug: tafamidis;Drug: tafamidis
    </Intervention>
    <Primary_outcome>Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay;Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in Neuropathy Impairment Score (NIS); NIS (Total), NIS-LL (Lower Limb) and NIS-UL (Upper Limb) at Week 26, Week 52 and Week 78;Change From Baseline in Scores of the Total Quality of Life (TQOL) and 5 Domains as Measured by the Norfolk QOL - Diabetic Neuropathy (Norfolk QOL-DN) at Week 26, Week 52 and Week 78.;Change From Baseline in Summated 7 Nerve Tests Normal Deviate Score (? 7 NTs Nds) as Measured by Nerve Conduction Studies (NCS), Vibration Detection Threshold (VDT) and Heart Rate Response to Deep Breathing (HRDB) at Week 26, Week 52, and Week 78;Change From Baseline in Summated 3 Nerve Tests Small Fiber Normal Deviate Score (? 3 NTSF Nds) as Measured by Cooling and Heat Pain Thresholds by QST and HRDB at Week 26, Week 52 and Week 78;Change From Baseline in Modified Body Mass Index (mBMI) at Week 8, Week 26, Week 52 and End of Study;Change From Baseline in Ambulatory Status at Week 26, Week 52 and Week 78;Number of Participants With Transthyretin (TTR) Stabilization at Week 26, Week 52, and Week 78 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay
    </Secondary_outcome>
    <Secondary_ID>B3461010
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>09/09/2015
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01435655
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>5000478
    </Internal_Number>
    <TrialID>EUCTR2011-000776-34-SE
    </TrialID>
    <Last_Refreshed_on>10 July 2015
    </Last_Refreshed_on>
    <Public_title>THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS
    </Public_title>
    <Scientific_title>THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS:&#x0D;
An open label extension study of ”the diflunisal trial” (IND 68092), and an open label observational study on previously untreated patients with familial transthyretin amyloidosis.&#x0D;
 - DFNS01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Umea University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20110504
    </Date_registration3>
    <Date_registration>04/05/2011
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000776-34
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>07/06/2011
    </Date_enrollement>
    <Target_size/>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1

    </Study_design>
    <Countries>Sweden
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Biopsy and genetically proven systemic transthyretin amyloidosis caused by a TTR gene mutation. The amyloid shall be proven to be of tranthyrein type, and the fibril composition settled.&#x0D;&lt;br&gt;2. Age = 18 years.&#x0D;&lt;br&gt;3. Negative pregnancy test and contraception for sexually active women of child bearing potential.&#x0D;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 10&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 30&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Concomitant use of non-study NSAIDs&#x0D;&lt;br&gt;2. Heart failure with symptoms at daily activities (NYHA class =III)&#x0D;&lt;br&gt;3. Renal insufficiency (kreatinine clearence &lt; 30 ml calculated from the Cocroft-Gault formula)&#x0D;&lt;br&gt;4. Active non-haemorrhoidal bleeding within the last 18 month.&#x0D;&lt;br&gt;5. Non-treated peptic ulcer disease.&#x0D;&lt;br&gt;6. Anticoagulation therapy, low dose ASA permitted.&#x0D;&lt;br&gt;7. Non-steroidal or aspirin allergy/hypersensitivity&#x0D;&lt;br&gt;8. Thrombocytopenia (&lt; 100,000 platelets/mm3)&#x0D;&lt;br&gt;9. Inability or unwillingness of subject to give written informed consent&#x0D;&lt;br&gt;10. By the investigator regarded as unable to follow the study guidelines and scheduled controls.&#x0D;&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Familial transthyretin amyloidosis &lt;br&gt;MedDRA version: 13.1
Level: LLT
Classification code 10019893
Term: Hereditary neuropathic amyloidosis, Swedish type
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    </Condition>
    <Intervention>&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: DIFLUNISAL&lt;br&gt;CAS Number: 22494-42-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To follow the development of neurological, nutritional and cardiac manifestations of transthyretin amyloidosis in patients treated by Diflunisal 250 mg twice daily.;Secondary Objective: collect and report adverse reactions;Primary end point(s): Changes in the Kumamoto scale;Timepoint(s) of evaluation of this end point: After 12 and 18 month treatment. Dependent of when results from the ongoing international study can be presented a 24 month evaluation can be performed in this study.
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): 1. changes in nutritional status measured by the modified body mass index (mBMI)&#x0D;&lt;br&gt;2. neurological impairment measured by the PND-score&#x0D;&lt;br&gt;3. cardiac impairment measured by echocardiographic measurement of septal thickness and by proBNP in blood samples.&#x0D;&lt;br&gt;;Timepoint(s) of evaluation of this end point: After 12 and 18 month of treatment. Dependent of when results from the ongoing international study can be presented a 24 month evaluation can be performed in this study.
    </Secondary_outcome>
    <Secondary_ID>DFNS01
    </Secondary_ID>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>5146075
    </Internal_Number>
    <TrialID>EUCTR2010-019829-34-IT
    </TrialID>
    <Last_Refreshed_on>12 October 2015
    </Last_Refreshed_on>
    <Public_title>AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DIFLUNISAL IN TRANSTHYRETIN HEREDITARY AMYLOIDOSIS - ND
    </Public_title>
    <Scientific_title>AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DIFLUNISAL IN TRANSTHYRETIN HEREDITARY AMYLOIDOSIS - ND                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>OSPEDALE POLICLINICO S. MATTEO
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100421
    </Date_registration3>
    <Date_registration>21/04/2010
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-019829-34
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>20/05/2010
    </Date_enrollement>
    <Target_size/>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: 
Placebo: 
Other: 

    </Study_design>
    <Countries>Italy
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Patients who have successfully completed protocol IND68092 (The Diflunisal Trial)  2. If female, patient is post-menopausal or willing to use an acceptable method of birth control throughout the study.  3. Patient is, in the opinion of the investigator, willing and able to comply with the investigational product regimen and all other study requirements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Chronic use of non-protocol, approved non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3 to 4 times/month.  2. If female, patient is pregnant or breastfeeding.  3. Any clinically significant medical condition that, in the opinion of the investigator, would place the patient at an increased risk to participate in the study&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>transthyretin amyloidosis &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10019901
Term: Hereditary sensory neuropathy

    </Condition>
    <Intervention>&lt;br&gt;Trade Name: Dolobid&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Diflunisal&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: Evaluation of safety and efficacy for diflunisal in patients with transthyretin amyloidosis;Secondary Objective: To continue to provide diflunisal to patients with ATTR who have completed the randomized, double-blind study with diflunisal versus placebo (The Diflunisal Trial).;Primary end point(s): Evaluation of neuropathy
    </Primary_outcome>
    <Secondary_ID>IND68092OL
    </Secondary_ID>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>2554230
    </Internal_Number>
    <TrialID>EUCTR2009-013030-25-FI
    </TrialID>
    <Last_Refreshed_on>24 April 2012
    </Last_Refreshed_on>
    <Public_title>A Principal Open-Label Study to Compare the Brain Uptake of [18F]flutemetamol with Brain Amyloid Levels Determined Post-Mortem - GE-067-007 Brain Amyloid Study
    </Public_title>
    <Scientific_title>A Principal Open-Label Study to Compare the Brain Uptake of [18F]flutemetamol with Brain Amyloid Levels Determined Post-Mortem - GE-067-007 Brain Amyloid Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>GE Healthcare Ltd. and its Affiliates
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20100224
    </Date_registration3>
    <Date_registration>24/02/2010
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-013030-25
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>12/05/2010
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: 
Open: 
Single blind: 
Double blind: 
Parallel group: 
Cross over: 
Other: 
If controlled, specify comparator, Other Medicinial Product: 
Placebo: 
Other: 

    </Study_design>
    <Countries>Finland;United Kingdom;Belgium
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(1) The subject has a short life expectancy (approximately 1 year or less) as estimated by the Investigator.&lt;br&gt;(2) The subject is 70 years of age or older if cognitively normal, or 55 years of age or older if terminal because of dementia.&lt;br&gt;(3) Informed consent has been signed and dated by the subject and/or the subject’s legally acceptable representative if applicable, in accordance with local regulations.&lt;br&gt;(4) The subject has a caregiver who is reliable and will ensure that the subject complies with the protocol, if necessary in the judgment of the Investigator.&lt;br&gt;(5) The subject’s general health is adequate to undergo the study procedures.&lt;br&gt;(6) For women who are either surgically sterile (have had a documented bilateral oophorectomy and/or documented hysterectomy) or are postmenopausal (cessation of menses for more than 2 years), enrollment in the study without a pregnancy test at screening is allowed. For women of childbearing potential, the results of a serum and urine human chorionic gonadotropin pregnancy test (with the result known on the&lt;br&gt;day of and before the Flutemetamol (18F) Injection administration) must be negative.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(1) The subject has known or suspected structural brain abnormalities, such as infarcts or tumors, that may&lt;br&gt;interfere with the interpretation of PET images.&lt;br&gt;(2) The subject has a contraindication for PET.&lt;br&gt;(3) The subject is pregnant or lactating.&lt;br&gt;(4) The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or to any of the excipients.&lt;br&gt;(5) The subject is unable to tolerate or cooperate with study procedures.&lt;br&gt;(6) The subject has participated in any clinical study using an investigational agent within 30 days of dosing.&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>The subjects have a short life expectancy.

GE-067-007 will determine the level of association between brain uptake of (18F)flutemetamol and brain amyloid levels. Assessments will be based on analysis of PET images and the quantitative immunohistochemical estimates of levels of amyloid as determined from post-mortem analysis of corresponding brain tissue samples. &lt;br&gt;MedDRA version: 12.1
Level: LLT
Classification code 10048669
Term: Terminal state

    </Condition>
    <Intervention>&lt;br&gt;Product Name: Flutemetamol (18F) Injection&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: [18F] flutemetamol&lt;br&gt;CAS Number: 765922-62-1&lt;br&gt;Concentration unit: MBq megabecquerel(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 111 -370&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To determine the level of association between quantitative regional estimates of brain&lt;br&gt;uptake of [18F]flutemetamol (from analysis of positron emission tomography [PET] images) and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples.;Secondary Objective: (1) To determine the level of association between quantitative regional estimates of brain uptake of [18F]flutemetamol (from analysis of PET images) and quantitative histochemical regional estimates of brain levels of amyloid from post-mortem analysis of corresponding brain tissue samples. The quantitative estimates of brain uptake of [18F]flutemetamol SUVR will be the same estimates defined for the primary&lt;br&gt;objective.&lt;br&gt;(2) To determine the level of association between quantitative regional estimates of brain uptake of [18F]flutemetamol (from analysis of PET images) and quantitative biochemical (enzyme-linked immunosorbent assay [ELISA]) regional estimates of brain levels of amyloid from post-mortem analysis of corresponding brain tissue samples.;Primary end point(s): The primary endpoint will be the region-specific estimates of cortical tracer uptake determined from quantitative analysis of the [18F]flutemetamol PET images. The quantitative estimate will be the SUVR. Regions of interest (ROI) selected for estimation of [18F]flutemetamol uptake will correspond to the 1 cm3 cubes of tissue taken for amyloid analysis. There will be up to 25 such regions analyzed per brain hemisphere. The number and location of these regions were chosen to provide samples representative of the entire cortex. The uptake estimates for the primary endpoint will be determined for the ROI from the left hemisphere of the brain.
    </Primary_outcome>
    <Secondary_ID>GE-067-007
    </Secondary_ID>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>2807991
    </Internal_Number>
    <TrialID>EUCTR2009-011535-12-DE
    </TrialID>
    <Last_Refreshed_on>2 October 2012
    </Last_Refreshed_on>
    <Public_title>In preparation
    </Public_title>
    <Scientific_title>Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Pfizer Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090518
    </Date_registration3>
    <Date_registration>18/05/2009
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-011535-12
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>26/08/2009
    </Date_enrollement>
    <Target_size>110
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no

    </Study_design>
    <Countries>Portugal;Germany;Argentina;France;Italy;United States;Sweden;Brazil
    </Countries>
    <Contact_Firstname>Clinical Trials.gov Call Center 
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>235 East 42nd Street
    </Contact_Address>
    <Contact_Email>ClinicalTrials.govCallCenter@pfizer.com
    </Contact_Email>
    <Contact_Tel>+18007181021
    </Contact_Tel>
    <Contact_Affiliation>Pfizer Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.  Patient has successfully completed either Protocol Fx-006 or Fx1A-201.&lt;br&gt;2.  If female, patient is post-menopausal, surgically sterilized, or willing to use two acceptable methods of birth control (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study and for 3 months from the end of the study.  (A condom alone is not considered an acceptable method of birth control.).  &lt;br&gt;3.  Patient is, in the opinion of the investigator, willing and able to comply with the investigational product regimen and all other study requirements.&lt;br&gt;Sub-study:&lt;br&gt;4.Decrease in creatinine clearance to &lt; 30 mL/minute, or the need for chronic dialysis.&lt;br&gt;5.Willing to provide written informed consent for this sub-study.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 110&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.  Patient has not successfully completed either Protocol Fx-006 or Fx1A-201.&lt;br&gt;2.  Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3 to 4 times/month.  The following NSAIDs are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethicin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam, and sulindac.&lt;br&gt;3.  If female, patient is pregnant or breast feeding.&lt;br&gt;4.  Clinically significant medical condition that, in the opinion of the investigator, would place the patient at an increased risk to participate in the study.&lt;br&gt;5. An alanine transaminase (ALT) and aspartate transaminase, (AST) value &gt;3X ULN that in the medical judgement of the investigator is due to reduced liver function or active disease.&lt;br&gt;6.  The patient has received a liver or heart transplant.&lt;br&gt;Sub-study:&lt;br&gt;7. Unwilling to provide written informed consent for this sub-study.&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin Amyloidosis (ATTR) &lt;br&gt;MedDRA version: 14.1
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy
System Organ Class: 10010331 - Congenital, familial and genetic disorders
;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
    </Condition>
    <Intervention>&lt;br&gt;Product Name: Tafamidis meglumine&lt;br&gt;Product Code: Fx-1006A&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: tafamidis&lt;br&gt;CAS Number: 951395-08-7&lt;br&gt;Current Sponsor code: Fx-1006A&lt;br&gt;Other descriptive name: [d-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)]&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: To obtain additional, long-term, open-label safety and efficacy data for Fx-1006A in patients with transthyretin (TTR) amyloidosis (ATTR).;Secondary Objective: To continue to provide the investigational product Fx-1006A until market availability or  until 31 December 2012 or whichever is earliest, to patients with ATTR who have completed Protocol Fx-006 or Protocol Fx1A-201.;Primary end point(s): Safety endpoints:&lt;br&gt; - The incidence of treatment-emergent adverse events (TEAEs), physical examinations, clinical laboratory testing, use of concomitant medications and vital signs.&lt;br&gt;&lt;br&gt;Efficacy endpoints:&lt;br&gt; - The Neuropathy Impairment Score (NIS)&lt;br&gt; - The Total Quality of Life (TQOL) score as measured using the Norfolk Quality of Life for diabetic neuropathy (QOL-DN) questionnaire&lt;br&gt; - The Karnofsky Performance Scale Index&lt;br&gt;-Assessment of Patient Ambulation;Timepoint(s) of evaluation of this end point: End of  study
    </Primary_outcome>
    <Secondary_outcome>Secondary end point(s): None described at time of submission;Timepoint(s) of evaluation of this end point: Not applicable
    </Secondary_outcome>
    <Secondary_ID>Fx1A-303;NCT00925002
    </Secondary_ID>
    <Source_Support>Pfizer Inc.
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13435994
    </Internal_Number>
    <TrialID>JPRN-UMIN000001825
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Treatment of familial amyloid polyneuropathy (FAP) using diflunisal
    </Public_title>
    <Scientific_title>Treatment of familial amyloid polyneuropathy (FAP) using diflunisal - Treatment of FAP using diflunisal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Shinshu University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20090331
    </Date_registration3>
    <Date_registration>31/03/2009
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002202
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2009/04/01
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email>sekijima@shinshu-u.ac.jp
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation>Shinshu University department of Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: renal dysfunction  pregnancy  lactation
    </Exclusion_Criteria>
    <Condition>familial amyloid polyneuropathy (FAP)
    </Condition>
    <Intervention>Orally administration of diflunisal
    </Intervention>
    <Primary_outcome>Clnical FAP scale  compound muscle action potential
    </Primary_outcome>
    <Secondary_outcome>cardiac function  mBMI
    </Secondary_outcome>
    <Source_Support>Grant-in-aid for Scientific Research
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_completed>01/03/2014
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>13965478
    </Internal_Number>
    <TrialID>NL-OMON31535
    </TrialID>
    <Last_Refreshed_on>13 May 2024
    </Last_Refreshed_on>
    <Public_title>Cerebral hypoperfusion in familiar amyloid polyneuropathy
    </Public_title>
    <Scientific_title>Cerebral hypoperfusion in familiar amyloid polyneuropathy - FAP-PET                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Universitair Medisch Centrum Groningen
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081201
    </Date_registration3>
    <Date_registration>2008-12-01
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/31535
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>99
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2008-03-01
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Observational invasive
    </Study_type>
    <Study_design>Non-randomized controlled trial, Open (masking not used), Active, Other, Diagnostic
    </Study_design>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Hanzeplein 1
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Universitair Medisch Centrum Groningen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;Patients with familiar amyloid polyneuropathy. &lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;- prior stroke, contusion or other neurological or psychiatric condition which more probable to cause cognitive deficits &lt;br&gt;- prior exposure to radiation in the setting of scientific research &lt;br&gt;- pregnancy &lt;br&gt;- age &lt;18years &lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>systemisch amyloïdose &lt;br&gt;familiar amyloid polyneuropathy &lt;br&gt;Systemic amyloidosis;10007963
    </Condition>
    <Intervention>&lt;p&gt;&lt;/p&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>&lt;p&gt;Cerebral perfusion and metabolism measured with water-PET en FDG-PET.&lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Not applicable.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL20491.042.08
    </Secondary_ID>
    <Source_Support>Onderzoeksbudget afdeling Neurologie;UMCG
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6492086
    </Internal_Number>
    <TrialID>NCT00791492
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
    </Public_title>
    <Scientific_title>An Open-Label Extension Of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Pfizer
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081113
    </Date_registration3>
    <Date_registration>13/11/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00791492
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2008
    </Date_enrollement>
    <Target_size>86
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Argentina;Brazil;France;Germany;Portugal;Sweden;Argentina;Brazil;France;Germany;Portugal;Sweden;Argentina;Brazil;France;Germany;Portugal;Sweden;Argentina;Brazil;France;Germany;Portugal;Sweden;Argentina;Brazil;France;Germany;Portugal;Sweden;Argentina;Brazil;France;Germany;Portugal;Sweden;Argentina;Brazil;France;Germany;Portugal;Sweden;Argentina;Brazil;France;Germany;Portugal;Sweden
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jeff Packman;Jeff Packman;Jeff Packman;Jeff Packman
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>FoldRx Pharmaceuticals, Inc.;FoldRx Pharmaceuticals, Inc.;FoldRx Pharmaceuticals, Inc.;FoldRx Pharmaceuticals, Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Male and non-pregnant female patients meeting all of the following criteria are eligible&#x0D;&lt;br&gt;        for enrollment in this study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has completed the Month 18 visit of Study Fx-005.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study. (A&#x0D;&lt;br&gt;             condom alone is not considered an acceptable method of birth control.) If male with a&#x0D;&lt;br&gt;             female partner of childbearing potential, willing to use an acceptable method of birth&#x0D;&lt;br&gt;             control for the duration of the study. For both females and males, acceptable birth&#x0D;&lt;br&gt;             control must be used for at least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient agrees not to participate in another investigational drug or device study&#x0D;&lt;br&gt;             while participating in this open-label extension study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients meeting any of the exclusion criteria will not be enrolled in the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt;2 times upper limit of normal (ULN) that in the medical&#x0D;&lt;br&gt;             judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Male and non-pregnant female patients meeting all of the following criteria are eligible&#x0D;&lt;br&gt;        for enrollment in this study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has completed the Month 18 visit of Study Fx-005.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study. (A&#x0D;&lt;br&gt;             condom alone is not considered an acceptable method of birth control.) If male with a&#x0D;&lt;br&gt;             female partner of childbearing potential, willing to use an acceptable method of birth&#x0D;&lt;br&gt;             control for the duration of the study. For both females and males, acceptable birth&#x0D;&lt;br&gt;             control must be used for at least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient agrees not to participate in another investigational drug or device study&#x0D;&lt;br&gt;             while participating in this open-label extension study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients meeting any of the exclusion criteria will not be enrolled in the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt;2 times upper limit of normal (ULN) that in the medical&#x0D;&lt;br&gt;             judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Male and non-pregnant female patients meeting all of the following criteria are eligible&#x0D;&lt;br&gt;        for enrollment in this study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has completed the Month 18 visit of Study Fx-005.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study. (A&#x0D;&lt;br&gt;             condom alone is not considered an acceptable method of birth control.) If male with a&#x0D;&lt;br&gt;             female partner of childbearing potential, willing to use an acceptable method of birth&#x0D;&lt;br&gt;             control for the duration of the study. For both females and males, acceptable birth&#x0D;&lt;br&gt;             control must be used for at least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient agrees not to participate in another investigational drug or device study&#x0D;&lt;br&gt;             while participating in this open-label extension study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients meeting any of the exclusion criteria will not be enrolled in the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt;2 times upper limit of normal (ULN) that in the medical&#x0D;&lt;br&gt;             judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Male and non-pregnant female patients meeting all of the following criteria are eligible&#x0D;&lt;br&gt;        for enrollment in this study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has completed the Month 18 visit of Study Fx-005.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study. (A&#x0D;&lt;br&gt;             condom alone is not considered an acceptable method of birth control.) If male with a&#x0D;&lt;br&gt;             female partner of childbearing potential, willing to use an acceptable method of birth&#x0D;&lt;br&gt;             control for the duration of the study. For both females and males, acceptable birth&#x0D;&lt;br&gt;             control must be used for at least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient agrees not to participate in another investigational drug or device study&#x0D;&lt;br&gt;             while participating in this open-label extension study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients meeting any of the exclusion criteria will not be enrolled in the study:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt;2 times upper limit of normal (ULN) that in the medical&#x0D;&lt;br&gt;             judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy;ATTR-PN;Familial Amyloid Polyneuropathy;ATTR-PN;Familial Amyloid Polyneuropathy;ATTR-PN;Familial Amyloid Polyneuropathy;ATTR-PN
    </Condition>
    <Intervention>Drug: Fx-1006A;Drug: Fx-1006A;Drug: Fx-1006A;Drug: Fx-1006A
    </Intervention>
    <Primary_outcome>Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6;Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12;Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6;Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12;Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6;Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12;Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6;Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in Neuropathy Impairment Score - Lower Limb (NIS-LL) Score at Month 6 and 12;Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6 and 12;Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6 and 12;Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6 and 12;Change From Baseline in Modified Body Mass Index (mBMI) at Month 6 and 12;Change From Baseline in Troponin I Concentration at Week 6, Month 3, 6 and 12;Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 6, Month 3, 6 and 12;Intraepidermal Nerve Fiber (IENF) Density;Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer
    </Secondary_outcome>
    <Secondary_ID>B3461021;FX-006
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>17/12/2012
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00791492
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>2684998
    </Internal_Number>
    <TrialID>EUCTR2008-001262-87-PT
    </TrialID>
    <Last_Refreshed_on>24 July 2012
    </Last_Refreshed_on>
    <Public_title>
		&#x09;
    </Public_title>
    <Scientific_title>An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy - Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>FoldRx Pharmaceuticals, Inc.
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20080421
    </Date_registration3>
    <Date_registration>21/04/2008
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-001262-87
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>
		&#x09;
    </Inclusion_agemin>
    <Inclusion_agemax>
		&#x09;
    </Inclusion_agemax>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>04/07/2008
    </Date_enrollement>
    <Target_size>107
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no

    </Study_design>
    <Countries>Portugal;Germany;France;Sweden
    </Countries>
    <Contact_Firstname>
			&#x09;
    </Contact_Firstname>
    <Contact_Lastname>
			&#x09;
    </Contact_Lastname>
    <Contact_Address>
			&#x09;
    </Contact_Address>
    <Contact_Email>
			&#x09;
    </Contact_Email>
    <Contact_Tel>
			&#x09;
    </Contact_Tel>
    <Contact_Affiliation>
			&#x09;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Inclusion Criteria for male and non-pregnant female patients:&lt;br&gt;- Patient has completed the Month 18 visit of Study Fx-005.&lt;br&gt;- If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study. (A condom alone is not considered an acceptable method of birth control.)  If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study.  For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication.&lt;br&gt;- Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.&lt;br&gt;- Patient agrees not to participate in another investigational drug or device study while participating in this open-label extension study.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients meeting any of the exclusion criteria will not be enrolled in the study:&lt;br&gt;- Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month.  The following NSAID are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethicin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam, and sulindac.&lt;br&gt;- If female, patient is pregnant or breast feeding.&lt;br&gt;- Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST) &gt;2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease&lt;br&gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Transthyretin Amyloid Polyneuropathy (ATTR-PN) &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy

    </Condition>
    <Intervention>&lt;br&gt;Product Name: Fx-1006A&lt;br&gt;Product Code: Fx-1006A&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;CAS Number: 951395-08-7&lt;br&gt;Current Sponsor code: Fx-1006A&lt;br&gt;Other descriptive name: N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium;2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Primary end point(s): Safety endpoints:&lt;br&gt;- Incidence of patients experiencing treatment-emergent serious adverse events.&lt;br&gt;- Incidence of patients experiencing treatment-emergent = Grade 3 adverse events.&lt;br&gt;- Incidence of patients with treatment-emergent echocardiography (ECHO) findings considered by the Investigator to be clinically significant.&lt;br&gt;- Incidence of patients with treatment-emergent electrocardiogram (ECG) findings considered by the Investigator to be clinically significant.&lt;br&gt;- Incidence of patients with treatment-emergent Holter Monitor findings considered by the Investigator to be clinically significant.&lt;br&gt;- Incidence of patients discontinuing from the study because of clinical or laboratory adverse events.&lt;br&gt;&lt;br&gt;Efficacy endpoints:&lt;br&gt;- Response to treatment at Months 6 and 12, as indicated by either improvement (decrease from Baseline) or stabilization (change from baseline of 0 to &lt; 2) in the Neurologic Impairment Score – Lower Limb (NIS-LL) score.  The NIS-LL score for each study visit will be based on the average of two scores taken at least 24 hours apart within a one-week period.&lt;br&gt;- Change from Baseline to Months 6 and 12 in the Total Quality of Life (TQOL) score, as measured by the Norfolk QOL-DN.&lt;br&gt;- Change from Baseline to Months 6 and 12 in NIS-LL&lt;br&gt;- Change from Baseline to Months 6 and 12 in the five domains of the Norfolk QOL-DN&lt;br&gt;- Change from Baseline to Months 6 and 12 in “+7 composite score” as measured by nerve conduction studies (NCS), vibration detection threshold (VDT) and heart rate response to deep breathing (HRDB)&lt;br&gt;- Change from Baseline to Months 6 and 12 in heat, pain and cooling thresholds as measured by Quantitative Sensory Testing (QST) utilizing CASE IV&lt;br&gt;- Change from Baseline to Months 6 and 12 in modified Body Mass Index (mBMI)&lt;br&gt;- Change from Baseline to Week 6 and Months 3, 6, and 12 in troponin I and NT-pro-BNP levels&lt;br&gt;- IENF density at Baseline&lt;br&gt;- TTR stabilization at Months 6 and 12, as measured by a validated immunoturbidimetric assay&lt;br&gt;&lt;br&gt;&lt;br&gt;;Main Objective: - To evaluate the long-term safety and tolerability of chronic administration of Fx-1006A in patients with Transthyretin Amyloid Polyneuropathy (ATTR-PN);&lt;br&gt;- To evaluate the long-term effects of Fx-1006A on disease progression in patients with ATTR-PN.&lt;br&gt;;Secondary Objective: - To determine the pharmacodynamic stabilization effect of Fx-1006A on human V30M transthyretin (TTR);&lt;br&gt;- To obtain additional pharmacokinetic samples for population pharmacokinetics analysis in this patient population.&lt;br&gt;
    </Primary_outcome>
    <Secondary_ID>Fx-006;Not applicable
    </Secondary_ID>
    <Source_Support>
		&#x09;
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6489291
    </Internal_Number>
    <TrialID>NCT00630864
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
    </Public_title>
    <Scientific_title>The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Pfizer
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20080227
    </Date_registration3>
    <Date_registration>27/02/2008
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00630864
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2008
    </Date_enrollement>
    <Target_size>21
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 2
    </Phase>
    <Countries>United States;France;Germany;Italy;France;Germany;Italy;United States;United States;France;Germany;Italy;France;Germany;Italy;United States;United States;France;Germany;Italy;France;Germany;Italy;United States;United States;France;Germany;Italy;France;Germany;Italy;United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has amyloid documented by biopsy (in accordance with institutional site&#x0D;&lt;br&gt;             standard of care).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has documentation of one of the following targeted TTR mutations: Ser77Tyr,&#x0D;&lt;br&gt;             Thr60Ala, Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe, Thr49Ala, Ile107Val, Val30Ala,&#x0D;&lt;br&gt;             Gly47Ala, Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr, Ile107Met. Patients with mutations&#x0D;&lt;br&gt;             other than those listed may be enrolled only after approval by the Sponsor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has peripheral and/or autonomic neuropathy and/or cardiomyopathy with a&#x0D;&lt;br&gt;             Karnofsky Performance Status = 50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is aged =18 to 75 years, inclusive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use two&#x0D;&lt;br&gt;             acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study and&#x0D;&lt;br&gt;             for 3 months from the end of the study. (A condom alone is not considered an&#x0D;&lt;br&gt;             acceptable method of birth control.) If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use two acceptable methods of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, acceptable birth control must be used for at&#x0D;&lt;br&gt;             least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has primary or secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has TTR-associated amyloidosis with V30M mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is expected to undergo liver transplantation within 12 months after&#x0D;&lt;br&gt;             enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis&#x0D;&lt;br&gt;             C virus (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has renal insufficiency (creatinine clearance &lt; 30 ml/min).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt; 2 times upper limit of normal (ULN) that in the&#x0D;&lt;br&gt;             medical judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a New York Heart Association (NYHA) Functional Classification = III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes&#x0D;&lt;br&gt;             Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse,&#x0D;&lt;br&gt;             and chronic inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to&#x0D;&lt;br&gt;             obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g.,&#x0D;&lt;br&gt;             symptomatic left ventricular dysfunction from any cause other than amyloid, patients&#x0D;&lt;br&gt;             with a primary diagnosis of symptomatic valvular heart disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a co-morbidity anticipated to limit survival to less than 12 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline (Day 0).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has amyloid documented by biopsy (in accordance with institutional site&#x0D;&lt;br&gt;             standard of care).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has documentation of one of the following targeted TTR mutations: Ser77Tyr,&#x0D;&lt;br&gt;             Thr60Ala, Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe, Thr49Ala, Ile107Val, Val30Ala,&#x0D;&lt;br&gt;             Gly47Ala, Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr, Ile107Met. Patients with mutations&#x0D;&lt;br&gt;             other than those listed may be enrolled only after approval by the Sponsor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has peripheral and/or autonomic neuropathy and/or cardiomyopathy with a&#x0D;&lt;br&gt;             Karnofsky Performance Status = 50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is aged =18 to 75 years, inclusive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use two&#x0D;&lt;br&gt;             acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study and&#x0D;&lt;br&gt;             for 3 months from the end of the study. (A condom alone is not considered an&#x0D;&lt;br&gt;             acceptable method of birth control.) If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use two acceptable methods of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, acceptable birth control must be used for at&#x0D;&lt;br&gt;             least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has primary or secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has TTR-associated amyloidosis with V30M mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is expected to undergo liver transplantation within 12 months after&#x0D;&lt;br&gt;             enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis&#x0D;&lt;br&gt;             C virus (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has renal insufficiency (creatinine clearance &lt; 30 ml/min).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt; 2 times upper limit of normal (ULN) that in the&#x0D;&lt;br&gt;             medical judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a New York Heart Association (NYHA) Functional Classification = III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes&#x0D;&lt;br&gt;             Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse,&#x0D;&lt;br&gt;             and chronic inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to&#x0D;&lt;br&gt;             obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g.,&#x0D;&lt;br&gt;             symptomatic left ventricular dysfunction from any cause other than amyloid, patients&#x0D;&lt;br&gt;             with a primary diagnosis of symptomatic valvular heart disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a co-morbidity anticipated to limit survival to less than 12 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline (Day 0).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has amyloid documented by biopsy (in accordance with institutional site&#x0D;&lt;br&gt;             standard of care).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has documentation of one of the following targeted TTR mutations: Ser77Tyr,&#x0D;&lt;br&gt;             Thr60Ala, Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe, Thr49Ala, Ile107Val, Val30Ala,&#x0D;&lt;br&gt;             Gly47Ala, Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr, Ile107Met. Patients with mutations&#x0D;&lt;br&gt;             other than those listed may be enrolled only after approval by the Sponsor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has peripheral and/or autonomic neuropathy and/or cardiomyopathy with a&#x0D;&lt;br&gt;             Karnofsky Performance Status = 50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is aged =18 to 75 years, inclusive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use two&#x0D;&lt;br&gt;             acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study and&#x0D;&lt;br&gt;             for 3 months from the end of the study. (A condom alone is not considered an&#x0D;&lt;br&gt;             acceptable method of birth control.) If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use two acceptable methods of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, acceptable birth control must be used for at&#x0D;&lt;br&gt;             least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has primary or secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has TTR-associated amyloidosis with V30M mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is expected to undergo liver transplantation within 12 months after&#x0D;&lt;br&gt;             enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis&#x0D;&lt;br&gt;             C virus (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has renal insufficiency (creatinine clearance &lt; 30 ml/min).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt; 2 times upper limit of normal (ULN) that in the&#x0D;&lt;br&gt;             medical judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a New York Heart Association (NYHA) Functional Classification = III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes&#x0D;&lt;br&gt;             Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse,&#x0D;&lt;br&gt;             and chronic inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to&#x0D;&lt;br&gt;             obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g.,&#x0D;&lt;br&gt;             symptomatic left ventricular dysfunction from any cause other than amyloid, patients&#x0D;&lt;br&gt;             with a primary diagnosis of symptomatic valvular heart disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a co-morbidity anticipated to limit survival to less than 12 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline (Day 0).&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has amyloid documented by biopsy (in accordance with institutional site&#x0D;&lt;br&gt;             standard of care).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has documentation of one of the following targeted TTR mutations: Ser77Tyr,&#x0D;&lt;br&gt;             Thr60Ala, Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe, Thr49Ala, Ile107Val, Val30Ala,&#x0D;&lt;br&gt;             Gly47Ala, Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr, Ile107Met. Patients with mutations&#x0D;&lt;br&gt;             other than those listed may be enrolled only after approval by the Sponsor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has peripheral and/or autonomic neuropathy and/or cardiomyopathy with a&#x0D;&lt;br&gt;             Karnofsky Performance Status = 50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is aged =18 to 75 years, inclusive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is post-menopausal, surgically sterilized, or willing to use two&#x0D;&lt;br&gt;             acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine&#x0D;&lt;br&gt;             device, diaphragm with spermicide, condom with spermicide) throughout the study and&#x0D;&lt;br&gt;             for 3 months from the end of the study. (A condom alone is not considered an&#x0D;&lt;br&gt;             acceptable method of birth control.) If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use two acceptable methods of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, acceptable birth control must be used for at&#x0D;&lt;br&gt;             least 3 months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than&#x0D;&lt;br&gt;             3-4 times/month (ibuprofen and nimesulide will be permitted).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has primary or secondary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has TTR-associated amyloidosis with V30M mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient is expected to undergo liver transplantation within 12 months after&#x0D;&lt;br&gt;             enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis&#x0D;&lt;br&gt;             C virus (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has renal insufficiency (creatinine clearance &lt; 30 ml/min).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has liver function test abnormalities: alanine transaminases (ALT) and/or&#x0D;&lt;br&gt;             aspartate transaminases (AST) &gt; 2 times upper limit of normal (ULN) that in the&#x0D;&lt;br&gt;             medical judgment of the investigator are due to reduced liver function or active liver&#x0D;&lt;br&gt;             disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a New York Heart Association (NYHA) Functional Classification = III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes&#x0D;&lt;br&gt;             Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse,&#x0D;&lt;br&gt;             and chronic inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to&#x0D;&lt;br&gt;             obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g.,&#x0D;&lt;br&gt;             symptomatic left ventricular dysfunction from any cause other than amyloid, patients&#x0D;&lt;br&gt;             with a primary diagnosis of symptomatic valvular heart disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has a co-morbidity anticipated to limit survival to less than 12 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient has received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline (Day 0).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transthyretin-associated Amyloidosis With Polyneuropathy;Transthyretin-associated Amyloidosis With Polyneuropathy;Transthyretin-associated Amyloidosis With Polyneuropathy;Transthyretin-associated Amyloidosis With Polyneuropathy
    </Condition>
    <Intervention>Drug: Fx-1006A;Drug: Fx-1006A;Drug: Fx-1006A;Drug: Fx-1006A
    </Intervention>
    <Primary_outcome>Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Week 6;Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Week 6
    </Primary_outcome>
    <Secondary_outcome>Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Month 6 and 12
    </Secondary_outcome>
    <Secondary_ID>B3461022;FX1A-201
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>17/12/2012
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00630864
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6485522
    </Internal_Number>
    <TrialID>NCT00409175
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
    </Public_title>
    <Scientific_title>Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Pfizer
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20061206
    </Date_registration3>
    <Date_registration>06/12/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00409175
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2007
    </Date_enrollement>
    <Target_size>128
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>United States;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States;United States;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States;United States;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States;United States;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jeff Packman;Jeff Packman;Jeff Packman;Jeff Packman
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>FoldRx Pharmaceuticals, Inc.;FoldRx Pharmaceuticals, Inc.;FoldRx Pharmaceuticals, Inc.;FoldRx Pharmaceuticals, Inc.
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Amyloid documented by biopsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Documented V30M TTR mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status =50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient is 18-75 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control. If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use an acceptable method of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, birth control must be used for at least 3&#x0D;&lt;br&gt;             months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Primary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. No recordable sensory threshold for vibration perception in both feet, as measured by&#x0D;&lt;br&gt;             CASE IV.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus&#x0D;&lt;br&gt;             (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Renal insufficiency or liver function test abnormalities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. New York Heart Association (NYHA) Functional Classification =III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV&#x0D;&lt;br&gt;             treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic&#x0D;&lt;br&gt;             inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Co-morbidity anticipated to limit survival to less than 18 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Amyloid documented by biopsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Documented V30M TTR mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status =50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient is 18-75 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control. If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use an acceptable method of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, birth control must be used for at least 3&#x0D;&lt;br&gt;             months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Primary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. No recordable sensory threshold for vibration perception in both feet, as measured by&#x0D;&lt;br&gt;             CASE IV.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus&#x0D;&lt;br&gt;             (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Renal insufficiency or liver function test abnormalities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. New York Heart Association (NYHA) Functional Classification =III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV&#x0D;&lt;br&gt;             treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic&#x0D;&lt;br&gt;             inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Co-morbidity anticipated to limit survival to less than 18 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Amyloid documented by biopsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Documented V30M TTR mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status =50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient is 18-75 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control. If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use an acceptable method of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, birth control must be used for at least 3&#x0D;&lt;br&gt;             months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Primary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. No recordable sensory threshold for vibration perception in both feet, as measured by&#x0D;&lt;br&gt;             CASE IV.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus&#x0D;&lt;br&gt;             (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Renal insufficiency or liver function test abnormalities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. New York Heart Association (NYHA) Functional Classification =III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV&#x0D;&lt;br&gt;             treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic&#x0D;&lt;br&gt;             inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Co-morbidity anticipated to limit survival to less than 18 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Amyloid documented by biopsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Documented V30M TTR mutation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status =50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patient is 18-75 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. If female, patient is post-menopausal, surgically sterilized, or willing to use an&#x0D;&lt;br&gt;             acceptable method of birth control. If male with a female partner of childbearing&#x0D;&lt;br&gt;             potential, willing to use an acceptable method of birth control for the duration of&#x0D;&lt;br&gt;             the study. For both females and males, birth control must be used for at least 3&#x0D;&lt;br&gt;             months after the last dose of study medication.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Patient is, in the opinion of the investigator, willing and able to comply with the&#x0D;&lt;br&gt;             study medication regimen and all other study requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Primary amyloidosis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. If female, patient is pregnant or breast feeding.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Prior liver transplantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. No recordable sensory threshold for vibration perception in both feet, as measured by&#x0D;&lt;br&gt;             CASE IV.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus&#x0D;&lt;br&gt;             (HCV), and/or human immunodeficiency virus (HIV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Renal insufficiency or liver function test abnormalities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. New York Heart Association (NYHA) Functional Classification =III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV&#x0D;&lt;br&gt;             treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic&#x0D;&lt;br&gt;             inflammatory diseases).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Co-morbidity anticipated to limit survival to less than 18 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Patient received an investigational drug/device and/or participated in another&#x0D;&lt;br&gt;             clinical investigational study within 60 days before Baseline.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy;Familial Amyloid Polyneuropathy;Familial Amyloid Polyneuropathy;Familial Amyloid Polyneuropathy
    </Condition>
    <Intervention>Drug: Fx-1006A;Drug: Placebo;Drug: Fx-1006A;Drug: Placebo;Drug: Fx-1006A;Drug: Placebo;Drug: Fx-1006A;Drug: Placebo
    </Intervention>
    <Primary_outcome>Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18;Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18;Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18;Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18
    </Primary_outcome>
    <Secondary_outcome>Change From Baseline in Neuropathy Impairment Score- Lower Limb (NIS-LL) Score at Month 6, 12 and 18;Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 and 12;Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6 and 12;Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, 12 and 18;Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6, 12 and 18;Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6, 12 and 18;Change From Baseline in Modified Body Mass Index (mBMI) at Month 6, 12 and 18;Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer
    </Secondary_outcome>
    <Secondary_ID>B3461020;FX-005
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>17/12/2012
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00409175
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>2470086
    </Internal_Number>
    <TrialID>EUCTR2006-002792-41-SE
    </TrialID>
    <Last_Refreshed_on>19 March 2012
    </Last_Refreshed_on>
    <Public_title>Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study
    </Public_title>
    <Scientific_title>Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>FoldRx Pharmaceuticals Limited
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20060901
    </Date_registration3>
    <Date_registration>01/09/2006
    </Date_registration>
    <Source_Register>EU Clinical Trials Register
    </Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-002792-41
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;
    </Inclusion_gender>
    <Date_enrollement>30/10/2006
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional clinical trial of medicinal product
    </Study_type>
    <Study_design>Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no

    </Study_design>
    <Countries>Portugal;Germany;United Kingdom;Spain;Sweden
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address/>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- Documented amyloid by biopsy&lt;br&gt;- Documented V30M TTR mutation&lt;br&gt;- Peripheral and/or autonomic neuropathy with a Karnofsky Performance Status &gt;50.&lt;br&gt;- Aged not less than 18 through 75 years&lt;br&gt;- Female patients must be post-menopausal, surgically sterilised, or willing to use two acceptable methods of birth control (ie. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study and for 3 months from the end of the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of child bearing potential, willing to use two acceptable methods of birth control for the duration of the study.  For both females and males, birth control must be used for at least 3 months after the last dose of study medication.&lt;br&gt;- Patient is, in the opinion of the Investigator, willing and able to comply with the study medication regimen and all other study requirements.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month.  The following NSAID are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethicin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam, and sulindac&lt;br&gt;- Patients has primary amyloidosis&lt;br&gt;- Patient is pregnant or breast feeding&lt;br&gt;- Prior liver transplantation&lt;br&gt;- No recordable sensory threshold for vibration perception in both feet, as measured by CASE IV&lt;br&gt;- Patients with positive results for HBsAg, anti-HCV, and/or HIV&lt;br&gt;- Renal insuffiency (creatinine clearance &lt; 30 ml/min)&lt;br&gt;- Liver function test abnormalities: alanine transaminase (ALT) and/or aspartate transaminase (AST) &gt; 2 times upper limit of normal that in the medical judgement of the Investigator are due to reduced liver function or active liver disease.&lt;br&gt;- NHYA Class &gt;3&lt;br&gt;- Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse and chronic inflammatory diseases)&lt;br&gt;- Comorbidity anticipated to limit survival to less than 18 months&lt;br&gt;- Patient has received an investigational drug/device and/or participated in another clinical investigation within 60 days before baseline (Day 0). &lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy (FAP). &lt;br&gt;MedDRA version: 9.1
Level: LLT
Classification code 10057949
Term: Familial amyloid polyneuropathy

    </Condition>
    <Intervention>&lt;br&gt;Product Code: Fx-1006A&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;Current Sponsor code: Fx-1006A&lt;br&gt;Other descriptive name: N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium;2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, soft&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;
    </Intervention>
    <Primary_outcome>Main Objective: - To evaluate the effect of Fx-1006A on disease progression in patients with Familial Amyloid Polyneuropathy (FAP).&lt;br&gt;- To evaluate the safety and tolerability of chronic administration of Fx-1006A in patients with FAP.;Secondary Objective: - To determine the pharmacodynamic stablisation effect of Fx-1006A on human V30M TTR.&lt;br&gt;- To determine the population pharmacokinetics in patients with FAP.;Primary end point(s): Co-primary efficacy end points:&lt;br&gt;&lt;br&gt;- Response to treatment at Month 18, as indicated by either improvement (decrease from baseline) or stabilisation (change from baseline of 0 to &lt;2) in the Neurologic Impairment Score - Lower Limb (NIS-LL) score.  The NIS-LL score for each study visit will be based on the average of two scores taken at least 24 hours apart within a one-week period.&lt;br&gt;- Change from baseline to 18 months in the Total Quality of Life (TQOL) score, as measured by the Norfolk QOL-DN.&lt;br&gt;&lt;br&gt;Secondary efficacy end points:&lt;br&gt;- Response to treatment, as indicated by either improvement or stabilisation in the NIS-LL score, at Months 6 and 12.&lt;br&gt;- Change from baseline to Months 6, 12 and 18 in NIS-LL.&lt;br&gt;- Change from baseline to 6 and 12 Months in the TQOL score, as measured by the Norfolk QOL-DN.&lt;br&gt;- Change from baseline to 6, 12 and 18 Months in the five domains of the Norfolk QOL-DN.&lt;br&gt;- Change from baseline through Month 18 in "+7 composite score" as measured by nerve conduction studies (NCS), vibration detection threshold (VDT) and heart beat response to deep breathing (HBDB).&lt;br&gt;- Change from baseline through Month 18 in heat pain and cooling thresholds as measured by Quantitative Sensory Testing (QST) utilising CASE IV.&lt;br&gt;- Change from baseline through Month 18 in modified Body Mass Index (mBMI).&lt;br&gt;- TTR stabilisation through Month 18, as measured by a validated immunoturbidimetric assay.&lt;br&gt;&lt;br&gt;Safety end points:&lt;br&gt;- Incidence of patients experiencing treatment-emergent SAEs&lt;br&gt;- Incidence of patients experiencing treatment-emergent &gt;Grade 3 AE&lt;br&gt;- Incidence of patients experiencing treatment-emergent &gt;Grade 3 clinical laboratory findings.&lt;br&gt;- Incidence of patients with treatment-emergent echocardiography (ECHO) findings considered by the Investigator to be clinically significant.&lt;br&gt;- Incidence of patients with treatment-emergent electrocardiogram (ECG) findings considered by the Investigator to be clinically significant.&lt;br&gt;- Incidence of patients discontinuing from the study because of clinical or laboratory adverse events. 
    </Primary_outcome>
    <Secondary_ID>Fx-005
    </Secondary_ID>
    
  </Trial>

    
  <Trial><Export_date>06/09/2024 16:01:13</Export_date>
    <Internal_Number>6607176
    </Internal_Number>
    <TrialID>NCT00294671
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>The Effect of Diflunisal on Familial Amyloidosis
    </Public_title>
    <Scientific_title>The Effect of Diflunisal on Familial Amyloidosis
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20060221
    </Date_registration3>
    <Date_registration>21/02/2006
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00294671
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>Yes
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 2006
    </Date_enrollement>
    <Target_size>130
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>United States;Italy;Japan;Sweden;United Kingdom;Italy;Japan;Sweden;United Kingdom;United States;Portugal;United States;Italy;Japan;Sweden;United Kingdom;Italy;Japan;Sweden;United Kingdom;United States;Portugal;United States;Italy;Japan;Sweden;United Kingdom;Italy;Japan;Sweden;United Kingdom;United States;Portugal;United States;Italy;Japan;Sweden;United Kingdom;Italy;Japan;Sweden;United Kingdom;United States;Portugal;United States;Italy;Japan;Sweden;United Kingdom;Italy;Japan;Sweden;United Kingdom;United States;Portugal
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>John L. Berk, MD;John L. Berk, MD;John L. Berk, MD;John L. Berk, MD;John L. Berk, MD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Boston University;Boston University;Boston University;Boston University;Boston University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 to 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Biopsy proven amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Genotyping of variant transthyretin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of peripheral or autonomic neuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of other non-steroidal anti-inflammatory drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other causes of sensorimotor polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anticipated survival &lt;2 years or liver transplantation in &lt;1 yr&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Liver transplantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Profound nerve, heart or kidney impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or unwillingness to use contraception by women of childbearing age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active or recent gastrointestinal bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-steroidal or aspirin drug allergy/hypersensitivity&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 to 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Biopsy proven amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Genotyping of variant transthyretin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of peripheral or autonomic neuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of other non-steroidal anti-inflammatory drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other causes of sensorimotor polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anticipated survival &lt;2 years or liver transplantation in &lt;1 yr&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Liver transplantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Profound nerve, heart or kidney impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or unwillingness to use contraception by women of childbearing age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active or recent gastrointestinal bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-steroidal or aspirin drug allergy/hypersensitivity&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 to 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Biopsy proven amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Genotyping of variant transthyretin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of peripheral or autonomic neuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of other non-steroidal anti-inflammatory drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other causes of sensorimotor polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anticipated survival &lt;2 years or liver transplantation in &lt;1 yr&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Liver transplantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Profound nerve, heart or kidney impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or unwillingness to use contraception by women of childbearing age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active or recent gastrointestinal bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-steroidal or aspirin drug allergy/hypersensitivity&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 to 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Biopsy proven amyloidosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Genotyping of variant transthyretin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signs of peripheral or autonomic neuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use of other non-steroidal anti-inflammatory drugs&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other causes of sensorimotor polyneuropathy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Anticipated survival &lt;2 years or liver transplantation in &lt;1 yr&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Liver transplantation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Profound nerve, heart or kidney impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or unwillingness to use contraception by women of childbearing age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active or recent gastrointestinal bleeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-steroidal or aspirin drug allergy/hypersensitivity&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Familial Amyloid Polyneuropathy;Familial Amyloidosis;Familial Amyloid Polyneuropathy;Familial Amyloidosis;Familial Amyloid Polyneuropathy;Familial Amyloidosis;Familial Amyloid Polyneuropathy;Familial Amyloidosis
    </Condition>
    <Intervention>Drug: diflunisal;Other: placebo;Drug: diflunisal;Other: placebo;Drug: diflunisal;Other: placebo;Drug: diflunisal;Other: placebo
    </Intervention>
    <Primary_outcome>Neurologic Impairment Score + 7 (NIS+7);Neurologic Impairment Score + 7 (NIS+7);Neurologic Impairment Score + 7 (NIS+7)
    </Primary_outcome>
    <Secondary_outcome>Kumamoto Neurologic Scale;;Modified Body Mass Index (mBMI);;Quality of Life Questionnaire: SF-36 Physical Component Score;Quality of Life Questionnaire: SF-36 Mental Component Score
    </Secondary_outcome>
    <Secondary_ID>FD R 002532;R01NS051306;R01NS051306
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Food and Drug Administration (FDA);National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>17/03/2017
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00294671
    </results_url_link>
    
  </Trial>
</Trials_downloaded_from_ICTRP>